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ABSTRACT OF THE DISSERTATION
CONJUGATED POLYMER-BASED BIOMATERIALS THROUGH CONTROLLED SELFASSEMBLY
by
Megan Twomey
Florida International University, 2016
Miami, Florida
Professor Joong Ho Moon, Major Professor
Synthetic polymeric materials have gained significant use as biological materials (biomaterials) in biomedical
and pharmaceutical applications. As a result, a demand for well-defined polymers with tunable properties
has emerged. The synthetic versatility of polymeric biomaterials allows the opportunity to understand the
structure-property relationship of materials and their cellular interactions. A novel class of polymeric
biomaterials are conjugated polymers (CPs), which possess desirable physicochemical and excellent
photophysical properties, including inherent fluorescence. The synthetic versatility of CPs allows easy
modification of the conjugated backbone to tune emission and side chain structures to adjust biocompatibility
through increased water solubility, controlled biodegradability, and incorporation of targeting units. The aim
of this dissertation is to better understand conjugated polymer nanoparticle (CPN) structure and self-assembly
in an aqueous environment, and how those structural features affect cellular interactions to establish a
structure-function relationship.
This work presents the fabrication of several different CPNs for cancer cell targeting and labelling, and
differentiation of biologically important molecules. Core−shell nanoparticles were prepared using a semiflexible cationic CPN complexed with hyaluronic acid (HA), a polyanion. The resulting CPNs exhibited high
cancer cell specificity with low adsorption to normal cells, as a result of HA’s affinity towards overexpressed
receptors on cancer cell surface. A systematic investigation on the aggregation properties of CPNs that vary
by side chain and backbone structures in response to different biologically important anionic polysaccharides
in a complex biological medium was conducted. Mitochondria-specific CPNs were fabricated from a semiflexible CPN modified with the mitochondrial-targeting triphenylphosphonium (TPP) group. The subcellular
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localization and cellular toxicity were dependent on backbone flexibility, hydrophilicity, and molecular
weight. Dual-targeting CPNs grafted with folic acid (FA) side chains and complexed with hyaluronic acid
(HA) were fabricated for improved uptake and bioimaging of cancer cells.
The work presented here shows how modifications to CPN backbone and side chain structures modulate their
cellular interactions. The physicochemical and biophysical properties of CPNs affect biocompatibility and
understanding those properties will lead to the development of novel CP-based biomaterials.

v

TABLE OF CONTENTS
CHAPTER

PAGE

I.

Introduction ....................................................................................................................................... 1
1.1 Materials chemistry....................................................................................................... 2
1.2 Challenges for polymeric biomaterials ......................................................................... 2
1.3 Conjugated polymers .................................................................................................... 3
1.4 Conjugated polymer nanoparticles ............................................................................... 6
1.5 Polymer characterization .............................................................................................. 7
1.6 Polymer self-assembly characterization........................................................................ 8
1.7 Biological use of nanoparticles ................................................................................... 12
1.8 Characterization of cellular interactions ..................................................................... 15
1.9 Summary ..................................................................................................................... 16
1.10 References................................................................................................................. 16

II.

Fabrication of core-shell nanoparticles via controlled aggregation of semi-flexible
conjugated polymer and hyaluronic acid ........................................................................................ 19
2.1 Abstract ....................................................................................................................... 20
2.2 Introduction................................................................................................................. 20
2.3 Results and Discussion ............................................................................................... 21
2.4 Conclusion .................................................................................................................. 27
2.5 Outlook ....................................................................................................................... 28
2.6 Experimental ............................................................................................................... 28
2.7 References................................................................................................................... 34

III.

Differential interactions of conjugated polymer nanoparticles with glycosaminoglycans in
synthetic urine ................................................................................................................................. 36
3.1 Abstract ....................................................................................................................... 37
3.2 Introduction................................................................................................................. 37
3.3 Results and Discussion ............................................................................................... 39
3.4 Conclusion .................................................................................................................. 46
3.5 Outlook ....................................................................................................................... 46
3.6 Experimental ............................................................................................................... 47
3.7 References................................................................................................................... 62

IV.

Mitochondria-specific conjugated polymer nanoparticles .............................................................. 64
4.1 Abstract ....................................................................................................................... 65
4.2 Introduction................................................................................................................. 65
4.3 Results and Discussion ............................................................................................... 66
4.4 Conclusion .................................................................................................................. 74
4.5 Outlook ....................................................................................................................... 74
4.6 Experimental ............................................................................................................... 75
4.7 References................................................................................................................. 107

V.

Dual targeting conjugated polymer nanoparticles of folate and hyaluronan receptors for
bioimaging .................................................................................................................................... 108
5.1 Abstract ..................................................................................................................... 109
5.2 Introduction............................................................................................................... 109
5.3 Results and Discussion ............................................................................................. 111

vi

5.4 Conclusion ................................................................................................................ 120
5.5 Outlook ..................................................................................................................... 120
5.6 Experimental ............................................................................................................. 121
5.7 References................................................................................................................. 148
VI.

General Conclusions ..................................................................................................................... 150

VITA ........................................................................................................................................................... 153

vii

LIST OF TABLES
TABLE

PAGE

3.1

Key photophysical and physical properties of CPNs ...................................................................... 40

S3.1

Summary of NTA data for CPN/GAG complexes .......................................................................... 60

S3.2

Summary of canonical scores from LDA plot................................................................................. 61

S3.3

Squared Mahalanobis distances to each group centroid .................................................................. 61

S4.1

Hydrodynamic diameters and zeta potential of CPNs ..................................................................... 97

viii

LIST OF FIGURES
FIGURE

PAGE

1.1

Common examples of conjugated polymers. .................................................................................... 3

1.2

Example configuration of delocalized electrons in a π conjugated system. ...................................... 4

1.3

Sonogashira and Glaser coupling for PPE and PPB synthesis .......................................................... 5

1.4

Jablonski diagram showing processes when a molecule is irradiated by light .................................. 6

1.5

Example GPC chromatogram illustrating molecular weight distribution ......................................... 7

1.6

Schematic representation of the spectral shift in H and J-aggregates based on
chromophore arrangement ................................................................................................................ 9

1.7

Schematic representation of zeta potential of a negatively charged particle ................................... 11

1.8

Schematic representation of the enhanced retention and permeability effect (EPR) that occurs in
diseased tissue ................................................................................................................................. 13

2.1

Chemical structure of the semi-flexible PPB and schematic presentation of structural
reorganization of the semi-flexible PPB upon HA complexation ................................................... 22

2.2

Absorbance and emission spectra of semi-flexible PPB and rigid PPE before and after
HA complexation ............................................................................................................................ 23

2.3

AFM topographic (a, c) and phase (b, d) images of the semi-flexible PPB (a, b) and
semi-flexible PPB/HA nanoparticles formed at 1:3 molar ratio (c, d). The semi-flexible
PPB/HA exhibits elongated particles on a mica surface (c), and the phase image (d) reveals
that the complexes are core−shell nanoparticles. ............................................................................ 24

2.4

Topography and phase images and size analysis histograms of semi-flexible PPB,
semi-flexible PPB/HA (1:1), and semi-flexible PPB/HA (1:3)....................................................... 25

2.5

Normalized fluorescent mean intensity ratios of various cells treated with the semi-flexible
PPB/HA (1:3) up to 3 h. .................................................................................................................. 26

2.6

Fluorescent microscopic and contrast images of HeLa/HEK mixed cells, HEK cells, and HeLa
cells incubated with the semi-flexible PPB/HA for 1 h. ................................................................. 27

S2.1

DLS and zeta potential of the semi-flexible PPB/HA complex ...................................................... 31

S2.2

DLS and zeta potential of the control PPE/HA complex. ............................................................... 31

S2.3

Topography and phase images, size distribution, and height histograms for control PPE/HA. ...... 32

S2.4

Cytotoxicity of the core-shell nanoparticles. ................................................................................... 33

3.1

Chemical structures of glycosaminoglycans (GAGs). .................................................................... 38

3.2

Chemical structures of CPs with different side chains (P1 and P2), PPE with flexible backbone
(P3), and PPB with flexible backbone (P4)..................................................................................... 39

ix

3.3

Average hydrodynamic diameters of CPN-1, CPN-2, CPN-3, and CPN-4 upon complexation
with hyaluronic acid, chondroitin sulfate, dermatan sulfate, and heparin sulfate ........................... 41

3.4

Average size distributions of CPNs complexed with GAGs measured by NTA ............................ 41

3.5

Effect of GAG complexation on absorption and emission for CPN-1, CPN-2, CPN-3, and
CPN-4 in water. .............................................................................................................................. 43

3.6

Hierarchical cluster analysis (HCA) of CPN-2+GAGs in water. .................................................... 44

3.7

Emission spectra of CPN-1, CPN-2, CPN-3, and CPN-4 in the presence of GAG-containing
urine simulant.................................................................................................................................. 45

3.8

An LDA plot between two largest canonical correlations of emission intensity ratios of CPNs
with and without GAGs in a urine simulant. ................................................................................... 45

S3.1

Absorption and emission spectra for P2 in DMF ............................................................................ 52

S3.2

1

S3.3

Absorption and emission spectra for CPN-2 in water. .................................................................... 53

S3.4

1

S3.5

FT-IR of P2. .................................................................................................................................... 54

S3.6

Absorption and emission spectra for P3 in DMF. ........................................................................... 54

S3.7

1

S3.8

Absorption and emission spectra for CPN-3 in water. .................................................................... 55

S3.9

1

S3.10

FT-IR of P3. .................................................................................................................................... 56

S3.11

NTA of CPN-1 in water .................................................................................................................. 57

S3.12

NTA of CPN-2 in water .................................................................................................................. 57

S3.13

NTA of CPN-3 in water .................................................................................................................. 58

S3.14

NTA of CPN-4 in water .................................................................................................................. 58

S3.15

Zeta potential of CPN-1 in water .................................................................................................... 59

S3.16

Zeta potential of CPN-2 in water .................................................................................................... 59

S3.17

Zeta potential of CPN-3 in water .................................................................................................... 59

S3.18

Zeta potential of CPN-4 in water .................................................................................................... 60

H NMR (400 MHz) of P2 in DMSO-d 6 . ....................................................................................... 53

H NMR (600 MHz) of CPN-2 in D 2 O........................................................................................... 53

H NMR (400 MHz) of P3 in DMSO-d 6 . ....................................................................................... 55

H NMR (600 MHz) of CPN-3 in D 2 O........................................................................................... 56

x

4.1

Chemical structures of PPEs with (PPE-1) and without (PPE-2) biodegradable linkers in
the backbone and a schematic illustration of cellular entry and mitochondria localization
of biodegradable CPNs. CPN-1and CPN-2 were fabricated with the corresponding PPEs via
self-assembly in water. .................................................................................................................... 66

4.2

Microscopic images of HeLa cells incubated with CPNs for 18 h followed by mitochondria
and nuclear staining. ....................................................................................................................... 68

4.3

Confocal microscopic images of HeLa cells incubated with CPN-1 0.2 µM and 2 µM for
18 h followed by mitochondria staining. ......................................................................................... 69

4.4

Absorption and emission spectra of CPN-1 treated with 10 mM glutathione (GSH) for 0 and
18 h at 37˚C..................................................................................................................................... 69

4.5

Microscopic images of HeLa cells incubated with CPN-3 for 18 h followed by mitochondrial
and nuclear staining ........................................................................................................................ 70

4.6

Confocal microscopic images of HeLa cells incubated with CPN/HA for 18 h followed
by mitochondria and nucleus staining... .......................................................................................... 71

4.7

Fluorescence analysis of mitochondrial and cytosolic fractions of HeLa cells incubated with
CPNs .............................................................................................................................................. 72

4.8

Endocytosis inhibition study under pharmacological inhibitors treatments .................................... 73

4.9

Time-course localizations of A) CPN-1 and B) CPN-2 on endosomes and mitochondria .............. 74

S4.1

1

S4.2

13

S4.3

1

S4.4

1

S4.5

31

S4.6

FT-IR of PPE-1-Br .......................................................................................................................... 84

S4.7

FT-IR of PPE-1 ............................................................................................................................... 85

S4.8

UV-vis and emission spectra of PPE-1-Br in DCM. ....................................................................... 85

S4.9

UV-vis and emission spectra of PPE-1 in DMSO. .......................................................................... 86

S4.10

UV-vis and emission spectra of CPN-1 1% DMSO in water (v/v).. ............................................... 86

S4.11

1

S4.12

1

S4.13

31

H NMR of M3 in DMSO-d 6 .......................................................................................................... 79
C NMR of M3 in DMSO-d 6 ......................................................................................................... 80

H NMR of PPE-1-Br in CDCl 3 ..................................................................................................... 82
H NMR of PPE-1 in DMSO-d 6 . .................................................................................................... 83
P NMR of PPE-1 in in DMSO-d 6 ................................................................................................ 84

H NMR of PPE-2-Br in CDCl 3 ..................................................................................................... 88
H NMR of PPE-2 in DMSO-d 6 . .................................................................................................... 89
P NMR of PPE-2 in in DMSO-d 6 ................................................................................................ 89

xi

S4.14

FT-IR of PPE-2-Br .......................................................................................................................... 90

S4.15

FT-IR of PPE-2 ............................................................................................................................... 90

S4.16

UV-vis and emission spectra of PPE-2-Br in DCM. ....................................................................... 91

S4.17

UV-vis and emission spectra of PPE-2 in DMSO. .......................................................................... 91

S4.18

UV-vis and emission spectra of CPN-2 1% DMSO in water (v/v).. ............................................... 92

S4.19

1

S4.20

1

S4.21

31

S4.22

UV-vis and emission spectra of PPE-3-Br in DCM. ....................................................................... 95

S4.23

UV-vis and emission spectra of PPE-3 in DMSO. .......................................................................... 95

S4.24

UV-vis and emission spectra of CPN-3 1% DMSO in water (v/v).. ............................................... 96

S4.25

NTA for CPN-1 ............................................................................................................................... 97

S4.26

NTA for CPN-1/HA ........................................................................................................................ 98

S4.27

NTA for CPN-2............................................................................................................................... 98

S4.28

NTA for CPN-2/HA ........................................................................................................................ 99

S4.29

NTA for CPN-3 ............................................................................................................................... 99

S4.30

Zeta potential for CPN-1 ............................................................................................................... 100

S4.31

Zeta potential for CPN-1/HA ........................................................................................................ 100

S4.32

Zeta potential for CPN-2 ............................................................................................................... 100

S4.33

Zeta potential for CPN-2/HA ........................................................................................................ 101

S4.34

Zeta potential for CPN-3 ............................................................................................................... 101

S4.35

Cellular toxicity of CPN-1, CPN-2, and CPN-3 ........................................................................... 103

S4.36

Microscopic images of HeLa cells incubated with CPN-2 for 18 h followed by endosome
and nuclear staining ...................................................................................................................... 104

S4.37

Fluorescent intensity plots obtained at the FL2 channel ............................................................... 106

5.1

Chemical structures CPNs grafted with folic acid-modified PEG 2000 (CPN-PEG 2000 -FA) and
PEG 2000 only (CPN-PEG 2000 ) ....................................................................................................... 111

5.2

Absorption and emission spectra for CPN-PEG 2000 -FA and CPN-PEG 2000 in water.................... 112

H NMR of PPE-3-Br in CDCl 3 ..................................................................................................... 93
H NMR of PPE-3 in DMSO-d 6 . .................................................................................................... 94
P NMR of PPE-3 in in DMSO-d 6 ................................................................................................ 94

xii

5.3

Cellular uptake of CPN-PEG 2000 -FA and CPN-PEG 2000 complexed with 40 kDa and 100 kDa
HA at various ratios after 18 h incubation .................................................................................... 114

5.4

Plot of fluorescence intensities of CPN vs incubation time at optimized formulation of
CPN/HA showing six-fold enhancement of CPN-PEG 2000 -FA uptake and three-fold
enhancement of CPN-PEG 2000 ...................................................................................................... 116

5.5

UV-absorption and emission spectra for CPN-PEG 2000 -FA and CPN-PEG 2000 complexed
with 40 kDa HA at 1:1 and 1:2 molar ratios ................................................................................. 116

5.6

Mean sizes and size distributions as measured by NTA of CPN/HA complexes.......................... 117

5.7

Effect of endocytosis inhibitors of CPN-PEG 2000 -FA and CPN-PEG 2000 ..................................... 118

5.8

High-resolution fluorescence microscopic images of blue and red channel overlay, and
contrast images of cellular uptake in HeLa cells for CPN-PEG 2000 -FA, CPN-PEG 2000 -FA/HA,
CPN-PEG 2000 , and CPN-PEG 2000 /HA .......................................................................................... 119

S5.1

1

S5.2

UV-vis absorption spectra of folic acid in the supernatant showing complete removal of folic
acid from CPN PEG 2000 -FA solution via dialysis ......................................................................... 131

S5.3

FT-IR spectra of PPE1 and CPN-PEG 2000 -FA .............................................................................. 132

S5.4

1

S5.5

1

S5.6

FT-IR spectra of PPE2 and CPN-PEG 2000 .................................................................................... 135

S5.7

1

S5.8

1

S5.9

13

S5.10

IR Spectrum of M2 showing –N 3 stretch at 2095.8 cm-1 .............................................................. 140

S5.11

13

S5.12

1

S5.13

13

S5.14

1

S5.15

13

S5.16

1

S5.17

13

H NMR spectra of PPE1 and CPN-PEG 2000 -FA in DMSO-d 6 .................................................... 130

H NMR spectrum of PPE2 in DMSO-d 6 ..................................................................................... 134
H NMR spectrum of CPN-PEG 2000 in DMSO-d 6 ........................................................................ 134

H NMR spectrum of M1 in CDCl 3 . ............................................................................................. 139
H NMR spectrum of M2 in CDCl 3 . ............................................................................................. 139
C NMR spectrum of M2 in CDCl 3 . ............................................................................................ 140

C NMR spectrum of M1 in CDCl 3 . ............................................................................................ 141

H NMR spectrum of 7 in DMSO-d 6 ............................................................................................ 141
C NMR spectrum of 7 in DMSO-d 6 ........................................................................................... 142

H NMR spectrum of 8 in DMSO-d 6 ............................................................................................ 142
C NMR spectrum of 8 in DMSO-d 6 ........................................................................................... 143

H NMR spectrum of 9 in DMSO-d 6 ............................................................................................ 143
C NMR spectrum of 9 in DMSO-d 6 ........................................................................................... 144

xiii

S5.18

1

S5.19

13

S5.20

1

S5.21

Absorption and emission spectra for PPE2 in THF ...................................................................... 146

S5.22

Zeta potential for CPN-PEG 2000 -FA (a) and CPN-PEG 2000 (b). ................................................... 146

S5.23

Toxicity of CPNs toward HeLa cells ............................................................................................ 147

S5.24

Quenching experiment of CPN-PEG 2000 -FA and CPN-PEG 2000 with trypan blue ....................... 147

S5.25

Representative scatterplots and intensity plots for optimized conditions for
CPN-PEG 2000 -FA/HA and CPN-PEG 2000/ /HA.............................................................................. 148

H NMR spectrum of 10 in DMSO-d 6 .......................................................................................... 144
C NMR spectrum of 10 in DMSO-d 6 ......................................................................................... 145

H NMR spectrum of 1:1 mixture of M3 and 10 in DMSO-d 6 ..................................................... 145

xiv

LIST OF SCHEMES
SCHEME

PAGE

S2.1

Synthesis of control PPE without flexible linker ............................................................................ 29

S3.1

Synthetic route to P2 ....................................................................................................................... 49

S3.2

Boc-deprotection of P2 to yield CPN-2 .......................................................................................... 49

S3.3

Synthetic route to P3 ....................................................................................................................... 50

S3.4

Boc-deprotection of P3 to yield CPN-3 .......................................................................................... 50

4.1

TPP (R1)-containing polymers with (PPE-L) and without (PPE) biodegradable linker and
boronate-moiety (R2). ..................................................................................................................... 75

S4.1

Synthetic route to M1 ...................................................................................................................... 76

S4.2

Synthetic route to M2 ...................................................................................................................... 77

S4.3

Synthetic route to M3 ...................................................................................................................... 78

S4.4

Synthetic route to PPE-1 ................................................................................................................. 80

S4.5

Synthetic route to PPE-2 ................................................................................................................. 87

S5.1

Synthesis of monomers (M1, M2) and heterodifunctional PEG2000 (M3) .................................. 124

S5.2

Synthesis of water-soluble PPE1 from readily available monomers via Sonogashira coupling
and grafting to yield CPN-PEG 2000 -FA......................................................................................... 129

S5.3

Click reaction of alkyne end-functionalized PEG 2000 onto azide end-functionalized PPE2 to
yield CPN-PEG 2000 . ...................................................................................................................... 133

xv

ABBREVIATIONS AND ACRONYMS
AA

acetic acid

AFM

atomic force microscopy

Boc

t-butyl carbamate

BTz

benzothiadiazole

CD44

Cluster Determinant 44 receptor

CMC

carboxymethyl cellulose

CME

clathrin-mediated endocytosis

CvME

caveolae-mediated endocytosis

CP

conjugated polymer

CPE

conjugated polymer electrolyte

CPN

conjugated polymer nanoparticle

CS

chondroitin sulfate

DCM

dichloromethane

DIPA

N,N-diisopropylamine

DLS

dynamic light scattering

dppf

1,1′-bis(diphenylphosphino)ferrocene

DMF

dimethylformamide

DMSO

dimethylsulfoxide

DS

dermatan sulfate

EtOH

ethanol

EPR

enhanced permeability and retention

EO

ethylene oxide

FDA

Food and Drug Administration

FA

folic acid

FR

folate receptor

FRET

fluorescence resonance energy transfer

xvi

FT-IR

Fourier transform infrared spectroscopy

GPC

gel permeation chromatography

GSH

glutathione

HA

hyaluronic acid

HBT

homo-coupled benzothiadiazole

HEK

human embryonic kidney

HeLa

human cervical carcinoma

HS

heparin sulfate

HOMO

highest occupied molecular orbital

HR-MS

high-resolution mass spectrometry

ISC

intersystem crossing

i

PrOH

isopropyl alcohol

LDA

linear discriminant analysis

LUMO

lowest unoccupied molecular orbital

MeCN

acetonitrile

MeOH

methanol

Mn

number average molecular weight

MPC

macropinocytosis

Mw

weight average molecular weight

m/z

mass-to-charge ratio

NMR

nuclear magnetic resonance

NP

nanoparticle

NTA

nanoparticle tracking analysis

OD

optical density

PA

poly(acetylene)

PCC

Pearson’s correlation coefficient

PEDOT

polyethylene-doxythiophene

xvii

PEG

polyethylene glycol

PDI

polydispersity index

Pd[Cl 2 (PPh 3 ) 2 ] bis(triphenylphosphine)palladium(II) dichloride
Pd(OAc) 2

palladium(II) acetate

Pd[(PPh 3 ) 4 ]

tetrakis(triphenylphosphine)palladium(0)

PPB

poly(p-phenylenebutadiynylene)

PPE

poly(p-phenyleneethynylene)

PPP

poly(p-phenylene)

PPV

poly(p-phenylenevinylene)

PPy

polypyrrole

PT

poly(thiophene)

PTFE

polytetrafluoroethylene

QY

quantum yield

R

substituent

RES

reticuloendothelial system

RHAMM

receptor for HA mediated motility

SEC

size exclusion chromatography

rt

room temperature

TEA

triethylamine

TFA

trifluoroacetic acid

THF

tetrahydrofuran

TPP

triphenylphosphonium

UV-Vis

ultraviolet-visible

xviii

CHAPTER I

Introduction

1

1.1

Materials chemistry

Synthetic polymeric materials have gained significant use as biological materials (biomaterials) in biomedical
and pharmaceutical applications. As a result, a demand for well-defined polymers with tunable properties
has emerged. The method of system’s materials chemistry utilizes the investigation of the interactions
between components of a system, to understand how those interactions drive the function and performance
of the overall system.1 The development of functional materials is built on rational design,
synthesis/fabrication, and systematic characterization of properties. In order to design a material for a desired
application successfully, an in-depth understanding of the structure-function relationship is crucial. This
understanding allows the development of a material that possesses the necessary and desired properties. More
importantly, an understanding of how those properties relate to a material’s chemical and physical structures.
The systematic approach to material design is essential as it is no longer effective to isolate only one
component to solve complex scientific challenges. As advances in effective material development occur, it
is increasingly evident that these advances are only achieved when an integrated approach is employed.
1.2

Challenges for polymeric biomaterials

Biomaterials are defined as substances other than food or drugs used for therapeutic and diagnostic
applications that can be composed of both natural and synthetic components.2 Biomaterials are usually
polymeric to address the biological, physical, and chemical demands of their applications. These biomaterials
have been at the forefront of treating diseases and improving healthcare, and are most often biologically
derived or inspired molecules. Modern biomaterials have been used as synthetic and natural replacements for
biological tissues, materials for medical device implantation, carriers for drug delivery systems, and materials
for array-based sensing for diagnostic applications.2 However, these materials still suffer from issues with
biocompatibility, mechanical properties, and proper degradation. There are several specific biological
challenges that need to be addressed to further biomaterial development (discussed in additional in section
1.9), including targeting materials for drug delivery to specific cells and organelles, materials for sensing
various biochemical signals, and strategies for improved biocompatibility of materials. Synthetic materials,
such as polymers, offer a simple and effective approach to address these issues. The synthetic versatility of
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polymeric materials allows an opportunity to understand the structure-property relationship of materials and
their cellular interactions.
1.3

Conjugated polymers

A novel class of polymeric biomaterials are conjugated polymers (CPs), which are polyunsaturated and
consist of a backbone chain of alternating single and double (or triple) bonds.10 Examples of CPs are depicted
in Figure 1.1. The semi-conductive properties of CPs are the result of the electronic conjugation of
delocalized pi (π) electrons (generalized example shown in Figure 1.2) along the backbone, which provides
these compounds with desirable physiochemical and excellent photophysical properties, including inherent
fluorescence.11 The energy band gap is defined by the highest occupied molecular orbital (HOMO) and lowest
unoccupied molecular orbital (LUMO) formed from the sp and sp2 hybridized carbon atoms along the
conjugated backbone and is the origin of the photophysical and semi-conductive properties.4

O
n

polyacetylene
(PA)

S

n

polythiophene
(PT)

N
H

n

O

S

n

polyethylenedioxythiophene
(PEDOT)

polypyrrole
(PPy)

n

poly(para-phenylene)
(PPP)

n
n

poly(para-phenylenevinylene)
(PPV)

poly(para-phenyleneethynylene)
(PPE)

Figure 1.1. Common examples of conjugated polymers.
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Figure 1.2. Example configuration of delocalized electrons of a π conjugated system.

Recently, CPs have been applied to several electronic and sensing applications, including solar cells, lightemitting diodes, and a variety of chemical and biological sensors.12-16 While these applications encompass a
wide variety of CPs, the Moon research group focuses on poly(para-phenyleneethynylene) (PPE) and
poly(para-phenylbutadiynylene) (PPB)-based polymers, because of their ease of synthesis, for biological
applications including cellular imaging, cancer cell targeting and labelling, and sensing of biologically
important substances. The synthetic versatility of CPs allow easy modification of the conjugated backbone
to tune emission and side chain structures to adjust biocompatibility through increased water solubility,
controlled biodegradability, and incorporation of targeting units.
1.3.1

Synthesis

The backbone and side chain structures of CPs gives rise to unique properties. The conjugated backbone
provides a structural platform for tuning the electronic properties, and side chain structure can be used to
modulate hydrophobicity/hydrophilicity and provide functionalization. The synthesis of PPEs and PPBs
utilizes the cross-coupling reactions of Sonogashira and Glaser, respectively. The Sonogashira reaction uses
a palladium catalyst, with a catalytic amount of copper and base, to couple an aryl (or vinyl) halide to a
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terminal alkyne, and has been shown to be very versatile.10 Glaser coupling is used for homocoupling of
terminal acetylenes in the presence of a copper catalyst under an oxygen-rich environment. Glaser coupling
also occurs with the Sonogashira reaction and results in a homocoupled side product when nonoxidative
conditions are not maintained. Generalized reactions for PPE and PPB synthesis using Sonogashira and
Glaser coupling, respectively, are shown in Figure 1.3.
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Figure 1.3. Sonogashira and Glaser coupling for PPE and PPB synthesis, respectively.
1.3.2.

Photophysics

In an ideal environment (i.e., organic solvent, contaminant-free), CP chains are well-solvated and exhibit
photophysical properties originating from the delocalized electrons along the conjugated backbone.2 These
delocalized π electrons (depicted in Figure 1.2) are responsible for the characteristic absorption of light and
subsequent relaxation from excited electronic states via fluorescence.3 The intrinsic fluorescence makes CPs
an advantageous choice over other macromolecules, specifically for sensing and imaging applications. The
semi-conductive and photophysical properties of CPs are driven by the HOMO-LUMO gap, which is also
responsible for the wavelength of absorbed and emitted light. These processes can be described by a Jablonski
diagram (Figure 1.4), which represents the energy states of a molecule’s electrons and the transitions between
states.5 When a molecule absorbs light, the electron in the ground singlet state (S 0 ) is excited to a vibrational
level in the excited singlet state (S 1 ), in a rapid process (~10-15 s). The excess in energy can be released in
several ways to return back to the ground state. Through internal conversion via non-radiative decay, the
excited electron relaxes to the lowest vibration level of the excited singlet state (S 1 ). In fluorescence, the
excited electron returns to the ground state (S 0 ) by emitting a photon, which is a fast (~10-9 s) and favorable
process, and responsible for the desirable photophysical properties of CPs. An alternative pathway for an
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excited electron to return to the ground state is via phosphorescence, where the electron undergoes
intersystem crossing (ISC) and spin-forbidden electronic transitions in a much slower process (~10-3 s). The
emission efficiency, or fluorescence brightness, is quantified using the quantum yield, which is the ratio of
photons emitted to photons absorbed. The brightness of new fluorescent materials is determined relative to a
known bright standard.
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Figure 1.4. Jablonski diagram showing the various processes when a molecule is irradiated by light.

1.4

Conjugated polymer nanoparticles

For biological applications, CPs must be compatible with aqueous environments. Because of the hydrophobic
nature of the conjugated backbone, ionic and hydrophilic side chains can be incorporated to achieve the
necessary aqueous solubility. When a CP dissolved in an organic solvent is added to an excess amount of
aqueous solvent, the hydrophobic CP chains aggregate and form nanoparticles. These CP nanoparticles (i.e.,
CPNs) are then purified via dialysis to remove the organic solvent. This type of nanoparticle (NP) preparation
is termed the reprecipitation method, and the resulting NPs are in the range of 5-150 nanometers (nm) in
diameter.6 The process of how CP chains aggregate and self-assemble in an aqueous environment is driven
by the hydrophobic backbone where both inter-chain aggregation and intra-chain collapse can occur. While
the hydrophobic effect is the main driving force of NP formation, the nature of polymer chain self-assembly
can be modulated by the side chain structure, where ionic groups can cause repulsion between chains and
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increased hydrophilicity can improve solubility. Recently, Ko et al. demonstrated controlled chain-chain
interactions of CPNs fabricated from primary amine-containing PPEs as exhibited by different aggregation
structures and photophysical properties determined by organic acid treatment of the CPs.28 The different
aggregation structures were the result of minimal π-π stacking in loosely aggregated CPNs treated with mild
acetic acid (AA) and extensive π-π stacking in densely aggregated CPNs treated with dicarboxylic tartaric
acid (TA). The resulting aggregation state of CPNs is, therefore, a cooperative assembly determined by the
π-π stacking, hydrogen bonding, and the interplay of hydrophobic, van der Waals, and electrostatic forces.8
In addition, NP formation can be adjusted on the basis of polymer stock concentration and molecular
weight/distribution of the polymer.7
1.5

Polymer characterization

To understand the structure-function relationship for a material and its application, it is necessary to
characterize the structure properly, which can be achieved using a variety of techniques. After synthesis and
purification, the polymer’s molecular weight is determined by gel permeation chromatography (GPC), which
is a type of size exclusion chromatography (SEC) and the most convenient method for use with polymers.9
The technique of GPC is a physical chromatographic separation determined by size, where larger molecules
pass through the porous column more rapidly than smaller molecules that elute slowly as they are retained
within the pores of the column. The molecular weight distribution is determined relative to standards (i.e.,
polystyrene or polyethyleneglycol) and described by the weight average molecular weight (M w ), number
average molecular weight (M n ), and polydispersity index (PDI). An example GPC chromatogram is depicted
in Figure 1.5.
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Figure 1.5. Example GPC chromatogram illustrating molecular weight distribution.
The chemical structure of a polymer can be ascertained quantitatively using nuclear magnetic resonance
(NMR) spectroscopy, which is an analytical structure determination method. The basic principles of NMR
rely on the changes in magnetic moments of magnetically active nuclei, such as 1H, 13C, 19F, and 31P, when
exposed to a radio frequency and a strong external magnetic field. The energy that is emitted upon relaxation
of the excited nuclei is characteristic to the nuclei themselves and the chemical environment they are exposed
to within the molecule. The NMR spectrum provides information about the proportion of nuclei generating
the signal given by the integrated area under each peak, and the nature of neighboring nuclei given by the
splitting pattern of the peak. The technique of NMR is a very powerful structural elucidation technique,
however, it provides structural information for the average polymer rather than exact structures of individual
polymer chains.

The presence of certain functional groups in a polymer can be determined using Fourier Transform-Infrared
(FT-IR) spectroscopy, which is a qualitative technique that provides structural information about the bonds
between atoms within a molecule. When IR radiation is passed through a sample, it is absorbed and
transmitted on the basis of frequencies of vibrations between the bonds of atoms present in the sample. The
absorption region is characteristic of a functional group as the radiation is characteristic of that bond and can
be used to confirm the presence or absence of certain groups in monomer and polymer samples.
1.6

Polymer self-assembly characterization

While chemical structure characterization is critical for developing new materials, it is crucial to understand
how that material exists in solution and, eventually upon interaction with biological interfaces. This will
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ultimately determine how well the material will perform its function and provide information to understand
structure-property relationship. The absorption and emission profiles of PPE- and PPB-containg CPNs are
characteristic of the electronic states of the polymer structure (discussed in section 1.5), which are generally
broad compared to small molecules, and more defined compared to PPV polymers due to the rigidity of the
conjugated backbone. The absorption and emission wavelength maxima are characteristic of the type of
conjugated backbone and conjugation length, this is the result of the configuration of the delocalized π
electron cloud (discussed in section 1.3). As conjugation length increases, the HOMO-LUMO gap decreases
and results in a bathochromic shift (towards red) of the wavelength maxima.
The effect of π-π stacking between polymer chains also drives the wavelength maxima and shape of
absorption and emission profiles. The CP chains can be compared to that of small organic dyes that exhibit
specific superstructures, J and H aggregates, as shown in Figure 1.6. When the delocalized π electron cloud
of neighboring polymer chains align face-to-face, there is a hypsochromic shift (towards blue) in wavelength
maxima due to an increase in energy between the HOMO and LUMO, this is called an H aggregate.35 In
comparison to when neighboring polymer chains align end-to-end, there is a bathochromic shift because of
a decrease of the HOMO-LUMO gap, this is called a J aggregate.35 Red shifting in wavelength maxima also
occurs when there is strong π-π stacking between polymer chains, which causes an increase in effective
conjugation length that decreases the HOMO-LUMO gap. Absorption and emission spectra are indicative of
polymer self-assembly, and used to observe and understand the changes in polymer aggregation when
external stimuli are applied (i.e., solvent, pH, salt concentration, or polyanions).
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Figure 1.6. Schematic representation of the spectral shift in H and J-aggregates based on chromophore
arrangement.
Absorption of light is not only characteristic of a material’s electronic states, but also the concentration of
absorbing molecules in solution. The absorbance (A) of a solution is defined as the logarithm ratio of incident
light (I 0 ) to transmitted light (I) and is described by the Beer-Lambert law:
𝑨𝑨 = 𝒍𝒍𝒍𝒍𝒍𝒍𝟏𝟏𝟏𝟏

𝑰𝑰𝟎𝟎
𝑰𝑰

= 𝜺𝜺𝜺𝜺𝜺𝜺

(Eq. 1.1)

where ε is the molar absorptivity (i.e.; an intrinsic property of the absorbing material) in mol-1·L·cm-1, l is
the path length of the absorbing solution in centimeters (cm), and c is the concentration of absorbing
material in mol·L-1.
In addition to characterizing the structural and photophysical properties of polymer self-assembly, it is
important to characterize the physical properties of the polymer nanoparticle. These properties will also
provide insight into understanding the material’s function and performance. Dynamic light scattering (DLS),
also called photon correlation spectroscopy, is a technique used to determine particle size by measuring the
intensity of light scattered by particles in suspension. Light is scattered after the interaction with the electric
field of a particle, which causes an incident photon to induce an oscillating dipole in the electron cloud and
radiation is dispersed in all directions as the dipole changes. The fundamental theory of DLS is built upon

10

the Brownian motion of spherical particles, which describes the random movements of particles because of
collisions caused by the solvent that surrounds those particles. The scattered light is recorded over time and
the correlation function is used to determine the mean size and polydispersity index, which is an estimate of
the distribution width. DLS relates the speed of the particles in terms of the diffusion constant to the particle
size as expressed by the Stoke-Einstein equation:
rh =

kT

6πηD

(Eq. 1.2)

where r h is the hydrodynamic radius, k is the Boltzmann constant, T is temperature in Kelvin, η is the solvent
viscosity, and D is the diffusion coefficient. The particle size, termed the hydrodynamic radius, is defined as
the radius of a hard sphere that diffuses at the same speed as the particle measured and is dependent on the
size of the particle core and the surface structure of the particle, including any ions in solution. Surface
structure is an important factor since the particle diffusion speed will be changed on the basis of the thickness
of the electric double layer of the particle.
The zeta potential (illustrated in Figure 1.7) is measured using electrophoresis, where the movement of a
charged particle relative to the medium under an applied electric field is recorded. The particle moves towards
the electrode of opposite charge and is opposed by viscous forces acting on the particle. When an equilibrium
is reached between these two forces, the particle moves with a constant velocity that is dependent on the
electric field strength, dielectric constant of the medium, viscosity of the medium, and zeta potential.
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Figure 1.7. Schematic representation of zeta potential of a negatively charged particle.

The velocity of the particle in an electric field is termed electrophoretic mobility and is related to the zeta
potential using the Henry equation:
UE =

2 ε Z f(κa)
3η

(Eq. 1.3)

where U E is the electrophoretic mobility, ε is the dielectric constant of the medium, Z is the zeta potential, η
is the viscosity of the medium, and f(κa) is the Henry’s function. For nano-sized particles in solution, or
colloids, the stability is dependent on the repulsive forces between the particles. Repulsion can be achieved
via steric repulsion, where adsorbed bulky groups prevent particles from coming into contact with each other,
and electrostatic stabilization, where particles are distributed on the basis of their like charges. In aqueous
suspensions, most colloids carry an electric charge, which can be the result of ionized surface groups,
differential loss of ions from the crystal lattice structure, and adsorbed charges species. The magnitude of the
zeta potential is a direct indication of particle stability; greater than +/- 30 mV is considered stable, and
indicative of the particle’s surface charge. The zeta potential provides important information about what is
happening at the interface of the material’s surface and its solution.
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While DLS is typically used to measure the bulk composition of particles in solution, it is only accurate for
monodispersed systems. Larger particles will scatter more light than smaller ones, and therefore, contribute
more to the overall size measurement. An emerging technique for analyzing single particles in a
polydispersed system is nanoparticle tracking analysis (NTA). A laser beam is passed through the sample
and the scattered light is captured by a charge-coupled device (CCD) camera mounted onto a microscope
that records a video at 30 frames per second.17 The software determines the displacement of individual
particles by tracking the x and y movement of each particle’s center, frame-by-frame. Once the displacement
is calculated, the diffusion coefficient and size are determined using the Stokes-Einstein equation (Eq. 1.1).
The technique of NTA is more favorable for polydispersed samples, like CPNs, and is capable of determining
size at much lower concentrations than DLS. However, DLS is a user friendly technique, with a short analysis
time, and provides reliable and consistent data since it measures the average sample.
1.7

Biological use of nanoparticles

Nanotechnology has made tremendous advancements for diagnostics, therapeutics, and imaging. The use of
nanoparticles offers several advantages over traditional delivery methods (i.e., free drugs) including
encapsulation, enhanced retention, controlled release, and reduced toxicity to off-target sites. In particular,
typical chemotherapeutics have a narrow therapeutic because of poor solubility, limited circulation time, and
cytotoxicity to healthy tissue. By using water-soluble polymers, nanoparticle-based drug delivery systems
can enhance aqueous solubility of therapeutics. Nanoparticles can be used to increase half-life and address
the pharmacokinetics issues to improve therapeutic effects. The tunability of nanoparticle structure is an
excellent platform to improve target-ability, in both reducing off-target effects, and enhanced retention and
accumulation in diseased tissue. Several nanocarrier therapeutics with a variety of formulations have been
approved by the Food and Drug Administration (FDA) for clinical trials and use, including inorganic
nanoparticles,20 liposomes, micelles,21 protein nanoparticles,22 polymeric micelles,23 polymer-drug
conjugates,24 and polymer nanoparticles.25 Nano-sized systems have a favorable small size that leads to
passive targeting and preferential delivery to diseased tissue because of the enhanced permeability and
retention (EPR) effect, as illustrated in Figure 1.8. The EPR effect arises as a consequence of the nature of
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tumor tissue, which is hypervascular, has up regulation of proangiogenic signaling, and poor lymphatic
drainage that allows for accumulation of large molecules (≥ 40 kDa) in the microenvironment.19 Additionally,
the small size has reduced side effects as nanoparticles escape recognition from the reticuloendothelial system
(RES) in healthy tissue.30

Healthy tissue

Lymphatic drainage

Bloodstream
Endothelial cells
Nanoparticles

Small molecules

Diseased tissue

Figure 1.8. Schematic representation of the enhanced retention and permeability (EPR) effect that occurs in
diseased tissue. Adapted from Stockhofe et al.36
1.7.1

Cellular uptake of nanoparticles

To develop materials for biological use, there are several barriers that must be traversed to be effective. The
first is the physiological barrier, where nanomaterials have been shown to easily traverse as a consequence
of their size. The second important barrier is the cellular barrier and in particular, the cell membrane. The
cellular membrane is responsible for the selective flow of ions and molecules into and out of the cell. Most
importantly, the cell membrane is responsible for the maintenance of separation between the cytosol and
extracellular environment.18 Extracellular molecules are selectively transported into the cell via endocytosis
pathways: phagocytosis (i.e., “cell-eating”), pinocytosis (i.e., “cell-drinking”), macropinocytosis (MPC), and
receptor-mediated endocytosis, including clathrin-mediated (CME) and caveolae-mediated (CvME).26 These
endocytosis mechanisms are based on the molecule’s size, properties, and internalization machinery.
However for most cell types, nanoparticles are internalized via MPC, CME, and CvME. The pathway of
MPC is a non-selective internalization of large volumes of extracellular medium where the cell membrane
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forms a pocket and pinches off a vesicle about 0.5-5 µm in diameter.31 The pathway of CME involves clathrincoated pits that form a polygonal clathrin lattice that bind ligands and molecules, where the clathrin-coated
pits pinch off clathrin-coated vesicles about 100-150 nm in size. The clathrin-coated vesicles depolymerize
going from early endosome to lysosome because of the drop in pH.31 The pathway of CvME involves small
hydrophobic domains with caveolin, which is a cholesterol binding protein. An approximately 50 nm
caveolar vesicle forms a caveosome and follows a non-acidic and non-digestive intracellular route.31
Depending on the mechanism of uptake, the cell will either recycle out or sort and traffic the nanoparticles
to a specific organelle for further processing.27 Recently, Mendez et al. demonstrated the subcellular
localization and toxicity of CPNs were dependent on the chemical structure of the side chains and conjugated
backbone.29 Cellular uptake and toxicity were modulated by adjusting amine-density of the side chain,
primary vs. tertiary, and hydrophilicity, primary amine vs. triethylene oxide. Therefore, it is important to
understand how the physicochemical and biophysical properties of nanocarriers affect the interaction with
the cell membrane, and subsequent uptake and trafficking. Synthetic nanoparticle systems have the unique
properties that allow for both passive and active targeting, making an excellent platform for improving
therapeutics.
1.8

Characterization of cellular interactions

The first step to characterize biophysical properties is to ensure the material is non-toxic to target cells. The
most commonly used assays measure viable cells, rather than dead cells, as there are several widely used and
high throughput methods established. In general, cells are treated with a compound that when metabolized
by viable cells forms a colored product that can be measured using a microplate reader, typically using
absorbance.
When determining quantitative cellular uptake of nanoparticles, flow cytometry is used. Briefly, a fluid
stream of cells is passed through a beam of light, and both fluorescence and scattered light are recorded.
Fluorescence intensity relative to the cell gives the quantitative uptake of the nanoparticle. Scattered light is
used to differentiate live cells from dead ones to obtain an accurate fluorescence value. Cellular uptake
pathways can be determined by pre-treating cells with commercially available pharmacological inhibitors.32
Clathrin-mediated endocytosis can be distinguished under a potassium depletion condition or by treating with
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chlorpromazine, which dissociates clathrin coated pits on the cell surface and disrupts the regulation of actin
cytoskeleton. Caveolae-mediated endocytosis can be distinguished when the presence of cholesterol is
disrupted. Methyl-β-cyclodextrin is known to deplete cholesterol from the plasma membrane by forming
inclusion complexes. Cholesterol is involved in both macropinocytosis and caveolae-mediated endocytosis.
Genistein inhibits tyrosine kinases that are involved in the pinching of caveolae. LY2994 inhibits
phosphatidylinositol 3-kinase, which recruits factors involved in macropinocytosis. Cytochalasin D inhibits
actin polymerization, leading to actin filament disassembly, and this disassembly affects both
macropinocytosis and caveolae-mediated endocytosis.32
Visualization of cellular uptake of fluorescent nanoparticles is achieved using high resolution microscopic
imaging. Trafficking and subcellular localization can be evaluated by co-staining with standard fluorescent
dyes as there are a wide variety of commercially available dyes to stain organelles. Co-localization of the
dyes (i.e.; green CPN and red commercial dye) is defined as the co-occurrence indicated by the spatial overlap
of the dyes. The correlation indicated by the co-distribution of the dyes in proportion to each other within
and between structures.33 To evaluate quantitatively co-localization, the Pearson’s Correlation Coefficient
(PCC) method is used to determine the degree of association between the dye signals on a pixel-by-pixel
basis. The PCC method takes into account the average intensity of each pixel and normalized so the PCC
score is independent of dye brightness and background signal. PCC values range from +1 and -1, indicating
perfectly linearly and inversely correlated, respectively.34
1.9

Summary

By exploring nanoparticles for biological use, a better understanding of the biological hurdles and ways to
improve nanoparticle design can be achieved. Nanoparticle design and improvement stems from a thorough
characterization of material composition, size, shape, surface modification, and flexibility, which will
ultimately determine biocompatibility. The aim of my dissertation is to better understand CPN structure and
aggregation, and how those structural features affect cellular interactions to establish a structure-function
relationship. Chapter 2 details the fabrication of core−shell nanoparticles using a semi-flexible cationic CPN
complexed with a polyanion, hyaluronic acid (HA), which has a high affinity towards receptor overexpressed
on cancer cells. The resulting fluorescent core−shell nanoparticles exhibited high cancer cell specificity with
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low adsorption to normal cells, compared to a rigid control CPN that formed random spherical complexes
with HA. The dramatic difference in ionic complex formation based on the flexibility of CPN backbone led
to the work in Chapter 3, which details a systematic investigation on the aggregation properties of CPNs that
vary by side chain and backbone structures in response to different biologically important anionic
polysaccharides. These differential interactions were analyzed using analytical statistical methods to
demonstrate that structurally diverse CPNs can be used for the differentiation of biological molecules in a
complex biological medium. Chapter 4 details the fabrication of a semi-flexible CPN modified with the
mitochondrial-targeting triphenylphosphonium (TPP) group. The subcellular localization and cellular
toxicity were affected by backbone flexibility and molecular weight, in a time-dependent fashion. In
accordance with Chapter 2, the TPP-containing CPNs were treated with HA to modulate solubility and
cellular interactions. Chapter 5 details the synthesis of dual-targeting red emissive CPNs grafted with folic
acid (FA) side chains and complexed with hyaluronic acid (HA). Modulation of uptake kinetics and amount
of internalized CPNs was achieved by the dual ligand-targeting CPNs designed for folate and hyaluronan
receptors.
1.10
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CHAPTER II

Fabrication of core-shell nanoparticles via controlled aggregation of semi-flexible conjugated polymer and
hyaluronic acid
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2.1

Abstract

Core-shell conjugated polymer nanoparticles (CPNs) were fabricated by complexing a semi-flexible
conjugated polymer (CP) with hyaluronic acid (HA). Incorporation of a small amount of flexible unit into
the rigid rod conjugated backbone introduces conjugated backbone reorganization under ionic complexation
to increase π-π interaction, resulting in core-shell nanoparticles with a hydrophobic core wrapped with a HA
shell. The core-shell nanoparticles exhibited no cellular toxicity and high cancer cell specificity with minimal
binding to normal cells.
2.2

Introduction

Recently, conjugated polymers (CPs) have attracted much attention for sensing,1−4 labeling,5−10 and
delivery11−13 of biological substances owing to their excellent photophysical and biophysical properties. CPs
are synthetic macromolecules containing fully conjugated π-electrons along the backbones, resulting in high
luminescence brightness, high photostability, and excellent energy transfer.14,15 By incorporating hydrophilic
polar side chains and functional entities such as sensing units or targeting ligands, various conjugated
polyelectrolytes (CPEs) and conjugated polymer nanoparticles (CPNs) have been synthesized and used for
biological applications in aqueous environments.16−18

The photophysical excellence and robustness of CP-based nanomaterials are typically useful for labeling
target cells or tissues. Biophysically, amphiphilicity of the CPEs and CPNs is important for cellular
interaction and subsequent cellular entry because the cell surface contains both negatively charged
proteoglycans and hydrophobic membrane lipids. Especially, particles with high surface-to-volume ratios
exhibit size, shape, and functional group-dependent cellular interactions and entry efficiency.19,20 Therefore,
functional modifications and structural modulations of CP-based nanomaterials are highly anticipated to
obtain desired biophysical properties for improved cellular applications.

Previously, we fabricated positively charged CPNs by treating a nonaqueous soluble, primary aminecontaining rigid rod CP with organic acids followed by dialysis.21,22 The aggregation structures of CPNs,
after complete removal of organic acids, were dependent on the nature of organic acids. Acetic acid treatment
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produced loose aggregation of rigid rod CP backbones, while increased π−π interactions among the
backbones were observed when the same batch of polymer was treated with tartaric acid (i.e., dicarboxylic
acid). From this observation, we hypothesized that if CPs containing flexible units along the backbones are
treated with polymeric acids, π−π interaction among the backbones will be dramatically increased because
the semiflexibility of the nonaqueous soluble backbones will help backbone reorganization to maximize
hydrophobic chain interaction. If complexation between the nonaqueous soluble CP and polyanion
contributes to increasing aqueous solubility of CPs, random complex formations is expected with no
significant spectral changes. To test this hypothesis and functionalize the CP with cancer cell-specific ligands,
we employed a linear polysaccharide, hyaluronic acid (HA), which contains N-acetyl-D-glucosamine and Dglucuronic acid units. HA has specific binding with cell surface receptors such as CD44 and RHAMM, which
are overexpressed in many cancer cells.23 Numerous cancer drugs and polymers have been modified with
HA for targeted drug and gene delivery.24−28

In this chapter, core-CP−shell-HA nanoparticles are obtained when semi-flexible CPs are treated with
polyanionic HA, while nonflexible CPs produce random complexes upon HA treatment. The core−shell
nanoparticles are nontoxic to cells and exhibit high cancer cell specificity through the specific binding of HA
to cancer cell surface receptors.

2.3

Results and Discussion

A semi-flexible poly(phenylenebutadiynylene) (PPB), which contains a small fraction of flexible
nonconjugating units along the rigid conjugated backbones, was prepared by following our published
method21 and used for the complexation with HA (Figure 2.1). The semi-flexible PPB was treated with
organic acids, dialyzed against water, and complexed with HA. The semi-flexible PPB exhibits characteristic
photophysical properties of the fully conjugated PPBs because the amount of nonconjugated unit is limited
(∼5−10%) not to perturb the π- electron conjugation along the backbone.
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Figure 2.1. (a) Chemical structure of the semi-flexible PPB. (b) A schematic presentation of structural
reorganization of the semi-flexible PPB upon HA complexation. The semi-flexible PPB in water was
prepared by deprotection of Boc group using organic acid treatments followed by dialysis.

The photophysical and physical properties of the semi-flexible PPB in water were similar to the
characteristics of loosely aggregated CPs with fully conjugated backbones. When the semi-flexible PPB was
mixed with HA, the resulting complex exhibited dramatic changes in both absorption and emission spectra.
As shown in Figure 2.2, a new strong absorption peak appeared at ∼474 nm (30 nm red-shifted upon

complexation) (Figure 2.2a), and the emission intensity of the complex decreased significantly (Figure 2.2b).
We believe that unlike complexes formed between conjugated rigid oligomers and polysaccharides, which
exhibit both red-shift and fluorescent increase through chain end-to-end alignment induced by linear
polysaccharides,29,30 the loosely aggregated, nonaqueous soluble PPBs connected with flexible linkers were
able to reorganize to increase interpolymer π−π interactions, similarly to the high molecular weight, fully
conjugated poly(phenyleneethynylene) (PPEs) at the air−water interface under mechanical forces.31 As a
control, a fully conjugated PPE containing the same amine side chains was treated with HA, and the
spectroscopic behaviors were monitored. We employed the structurally similar PPE as a control due to poor
solubility of PPB without flexible linkers. Upon complexation with HA, the control PPE exhibited only a
small increase in the absorption maximum (<5 nm) without a spectral shape change (Figure 2.2c), and the
fluorescent intensity decreased slightly (Figure 2.2d). This implies that no significant structural
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reorganization of PPE occurred upon HA complexation, supporting that the semiflexibility of PPB is
responsible for the significant spectral changes upon ionic complexation.

Figure 2.2 Absorbance and emission spectra of semi-flexible PPB (a, b) and rigid PPE (c, d) before and after
HA complexation. A sharp absorption peak at 474 nm (a) and decreased emission intensity of the semiflexible PPB after HA complexation supports the formation of ordered aggregation among the semi-flexible
conjugated backbones. No significant changes were observed upon HA complexation of the control PPE (c,
d).
While the hydrodynamic radius of the semi-flexible PPB at the low concentration (10 μM) could not be
determined due to insufficient scattering intensity from the loose aggregations, the ionic complexes produced
strong light scattering, implying the formation of dense particles. The hydrodynamic radius of the semiflexible PPB/HA complex was successfully determined to be 51.35 ± 0.77 nm. Zeta potential value of the
semi-flexible PPB/HA nanoparticles in water at neutral pH was −25.5 ± 11.7 mV (Supporting Information
Figure S2.1). The hydrodynamic radius of the control PPE/HA complex was determined to be 79.49 ± 0.18
nm, with a zeta potential of −32.6 ± 5.6 mV (Figure S2.2). The control PPE/HA was almost 30 nm larger
than the semi-flexible PPB/HA, implying that more loosely aggregated particles were formed.
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Atomic force microscopic (AFM) imaging of the semi-flexible PPB/HA nanoparticle supported the formation
of elongated core−shell nanoparticles with average size of 58 ± 13 nm (by measuring lateral sizes), as shown
in Figure 2.3c, while the semi-flexible PPB without HA complexation exhibited mixed particles with no
specific shapes (Figure 2.3a). AFM phase image also showed that core−shell particles were favorably formed
at a molar ratio of 1:3 of the semi-flexible PPB to HA. Both at the lower and higher ratios, no defined
core−shell nanoparticles were observed (Figure 2.4a). Higher density (represented as dark color) was
observed in the center of the nanoparticles, while lower density (bright color) was observed in the shell. Since
the particles were prepared on an aminosilanized mica surface, it is difficult to determine the shape and size
of the intact nanoparticles in water by the AFM imaging. The AFM images are believed to be flattened during
the sample preparation determined by the height analysis (Figure 2.4b). The topographic and phase images
of the control PPE/HA show circular particles with no core−shell shape, with an average size and height of
81 ± 9 and 4 ± 0.5 nm, respectively (Figure S2.3). The AFM imaging of the control PPE/HA further supports
that HA does not cause structural reorganization of rigid rod CPs.

Figure 2.3. AFM topographic (a, c) and phase (b, d) images of the semi-flexible PPB (a, b) and semi-flexible
PPB/HA nanoparticles formed at 1:3 molar ratio (c, d). The semi-flexible PPB/HA exhibits elongated
particles on a mica surface (c), and the phase image (d) reveals that the complexes are core−shell
nanoparticles.
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Figure 2.4. Topography and phase images (a) and size analysis histograms (b) of semi-flexible PPB, semiflexible PPB/HA (1:1), and semi-flexible PPB/HA (1:3), respectively.
Cancer cell specificity of the core−shell nanoparticle was examined by incubating various cells including
cancer and normal cells with the core−shell nanoparticles for different times, and the normalized mean
fluorescent intensity ratios to the control cells were plotted by analyzing flow cytometry data (Figure 2.5).
As shown in Figure 2.5, cancer cells overexpressing CD44 [i.e., human cervical carcinoma (HeLa) and
human pancreatic carcinoma cell lines (Panc-1)] exhibited an intensity increase as the incubation time
increased, while normal human embryonic kidney cells (HEK) and cancer cells with low CD44 expression
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exhibited low fluorescent intensity over the incubation times. The labeling specificity coincided well with
the CD44 expression levels, which were measured by incubating fluorescently labeled antibody against CD44
with various cells (inset of Figure 4). As expected, the core−shell nanoparticles exhibit no toxicity measured
by ATP consumption of the treated cells (Figure S2.4).

Figure 2.5. Normalized fluorescent mean intensity ratios of various cells treated with the semi-flexible
PPB/HA (1:3) up to 3 h. Cancer cells overexpressed CD44 (inset) exhibit higher fluorescent intensities than
those from cells with low CD44 expression, supporting specific labeling of cancer cells via HA−CD44
interaction.
The specific labeling of cancer cells by the core−shell particles was further confirmed by fluorescence
microscopic imaging of cancer cells co-cultured with normal HEK cells. Before co-culturing, HeLa cells
were pre-labeled with a fluorescent dye (CellTracker Red) to fluorescently distinguish the cancer cells from
normal cells. It is known that some fluorescent dyes have poor retention in the cell and can readily diffuse
through the cell membrane. CellTracker Red was used because it is converted into an impermeable dye by
forming covalent bonds inside cells. After incubating the cells for 1 h, the cells were rinsed, stained (for
labeling of nucleus), and fixed for microscopic imaging. Because the cancer cells possibly influence the
normal cell growth, each cell line was independently cultured and incubated with the core−shell nanoparticles
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under the same incubation condition. As shown in Figure 2.6, strong green fluorescent signals were observed
as scattered dots throughout the HeLa cells (pre-labeled with a red fluorescent dye), while much weaker
green signals were observed from the normal HEK cells, indicating that the core−shell nanoparticles
preferentially labeled HeLa cells through the specific HA−CD44 binding followed by endocytosis. For the
control cells cultured independently, HeLa cells exhibited many green fluorescent dots throughout the cytosol
(Figure 2.6, row 3), while the number and intensity of green dots observed from HEK were significantly low
(Figure 2.6, row 2).

Figure 2.6. Fluorescent microscopic (b−d) and contrast (a) images of HeLa/HEK mixed cells (1), HEK cells
(2), and HeLa cells (3) incubated with the semi-flexible PPB/HA for 1 h. HeLa cells were fluorescently prelabeled with a red dye (column c) before the core−shell nanoparticle incubation. Core−shell nanoparticles
were seen under the green channel (column b); the nuclei were stained with a blue dye; and merged images
were seen in column d. The core−shell nanoparticles preferentially labeled HeLa cells while exhibiting low
binding to normal HEK cell.
2.4

Conclusion

In summary, core−shell nanoparticles were fabricated by complexing a semi-flexible PPB with a linear
polysaccharide, HA. The resulting fluorescent core−shell nanoparticles exhibited high cancer cell specificity
with low adsorption to normal cells. Since the size and shape of nanomaterials significantly influence labeling
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and delivery efficiency of biological substances, the concept of core−shell nanoparticle formation through
controlled aggregation introduced in this work will contribute to novel biomaterials syntheses and
fabrications.

2.5

Outlook

This chapter presents a strategy for modulating particle shape using ionic complexation in a backbone
flexibility-dependent fashion. Since the publication of this work in Macromolecules, a systematic
investigation on ionic complexation of CPNs that vary by side chain and backbone structure was performed
(detailed in Chapter 3). The subcellular localization of amine-containing CPNs, including PPE and PPBbased, demonstrated side chain and backbone-dependent cellular uptake.32 The semi-flexible PPB polymer
showed increased Golgi uptake, compared to non-flexible amine-containing CPNs. The semi-flexible CPN
also showed improved uptake and accumulation, demonstrating that controlled subcellular localization leads
to enhanced internalization. The cellular uptake subcellular localization of the semi-flexible CPN complexed
with HA and a similar polyanion, carboxymethyl cellulose (CMC), was explored. While in this chapter, the
semi-flexible CPN displayed enhanced targeting of cancer cells over normal cells, there was no significant
increase in internalization of the polyplexes with HA and CMC. Complexation of the semi-flexible CPN with
HA and CMC led to increased accumulation in late endosome/lysosome as expected based on the dramatic
changes from spherical to core-sell particles. While HA complexation leads to increased labelling of cancer
cells, a strategy to improve targeting and increase internalization of CPNs is needed. A dual ligand approach
for targeting of folate and hyaluronan receptors is detailed in Chapter 5.
2.6

Experimental

Atomic force microscopy (AFM) experiments and analysis were performed by Namuna Panday. Toxicity
assays and flow cytometry experiments were performed by Yoonmi Na. Microscope imaging and processing
was completed by Dr. Eladio Mendez.
2.6.1

General: Chemicals and solvents were purchased from Fisher Scientific and used as received.

Deuterated solvents were purchased from Cambridge Isotope Laboratories (Cambridge, MA). Molecular
weight was determined using gel permeation chromatography (GPC) against polystyrene standards on a
Shimadzu HPLC system equipped with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet-visible
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(UV-vis) detector. The purification of the CPN was conducted using an Ultrafiltration Stirred Cell (Millipore)
with a 30 kDa molecular weight cut-off (MWCO) membrane (Ultracel ultrafiltration disc). UV-Vis spectrum
was recorded using Varian Cary 50 Bio spectrophotometer. Fluorescence spectrum was obtained using a
FluoroLog-3 Spectrofluorometer (Jobin Yvon/Horiba). NMR spectrum was recorded on a 600 MHz Avance
Bruker NMR spectrometer using a 5 mm BBI probe at 298 K. Fourier transform infrared (FT-IR) spectrum
was obtained on a PerkinElmer Spectrum 100 FT-IR Spectrometer, using sample mounted on an attenuated
total reflection cell.
2.6.2

Synthesis of control PPE without flexible linker: A Schlenk ﬂask was charged with M1 (41mg,

0.056, 1.0 equiv) and M2 (30 mg, 0.056 mmol, 1.0 eqiv) and, along with Pd[(PPh 3 ) 2 Cl 2 ] (4 mg, 0.0056 mmol
,0.1 equiv) and CuI (0.3 mg, 0.0028 mmol , 0.05 equiv), as shown in Scheme S2.1.
Scheme S2.1. Synthesis of control PPE without flexible linker.

The Schlenk ﬂask was evacuated and ﬁlled with N 2 three times. A solution of anhydrous dimethylformamide
(DMF) (4 mL) and freshly distilled triethylamine (1 mL) was degassed, and 1 mL of the mixed solution was
transferred to the Schlenk ﬂask using a cannular needle. The reaction was heated at 70 °C for 14 h. The
solution was then cooled to room temperature and transferred dropwise to cold ether, resulting in
precipitation. After centrifugation (5 min, 4000 rpm), the supernatant was decanted, the precipitate was
collected and dried to yield product. Yield: 44mg, 73%. 1H NMR (400 MHz, DMSO-d 6 , δ): 7.16 (s, 1H, ArH), 6.72 (s, 0.2H, NH-Boc), 4.21 (br, 1.84H, Ar-OCH 2 ), 3.80 (br, 2.16H, CH 2 O), 3.66 (br, 1.34H, OCH 2 ),
3.52 (br, 2.22H, CH 2 NH), 1.37 (s, 7.33H, C(CH 3 ) 3 ); FT-IR (Neat): ν = 3366 (br), 2933 (w), 2865 (s), 1704
(vs; C=O), 1507 (vs), 1457 (w), 1423 (w), 1365 (s), 1277 (w), 1247 (w), 1219 (s), 1172 (w), 1108 (s), 1057
(s), 1026 (w), 945 (s), 860 cm−1 (m); UV-vis (DMF): λ max 432 nm; ﬂuo λ max (400nm ex) =475 nm; QY =
37%; GPC Mn: 11.6 kDa, Mw: 16.4 kDa , PDI: 1.41.

Deprotection of Boc groups was carried out by mixing the polymer solution with acetic acid (2 mL) and
triﬂuoroacetic acid (1 mL) and allowed to stir at room temperature for 14 days. The mixture was then added
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to acetic acid (20 mL), allowed to stir overnight, and centrifuged, and supernatant was added drop wise (2
drops/s) to 500 mL water (18 Ω) while stirring. Using a solvent-resistant stir cell ﬁtted with a 30 kDa-MWCO
membrane, the solution was concentrated to approximately 10 mL, and dialyzed against 1 L of water. The
resulting solution was further dialyzed in a 10 KDa membrane for 3 days. 1H NMR (600 MHz, D 2 O, δ): 7.03
(br, 1H, Ar-H), 4.24-2.76 (br, 10.74H, CH 2 CH 2 OCH 2 CH 2 ), 1.36 (s, 0.46H); FT-IR (Neat): ν = 3417 (br),
2925 (w), 2865 (s), 1647 (br), 1495 (w), 1462 (w), 1418 (w), 1357 (w), 1283 (w), 1205 (s), 1094 (s), 1040
(w), 936 (w), 841 (w) cm−1 ; UV-vis (H 2 O): λ max 427 nm; ﬂuo λ max (400nm ex) =492 nm; QY = 2%.
2.6.3 CP/HA complex formation: Sodium hyaluronate (MW 100 K) was purchased from Lifecore and used
as received. A stock solution was prepared by dissolving 2 mg of HA in 1 mL of deionized water. The CP/HA
complex was formed by mixing CP (10 µM) with various molar equivalents of HA (i.e., 1:1, 1:3, and 1:9)
for 1 h.
2.6.4 Dynamic Light Scattering: Dynamic light scattering and zeta potential experiments were performed
by Zetasizer nano–ZS (Zen 3600, Malvern Instruments Ltd.) using a microcuvette and a folded capillary cell
(Catalog # DTS1060), respectively, at room temperature. At least three independent samples were prepared
and each sample was measured three times.
2.6.5 Atomic Force Microscopy: (3-aminopropyl)triethoxysilane (APTES) was vapor deposited to a freshly
cleaved mica surface for 80 min in a desiccator filled with dry Argon. 30 μL of CP/HA complex in DI water
was placed on the APTES coated mica and incubated for 30-45 min in a laminar flow hood. The droplet was
then rinsed away with ~1mL DI water (18 M ohm) and dried gently with dry Argon. Images were acquired
with a MultiMode5 AFM microscope (Bruker, Santa Barbara, CA) operated in tapping mode in air using a
1.58-1.62 V oscillation amplitude with uncoated silicon AFM tips (T190, vistaprobes, k ~ 40N/m) at a
resonance frequency of 190 kHz. Typically, areas of 1 × 1 μm2 were scanned at a rate of 0.5-1 Hz and a
resolution of 512 × 512 pixels. All the experiments were performed at room temperature. The images were
further processed by Image Analysis Software Gwyddion.
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Figure S2.1. DLS (top) and zeta potential (bottom) of the semi-flexible PPB/HA complex. Hydrodynamic
radius was measured with three replicates and zeta potential was measured with six replicates.

Figure S2.2. DLS (top) and zeta potential (bottom) of the control PPE/HA complex. Hydrodynamic radius
was measured with three replicates and zeta potential was measured with six replicates.
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Figure S2.3. Topography (a) and (b) phase images, size distribution (c), and height (d) histograms for control
PPE/HA.

2.6.6 Cell Culture: Human Embryonic Kidney (HEK) and human pancreatic cancer (Panc-1) cells were
maintained in DMEM (Hyclone, Logan, UT). Human cervical cancer (HeLa) and human breast cancer
(MCF7) cells were maintained in MEM/EBSS (Hyclone, Logan, UT). Both media contain 10% FBS
(Hyclone, Logan, UT) and 100 U/ml penicillin. All cells were incubated in a 5% CO 2 incubator at 37 °C.
Cells were seeded in a 12 well-plate and allowed to attach overnight (1 x 105) before incubation with coreshell nanoparticles for the time course experiments.
2.6.7 Cytotoxicity: CellTiter-Glo® Luminescent Cell Viability assay (Promega, Madison, WI) was used to
determine the cytotoxicity of the core-shell nanoparticles. HeLa cells (~5x103 cells/well) were seeded into a
96 well-plate for 1 day. The cells were then incubated with various concentrations of the core-shell
nanoparticle for 24 h. After the core-shell nanoparticle incubation and following the manufacturer's protocol
100 μL of CellTiter-Glo reagent was added to each well and the plate was incubated for 2 minutes. Cell
viability was monitored by measuring luminescence values of each well using a microplate well reader with
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a 528/20 emission filter (Synergy 2, BioTek, USA). Relative cell viability as a function of the core-shell
nanoparticle concentration was obtained by dividing the luminescence value of each sample by the control
value. All measurements were triplicated and standard deviation was included in the error bar.

Figure S2.4. Cytotoxicity of the core-shell nanoparticles measured by CellTiter-Glo® Luminescent Cell
Viability assay. No toxic effects of were observed under the experimental conditions.
2.6.8 Flow Cytometry: AccuriTM C6 Flow Cytometer (BD Biosciences, San Jose, CA) equipped with a
fluorescence detector was used to analyze the fluorescence intensity of cells incubated with the core-shell
nanoparticles. After incubation, cells were rinsed with PBS 2 times followed by centrifugation (Eppendorf
Centrifuge 5430 R) at 1,000 relative centrifugal force (rcf) for 7 min and resuspension in 400 μL FACS
buffer. The mean fluorescent intensity of cells treated with the core-shell nanoparticles was normalized to
that of untreated control cells. All measurements were triplicated and standard deviation was included in the
error bar. For each measurement, 10,000 events were recorded and analyzed.
2.6.9 Evaluation of CD44 expression levels: Cells were seeded in an appropriate medium at a density of 1
x 105 cells/ml in a 12-well plate and cultured for overnight. Each cell line was incubated with FITC-labeled
mouse anti-human CD44 (BD Pharmingen, San Diego, CA) for 30 min at 4 °C, according to the protocol
provided by the manufacturer. The cells were washed three times with cold PBS and resuspended in 400 μL
FACS buffer for flow cytometry.
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2.6.10 Microscopic imaging of mixed HeLa and HEK cells: To distinguish HeLa cells co-cultured with
HEK cells, HeLa cells were pre-labeled with the CellTrackerTM Red CMPTX (Invitrogen, Grand Island, NY)
before co-culturing with HEK cells. 1.75 μM of CellTracker Red was incubated with HeLa cells in a 12-well
plate (1 x 105 cells/ml) for 30 min at 37 °C. After replacing the labeling solution with a fresh medium (~1
ml), the cells were further incubated for 30 min at 37 °C. The HeLa cells labeled with CellTracker were then
trypsinized, washed, and re-suspended in 500 µL of culture medium. Equal amounts (1 x 105 cells/ml) of
both HeLa and HEK cells were mixed in DMEM medium (400 µL) containing 10% fetal bovine serum (FBS)
and 100 U/mL penicillin, and seeded in a glass-bottomed eight-well chamber slide (Lab-Tek, Thermo
Scientific). After overnight co-culture, cells were incubated with core-shell nanoparticles (final 10 µM) for
1 h. The cells were rinsed with PBS and were incubated with a Hoechst dye (5 μg/μL) (Invitrogen, Grand
Island, NY) for 10min. Finally the cells were fixed with 4% paraformaldehyde in PBS for 10 min at room
temperature. Fluorescence images of the cells were obtained using a DeltaVison microscope equipped with
40x lens. Band-pass filters were used for imaging nucleus (410-460 nm), core-shell nanoparticles (500-550
nm), and CellTracker Red (575-620 nm).
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3.1

Abstract

Four different conjugated polymer nanoparticles (CPNs) were used to differentiate structurally similar
glycosaminoglycans (GAGs) in a urine simulant. Unique emission response patterns of CPNs were analyzed
by linear discriminant analysis (LDA), confirming that structurally diverse CPNs are sensitive and effective
at differentiating GAGs in a complex biological medium.
3.2

Introduction

Changes in urinary glycosaminoglycan (GAG) levels can signify proliferation of several diseases including
kidney and bladder disorders, polysaccharide storage diseases, and certain cancers.1-4 However, detection or
differentiation of GAGs in a biological medium has been challenged by the structural similarity of GAGs
and interferences of the concomitant biomolecules commonly present in biological fluids. Conventional
GAG detection methods require sample preparation steps followed by complicated instrumental analysis or
biochemical assays.5-9 Recently, several researchers have developed conceptually important detection
methods on the basis of pattern recognition using nanoparticles, conjugated polyelectrolytes, and
liposomes.10-14 In those examples, differentiation of GAGs was demonstrated by using multivariate statistical
methods including linear discriminant analysis (LDA). While current sensory systems perform well in a
simplified solution (i.e., highly diluted media with buffers), few sensory systems have been reported for
sensitive detection of GAGs in complicated biological fluids. Development of simple and sensitive sensory
systems of GAGs in biological media is highly important and practical for future disease diagnostics.
Owing to their excellent photophysical properties, conjugated polymers (CPs) have attracted much attention
for optical detection of chemicals, metal ions, and biological substances.15-18 Many synthetic and fabrication
methods have been developed to increase aqueous compatibility of CPs to achieve necessary sensitivity for
specific analytes in aqueous environments.19 Depending on the aqueous solubility of CPs and the nature of
interaction between CPs and analytes, structural changes can occur in individual CP chains or multiple chain
aggregates, which correspond to changes in CP optical properties.20,21
Previously, positively charged conjugated polymer nanoparticles (CPNs) were fabricated by treating a nonaqueous soluble, primary amine-containing CP [i.e., poly(p-phenyleneethynylene) (PPE)] with organic acids
followed by dialysis.22 The aggregation structures and sizes of CPNs were dependent on the nature of organic
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acid treatment. Furthermore, it was found that CPNs fabricated with a semi-flexible CP [i.e., a flexible linker
containing poly(p-phenylenebutadiynylene) (PPB)] exhibited backbone reorganization to maximize
hydrophobic chain interaction when treated with an anionic linear polysaccharide, hyaluronic acid (HA).23,24
The structural reorganization of CPNs was evident by photophysical changes including a new sharp
absorption peak at longer wavelength and decreased fluorescence intensity. The physical change was
observed as an elongated particle shape shown in atomic force microscopic images.
From these observations, it was hypothesized that the aggregation status of cationic CPNs will be different
upon interaction with GAGs due to the differences in ionic strength of the GAGs exhibiting different degrees
of acetylation and sulfonation in the repeating disaccharide units (see Figure 3.1). While the hydrophobic
interaction among non-aqueous soluble CPs provides the structural integrity of CPNs in a biological medium,
the loosely aggregated CPNs will undergo backbone reorganization under polyelectrolyte interactions with
GAGs. Depending on the strength of ionic interactions, the aggregation properties of CPNs will change
accordingly, resulting in measurable spectral changes.

Figure 3.1. Chemical structures of glycosaminoglycans.

In this chapter, four different CPNs were used that act as both analyte receptors and signal transducers, and
analyzed their differential responses to each GAG in a urine simulant. A systematic investigation of the
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aggregation properties of CPNs that vary by side chain amine density, backbone flexibility, and type of
backbone structure in response to GAGs was conducted by monitoring changes in absorption/emission
profiles and size/size distributions. Finally, entire spectral responses of the structurally diverse CPNs were
analyzed by LDA to differentiate structurally similar GAGs at a physiologically relevant concentration25 in
a urine simulant. Side chain and backbone flexibility strongly affects both the physical and photophysical
properties of CPN/GAG complexes. A clear differentiation of recognition patterns was observed in a LDA
plot, supporting that structurally diverse CPNs are effective at differentiating GAGs in a complex biological
medium.
3.3

Results and Discussion

Four CPs having different side chain and backbone structures (Figure 3.2) were used to obtain an array of
CPNs with different aggregation natures. P1 was designed to compare a short ethylene oxide (EO) and
primary amine [after removal of N-tert-butoxycarbonyl (Boc) group] per repeating unit, to the side chains of
P2 with a higher amine density by replacing the EO side chain with a guanidinium group. P3 was designed
to increase backbone flexibility by introducing a non-conjugated, flexible moiety in the conjugated
phenyleneethynylene (PE) backbone, while maintaining the fluorescent nature and the side chain
functionality of P1. Lastly, P4 was used because the flexible phenylenebutadiynylene (PB) backbone induces
higher backbone aggregation than the structurally similar PE analogues.

Figure 3.2. Chemical structures of CPs with different side chains (P1 and P2), PPE with flexible backbone
(P3), and PPB with flexible backbone (P4).
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The cationic CPNs were fabricated using our previously published method,23 in which the corresponding P1P4 were treated with trifluoroacetic and acetic acid followed by dialysis. The resulting nanoparticles in water
were homogeneous yellow solutions, and the key characteristic properties are summarized in Table 3.1.
Table 3.1. Key photophysical and physical properties of CPNs.
Mna
λ max, abs b
λ max, em c
Hydrodynamic
Zeta potentiale
d
(kDa)
(nm)
(nm)
diameter (nm)
(mV)
17,457
417
482
140 ± 0.9
+ 40 ± 1.3
1
P1
14,079
411
479
179 ± 6.3
+ 54 ± 3.1
2
P2
14,489
422
464
117 ± 10.1
+ 48 ± 2.9
3
P3
35,907
444
466
134 ± 8.1
+ 30 ± 1.7
4
P4
a
Determined by gel permeation chromatography in tetrahydrofuran (THF) relative to polystyrene
standard. bMeasured in water. cExcited at 400 nm. dMeasured by single particle tracking analysis at 25°C in
water. Mean values ± standard deviation. eElectrophoretic measurement in water at pH 7. Mean value ±
standard deviation.
CPN

CP

The hydrodynamic diameters of CPNs were measured using nanoparticle tracking analysis (NTA), which
tracks the Brownian motion of each particle to accurately calculate the hydrodynamic diameter of particles
with size distributions.26 The hydrodynamic diameters of CPNs ranged from ~120 to ~180 nm in water. The
relatively larger diameter of CPN-2 can be attributed to the hydrophilic nature of side chains, which form
aggregates of more solvated chains. Upon complexation, diameters of CPNs changed as aggregation
properties of CPNs were affected by GAGs with different ionic strengths. As shown in Figure 3.3, CPN-2
showed decreased sizes upon complexation, while the rest of the CPNs exhibited increased sizes. The loosely
aggregated, more solvated P2 chains are believed to form compact and smaller complexes with GAGs (see
Figure 3.4). Increased sizes observed from the rest of the CPNs were likely due to the formation of
hydrophilic GAG shells on CPNs. Among them, CPN-4 showed the largest diameter increase, confirming
that the ionic interaction induces further CP chain aggregation due to the nature of PPB backbone with
flexibility. A complete summary of NTA results are given in Table S3.1.
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Figure 3.3. Average hydrodynamic diameters of CPN-1 (black square), CPN-2 (red circle), CPN-3 (blue
triangle point up), and CPN-4 (green triangle point down) upon complexation with hyaluronic acid (HA),
chondroitin sulfate (CS), dermatan sulfate (DS), and heparin sulfate (HS), respectively, measured by NTA in
triplicate.

Figure 3.4. Average size distributions of CPNs complexed with GAGs measured by NTA.
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The absorption and fluorescent profiles support the NTA data. GAGs induce changes in the aggregation
structures as evidenced by red shifts in absorption and decreased fluorescent intensity in emission spectra for
all CPNs (Figure 3.5). As expected, CPN-4 displayed dramatic changes in both absorption and emission
profiles due to extensive chain reorganization. CPN-3, which also has flexible linkers along the PPE
backbone, displayed relatively small changes in the absorption, implying that the chemical backbone
structure of the CP is an important contributor for chain reorganization. The structurally similar GAGs also
interact differently with CPNs with structural diversity. The carboxylated HA induced higher absorption
shifts compared to the sulfonated GAGs, although the effects were somewhat minimal, with the exception of
CPN-4. Due to the relatively weak ionic strength of carboxylic acid, compared to sulfonic acid, HA is
believed to form outer shell layers by contributing to increase π -π interaction among CPs. Meanwhile, GAGs
with sulfonic acids interact strongly with CPs, especially with CP chains of low molecular weights, resulting
in more solvated random complexes. As expected, the emission profiles of all CPNs were unique and
different upon complexation with GAGs; These spectral changes can then be used for differentiation of
GAGs. Hierarchical cluster analysis (HCA) of emission profiles show that the sulfonated GAGs cluster
together, indicating that there is differentiation based on functional group (see Figure 3.6). For simplicity,
one CPN emission data set in water (triplicate samples) was used for HCA to demonstrate role of functional
group in differentiation. The most structurally similar chondroitin sulfate (CS) and dermatan sulfate (DS)
form the closest cluster, and the most structurally different hyaluronic acid (HA) and heparin sulfate (HS)
form the furthest cluster.
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Figure 3.5. Effect of GAG complexation on absorption (left column) and emission (right column) for CPN1 (first row), CPN-2 (second row), CPN-3 (third row), and CPN-4 (fourth row) in water. Optical density of
CPNs was fixed at 0.1.
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Figure 3.6. Hierarchical cluster analysis (HCA) of CPN-2+GAGs in water.
The differentiation ability of CPNs in a complex aqueous medium was verified using LDA of fluorescence
spectral responses of CPNs to GAGs. This method can be used to establish a pattern for a "chemical nose"
type array sensor,27 which relies on a differential response of the receptor (i.e., CPN) to the analyte (i.e.,
GAG). After adding CPNs to the GAG solution (100 nM) in a commercially available urine simulant,
emission spectra (see Figure 3.7) of complexes were recorded and used for LDA. The ratios of fluorescent
intensity were analysed using the statistical software JMP® (version 11). The LDA plot depicting the first
two canonicals is shown in Figure 3.8. A summary of canonical scores can be found in Table S3.2. There is
a clear separation among the GAGs, with no overlap of groups with a 95% confidence limit. Three canonical
correlations account for 71.1, 16.7, and 12.2% of the variation, occupying 100% of the total variation between
the groups, indicating that GAG differentiation is maximized. Traditional discriminant functions correctly
predict 100% of group classification, based on their squared distances to each group centroid (Table S3.3).
These results confirm that loosely aggregated CPNs can undergo structural reorganization in the presence of
strong polyelectrolytes in a complex biological medium due to the hydrophobic CP backbone that provides
the necessary structural integrity to resist interference from environmental factors.

44

Figure 3.7. Emission spectra of CPN-1 (a), CPN-2 (b), CPN-3 (c), and CPN-4 (d) in the presence of GAGcontaining urine simulant. Excitation wavelength for all CPNs was 450 nm with 5 nm slit widths, and 0.5 s
integration time.

Figure 3.8. An LDA plot between two largest canonical correlations of emission intensity ratios of CPNs
with and without GAGs (100 nM) in a urine simulant. HA in black, HS in red, CS in blue, and DS in green,
with (+) marking the centroid of each group.
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3.4

Conclusion

In summary, a systematic investigation is reported on the aggregation properties of CPNs that vary by side
chain and backbone structures in response to GAGs by observing changes in absorption/emission profiles
and complex size/size distributions. This investigation demonstrated that side chain and backbone flexibility
strongly affect the photophysical and physical properties of CPN/GAG complex. Four CPNs and their
differential responses to each GAG were analyzed using the LDA method to demonstrate that structurally
diverse CPNs differentiate GAGs in a complex biological medium. The structure-function relationships
obtained from this work will lead to further improvements in designing functional polymers for sensing
biological and biomedical substances.
3.5

Outlook

This chapter presented a simple approach to differential sensing of biologically important molecules. A
systematic approach to understanding the effect of side chain and backbone structure was employed to
establish a structure-function relationship. To improve differential sensing, an array of more structurally
diverse CPNs could be utilized, which would lead to more dramatic differential interactions of CPNs and
analytes. Since publication of this work in Chemical Communications, controlled incorporation of homocoupled benzothiadiazole (HBT) blocks into the conjugated polymer backbone has been explored. The HBT
blocks provide an electron-accepting moiety in the backbone, which modulates the CP’s electronic properties
towards red emission. By developing a more structural diverse array, the sensitivity can be greatly improved.
The unique signal amplification of CPNs, where any interaction that occurs along the conjugated backbone
causes a perturbation in the electron transport that will affect the entire system, makes CPN-based sensors an
ideal platform for improving interactions with analytes (more in section 4.5). In addition, a more systematic
investigation of CPN structure was conducted to understand the polyanion complexation behavior.29 A series
of four conjugated polyelectrolytes (CPEs) with PPE and PPB-type connectivity and incorporation of a
flexible, non-conjugated linker were prepared and displayed backbone-dependent complexation with HA.
Cellular uptake and subcellular localization studies of these CPEs would provide more information how
exactly backbone connectivity affects cellular interactions.
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3.6

Experimental

3.6.1

General.

Chemicals and solvents were purchased from Fisher Scientific and used as received. Deuterated solvents
were purchased from Cambridge Isotope Laboratories (Cambridge, MA). Molecular weights were
determined using gel permeation chromatography (GPC) against polystyrene standards on a Shimadzu high
performance liquid chromatography (HPLC) system equipped with PLgel 5 μm MIXED-D columns and
SPD-20A ultraviolet-visible (UV-vis) detector a flow rate of 1.0 mL/min. UV-Vis spectra were recorded
using Varian Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3
Spectrofluorometer (Jobin Yvon/Horiba). Quantum yields (QYs) were determined using
9,10-diphenylanthracene (QY= 0.9) in cyclohexane as a fluorescence standard. Fourier transform infrared
(FT-IR) spectra were recorded on a PerkinElmer Spectrum 100 FT-IR Spectrometer. Fine powders from
lyophilized samples were directly mounted on an attenuated total reflection (ATR) cell of the spectrometer.
The purification of the CPNs was conducted using an Ultrafiltration Stirred Cell (Millipore) with a 10 kDa
molecular weight cut-off (MWCO) membrane (Ultracel ultrafiltration disc). Nuclear magnetic resonance
(NMR) spectra for the conjugated polymers (CPs) were recorded on a 400 MHz Avance Bruker NMR
spectrometer. Chemical shifts were reported in parts per million (ppm) for 1H NMR on the δ scale based on
the middle peak (δ = 2.50 ppm) of the dimethylsulfoxide (DMSO)-d 6 solvent as an internal standard. NMR
spectra for the conjugated polymer nanoparticles (CPNs) were recorded on a 600 MHz Avance Bruker NMR
spectrometer using a 5 mm BBI probe at 298 K. The 600 MHz NMR spectrometer is equipped with a gradient
system capable of producing magnetic field pulse gradients in the z‐direction of about 50 G cm‐1 and allowing

for water peak suppression [δ = 4.79 ppm in deuterium oxide (D 2 O)]. Chemical shifts were reported in parts
per million (ppm) for 1H NMR on the δ scale based on the middle peak (δ = 4.79 ppm) of D 2 O solvent as an
internal standard. Graphs were plotted using Origin 9.1 software (OriginLab, Northampton, MA, USA).
3.6.2

Polymer synthesis general procedure.

A Schlenk flask was charged with aryl halide monomer (1.0 equiv) and diacetylene monomer (1.0 equiv for
P2, 0.9 equiv for P3), and cystine linker when applicable (0.1 equiv for P3) along with Pd[(PPh 3 ) 2 Cl 2 ] (0.1
equiv) and CuI (0.05 equiv). The Schlenk flask was evacuated and filled with N 2 three times. A solution of
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anhydrous dimethylformamide (DMF) (3 mL) and morpholine (1 mL) was degassed, and 2 mL of the mixed
solution was transferred to the Schlenk flask using a cannular needle. The reaction mixture was heated at 50
°C for 18 h. The solution was then cooled to room temperature and transferred dropwise to cold ethyl ether,
resulting in precipitation. After centrifugation (5 min, 4000 rpm), the supernatant was decanted, and the
precipitate was redissolved in DMF (1 mL). The resulting polymer was characterized using GPC by diluting
an aliquot of polymer solution in 1 mL of HPLC grade tetrahydrofuran (THF) and filtered through 0.45 μm
polytetrafluoroethylene (PTFE) syringe filter prior to injection. The absorption and emission profiles were
measured in a 10 mm quartz cuvette (2 mL) using a diluted aliquot of the polymer solution in DMF. The
material was then reprecipitated in pure ether, the supernatant was decanted, and the precipitate was purified
two more times. The precipitated polymer was allowed to dry under high vacuum for 4 hours prior to FT-IR
and 1H NMR characterization.
3.6.3

CPN fabrication.

Boc‐deprotection of the polymer was carried out by adding the polymer solution in DMSO-d 6 to a stirred
mixture of trifluoroacetic acid (2 mL) and acetic acid (2 mL) and allowed to stir at room temperature for 2
days. The mixture was then diluted by addition of acetic acid (10 mL), and added dropwise (2 drops/s) to 500
mL water (18 Ω) while stirring. Using a solvent-resistant stir cell fitted with a 10 kDa-MWCO membrane,
the solution was concentrated to approximately 10 mL, and dialyzed against 2 L of water. The solution was
subsequently filtered through a cellulose syringe filter (0.45 µm), characterized, and stored for future use.
P1: Detailed monomer and polymer synthesis, CPN fabrication and characterization is described elsewhere.28
P2: Detailed monomer synthesis and characterization of monomers A and B1 is described elsewhere.28,29
Using the general procedure described above, the polymerization of monomer A (7.8 mg, 0.0147 mmol) and
monomer B1 (15.0 mg, 0.0147 mmol) in the presence of Pd[(PPh 3 ) 2 Cl 2 ] (1.4 mg, 0.00147 mmol) and CuI
(0.1 mg, 0.000735 mmol) yielded P2 (11.5 mg, 0.00866 mmol, 58.9%), see scheme S3.1. CPN fabrication
was carried out as described in the general procedure to yield CPN-2, see scheme S3.2.
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Scheme S3.1. Synthetic route to P2.
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H
N

O

A

NBoc

P2

NHBoc
B1

P2: 1H NMR (400 MHz, DMSO-d 6 ): δ 13.19 (s, 0.15H), 12.38 (s, 1.18H), 9.00 (s, 0.15H), 8.19 (s, 1.16 H),
7.11 (d, 2.07H), 6.70 (s, 1.23), 4.17 (br m, 4.39H), 3.85-3.76 (br m, 7.09H), 3.56-3.45 (br m, 13.5 H), 3.08
(s, 2.88H), 1.44-1.34 (d, 27.0 H). FT-IR (neat): 3351, 2973, 2965, 2928, 2256, 1709, 1630, 1583, 1505,
1455, 1411, 1366, 1301, 1273, 1245, 1146, 1113, 1050, 1023 cm-1. GPC: M w = 23,618 Da, M n = 14,079 Da,
PDI = 1.68. UV-Vis (DMF) λ max = 439 nm, fluo λ max (430 nm ex) = 475 nm, QY = 20%.
Scheme S3.2. Boc-deprotection of P2 to yield CPN-2.
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CPN-2: 1H NMR (600 MHz, D 2 O, δ): 7.06 (br, 2H, Ar-H), 4.30-3.19 (br, 11.87H, CH 2 CH 2 OCH 2 CH 2 ), 1.16
(s, 0.02H); FT-IR (Neat): ν = 3310, 2863, 1560, 1419, 1359, 1301, 1273, 1199, 1110, 1053, 1020 cm-1; UVvis (H 2 O): λ max = 411 nm; ﬂuo λ max (400 nm ex) = 479 nm; QY = 0.64%.
P3: Detailed monomer synthesis and characterization of monomers B2 and C is described elsewhere.1,2 Using
the general procedure described above, the polymerization of monomer A (20.0 mg, 0.0375 mmol), monomer
B2 (22.1 mg, 0.0337 mmol), and monomer C (3.2 mg, 0.00375 mmol) in the presence of Pd[(PPh 3 )Cl 2 ] (2.6
mg, 0.00375 mmol) and CuI (0.4 mg, 0.00187 mmol) yielded P3 (17.9 mg, 0.0225 mmol, 60.0%), see scheme
S3.3. CPN fabrication was carried out as described in the general procedure to yield CPN-3, see scheme
S3.4.
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Scheme S3.3. Synthetic route to P3.
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P3: 1H NMR (400 MHz, DMSO-d 6 ): δ 8.70 (s, 0.11H), 7.71 (s, 0.10H), 7.51 (s, 0.13H), 7.16 (s, 2.10), 6.70
(s, 1.06H), 6.39 (s, 0.12), 5.75 (s, 0.38), 4.00 (br m, 4.00H), 3.80 (br m, 4.87), 3.66 (br m, 2.27H), 3.19 (br
m, 3.44H), 1.35 (s, 11.18 H). FT-IR (neat): 3002, 2778, 2505, 1654, 1486, 1462, 1429, 1362, 1321, 1244,
1176, 1133, 1052, 1043 cm-1. GPC: M w = 23,181 Da, M n = 14,489 Da, PDI = 1.59. UV-Vis (DMF) λ max =
439 nm, fluo λ max (400 nm ex) = 511 nm, QY = 39%.
Scheme S3.4. Boc-deprotection of P3 to yield CPN-3.
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CPN-3: 1H NMR (600 MHz, D 2 O, δ): 7.00 (br, 2H, Ar-H), 4.24-3.26 (br, 17.34H, CH 2 CH 2 OCH 2 CH 2 ); FTIR (Neat): ν = 3357, 2873, 1581, 1444, 1420, 1351, 1302, 1199, 1093, 1047 cm-1; UV-vis (H 2 O): λ max = 422
nm; ﬂuo λ max (400 nm ex) = 464 nm; QY = 0.36%.
P4: Detailed monomer and polymer synthesis, CPN fabrication and characterization is described
elsewhere.23,28
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3.6.4

CPN/GAG complexation.

Sodium hyaluronate (HA) was purchased from Lifecore (MW 100 K) and used as received. A stock solution
was prepared by dissolving 2.0 mg of HA in 1 mL of deionized water. Heparin sodium was purchased from
Acros Organics and used as received. A stock solution was prepared by dissolving 4.0 mg of HS in 1 mL of
deionized water. Chondroitin sulfate A (CS) and chondroitin sulfate B (dermatan sulfate, DS) were purchased
from Sigma Aldrich and used as received. Stock solutions of CS and DS were prepared by dissolving 2.0 mg
and 1.0 mg, respectively, in 1 mL of deionized water. CPN and GAG were mixed and allowed to incubate
for 30 minutes prior to measurements. For consistency between the CPNs, the concentration was adjusted to
give an optical density of 0.1, which corresponds to approximately 10 μM (based on polymer repeating unit).
The GAG concentration used was 30 μM (based on GAG repeating unit). Samples were prepared in deionized
water, unless otherwise stated.
3.6.5

Determination of hydrodynamic diameters of CPNs.

Light scattering measurements were performed with a LM10 HS (NanoSight, Amesbury, United Kingdom),
equipped with a sCMOS camera, sample chamber with a 488 nm blue laser, and Viton fluoroelastomer oring. The samples were prepared in similar manner for absorption and emission measurements using water
(18 Ω) filtered through 0.45 μm PTFE syringe filters. The samples were injected into the sample chamber
with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid reached the tip of the
nozzle. All measurements were performed at 25°C using a LM14C temperature controller (NanoSight,
Amesbury, United Kingdom). Each sample was measured three times.
3.6.6

Determination of zeta potentials of CPNs.

Dynamic light scattering measurements were performed by Zetasizer nano–ZS (Zen 3600, Malvern
Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at room temperature. The samples were
prepared at approximately 0.5 mM in water (18 Ω), which was filtered through 0.45 μM PTFE syringe filter.
Each sample was measured six times.
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3.6.7

Hierarchical cluster analysis (HCA) of emission spectra.

The commercially available statistical software JMP® (version 11) was used for analysis. For simplicity, one
CPN emission data set in water (triplicate samples) was used for HCA to demonstrate role of functional group
in differentiation. The default distance calculation method, Ward's, was used for cluster distances.
3.6.8

CPN in synthetic urine.

SurineTM was purchased from Dyna-Tek Industries, Inc. (product #720) and used as received. SurineTM is a
urine simulant, with a proprietary formula, which contains creatinine and urea, and was used as media for
CPN/GAG measurements. For the differentiation application and to simulate detection of GAGs present in
urine, GAGs (100 nM) were mixed in SurineTM, then CPN was added to the GAG-containing urine simulant
and allowed to incubate for 30 minutes prior to measurements.
3.6.9

LDA of emission spectra.

The commercially available statistical software JMP® (version 11) was used for analysis. The data included
in the training matrix were the emission spectra ratios of CPN to CPN+GAG in urine simulant. The matrix
training set was 4 CPNs x 4 GAGs x 3 replicates, an input of 48 data sets (spectrum ratios). The discrimination
method used was the linear, common covariance method.
3.6.10

Supporting data

Fig. S3.1 Absorption and emission spectra for P2 in DMF (Excitation = 430 nm, slit widths = 3 nm,
integration time = 0.1 s).
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Fig. S3.2 1H NMR (400 MHz) of P2 in DMSO-d6.

Fig. S3.3 Absorption and emission spectra for CPN-2 in water (Excitation = 400 nm, slit widths = 3 nm,
integration time = 0.1 s).

Fig. S3.4 1H NMR (600 MHz) of CPN-2 in D 2 O.
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Fig. S3.5 FT-IR of P2 (neat).

Fig. S3.6 Absorption and emission spectra for P3 in DMF (Excitation = 400 nm, slit widths = 3 nm,
integration time = 0.1 s).
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Fig. S3.7 1H NMR (400 MHz) of P3 in DMSO-d6.

Fig. S3.8 Absorption and emission spectra for CPN-3 in water (Excitation = 400 nm, slit widths = 3 nm,
integration time = 0.1 s).
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Fig. S3.9 1H NMR (600 MHz) of CPN-3 in D 2 O.

Fig. S3.10 FT-IR of P3 (neat).
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Fig. S3.11 NTA of CPN-1 in water.

Fig. S3.12 NTA of CPN-2 in water.
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Fig. S3.13 NTA of CPN-3 in water.

Fig. S3.14 NTA of CPN-4 in water.
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Fig. S3.15 Zeta potential of CPN-1 in water.

Fig. S3.16 Zeta potential of CPN-2 in water.

Fig. S3.17 Zeta potential of CPN-3 in water.
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Fig. S3.18 Zeta potential of CPN-4 in water.
Table S3.1 Summary of NTA data for CPN/GAG complexes.
Mean
Mode
SDa
Sample
(nm)
(nm)
(nm)

a

CPN-1

140 ± 0.9

108 ± 8.4

63 ± 3.2

+ HA

174 ± 1.4

145 ± 9.4

65 ± 3.9

+ HS

171 ± 1.9

142 ± 7.7

58 ± 1.9

+ CS

177 ± 4.8

148 ± 13.3

82 ± 8.2

+ DS

167 ± 1.6

159 ± 0.6

58 ± 3.2

CPN-2

179 ± 6.3

125 ± 6.5

74 ± 5.8

+ HA

152 ± 2.7

138 ± 8.5

62 ± 5.3

+ HS

162 ± 1.1

124 ± 7.1

70 ± 3.3

+ CS

137 ± 2.1

111 ± 6.0

59 ± 3.7

+ DS

137 ± 2.3

114± 3.2

59 ± 3.7

CPN-3

118 ± 10.1

90 ± 7.8

66 ± 23.5

+ HA

150 ± 4.6

125 ± 4.6

57 ± 4.7

+ HS

151 ± 5.4

125 ± 2.5

45 ± 4.9

+ CS

165 ± 6.4

149 ± 1.6

60 ± 5.1

+ DS

140 ± 1.3

125 ± 4.2

47 ± 3.5

CPN-4

135 ± 8.1

95 ± 8.1

55 ± 3.8

+ HA

170 ± 4.4

132 ± 6.6

75 ± 8.2

+ HS

187 ± 2.7

144 ± 5.3

87 ± 11.8

+ CS

216 ± 2.6

151 ± 3.7

97 ± 5.2

+ DS

216 ± 1.9

148 ± 6.6

92 ± 2.8

SD is the standard deviation characteristic of the width of the mean peak.
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Table S3.2 Summary of canonical scores from LDA plot.
Canonical

Eigenvalue

Percent of
variation

51.1592
12.0357
8.8034

71.0561
16.7166
12.2273

1
2
3

Canonical
correlation
0.9903
0.9608
0.9476

Table S3.3 Squared Mahalanobis distances to each group centroid.
Row
Actual
CS
DS
1
CS
40.333331755
12294.647468
2
CS
40.33333189
12318.702339
3
CS
40.333331247
12295.354372
4
CS
40.333332814
12320.127561
5
CS
40.333332332
12284.219683
6
CS
40.33333311
12305.608646

Likelihood
ratio
0.00015
0.00782
0.10200

P-value
<0.0001
<0.0001
<0.0001

HA
4063.5247309
4091.8694316
4055.8629135
4063.8690325
4022.5165612
4078.0823462

HS
7101.4731662
7100.0157848
7077.7114241
7028.8745497
7068.8817155
7070.0813947

7
8
9
10
11
12

CS
CS
CS
CS
CS
CS

40.333332299
40.333332583
40.333332368
40.333332042
40.333332023
40.333331329

12324.225381
12297.892499
12290.603231
12317.900963
12321.138359
12327.718608

4101.1928134
4043.5769265
4079.2351324
4084.3114748
4086.9472166
4068.9691099

7029.6991414
7080.2601624
7099.9786147
7104.2194088
7088.7210233
7091.0784818

13
14
15
16
17
18

DS
DS
DS
DS
DS
DS

12336.168794
12308.32746
12285.66102
12322.927181
12284.738557
12309.48622

40.333332198
40.333331405
40.333332437
40.333333024
40.33333405
40.333333605

4485.4027952
4461.5478914
4444.505515
4494.3974088
4431.2023819
4465.5395729

5017.6750565
5024.6443335
4960.6845733
5092.3506657
5018.2556851
4968.2806311

19
20
21
22
23
24

DS
DS
DS
DS
DS
DS

12308.350358
12299.854928
12288.977123
12316.660014
12309.957045
12327.030404

40.333333771
40.333333821
40.333333818
40.333333525
40.333332342
40.333332195

4497.3940618
4458.0858604
4449.3440504
4479.2810227
4471.8327096
4490.8880232

4981.3115882
5006.5912977
5029.0243225
5006.1744725
5016.2428069
5031.904691

25
26
27
28
29
30

HA
HA
HA
HA
HA
HA

4071.5727552
4051.7432194
4038.7851613
4069.2033941
4043.7940084
4091.1485334

4479.4540603
4464.1781327
4447.7852168
4452.9086196
4465.4116832
4485.9916447

40.333334415
40.333333094
40.333333772
40.333333224
40.33333387
40.333333783

4189.6090669
4181.7118782
4226.4907325
4166.0945872
4101.2929977
4207.6709894

31
32
33

HA
HA
HA

4087.8395223
4079.9438813
4067.9651299

4435.7896652
4435.5311514
4520.1123035

40.333333211
40.333333177
40.333333286

4216.5914613
4219.9600424
4148.2627038
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34
35

HA
HA

4091.700492
4093.2678457

4486.0424938
4481.8711676

40.333333274
40.333333602

4184.9552956
4202.0467871

36
37
38
39
40
41

HA
HS
HS
HS
HS
HS

4052.9937363
7096.5304652
7074.0622865
7059.2479562
7096.8954728
7070.6823557

4474.345146
5022.950778
5010.9473948
4991.6573071
5039.1040348
4973.1371849

40.333333464
4191.1591296
4206.4649295
4181.3105117
4194.8850944
4165.069548

4153.3574859
40.333333658
40.333333755
40.333334356
40.333334461
40.33333396

42
43
44
45
46
47

HS
HS
HS
HS
HS
HS

7087.2351087
7056.5975622
7081.3330154
7060.9924572
7083.6742369
7095.8214509

5032.825679
4986.0591011
5052.2305167
4989.4852004
5025.4448787
5018.3121938

4206.7409419
4134.249703
4202.4199089
4150.13598
4194.4434217
4188.5907513

40.333333788
40.33333355
40.3333335
40.333333518
40.333333149
40.333333749
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HS

7077.9224838

5010.9858432

4182.5741073

40.333332594

3.7
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Mitochondria-specific conjugated polymer nanoparticles
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4.1

Abstract

Biodegradable conjugated polymer nanoparticles (CPNs) were prepared for high mitochondria targeting in
live cancer cells. The degradable CPNs are nontoxic and specifically localized to mitochondria of live tumor
cells through macropinocytosis followed by intracellular degradation and trafficking.
4.2 Introduction
Conjugated polymer nanoparticles (CPNs) are intrinsic fluorescent soft materials fabricated by self-assembly
of non-aqueous soluble conjugated polymers (CPs) in an aqueous solution.1,

2

Owing to their excellent

photophysical (i.e., high brightness and photostability) and biophysical properties (i.e., high cellular entry
and nontoxicity), CPNs have recently gained much attention for microscopic live cell/tissue imaging,3-5
biological sensing,6, 7 and nucleic acid delivery.8, 9 By introducing non-conjugated degradable linkers along
the conjugated backbones, biodegradable CPs were synthesized and exhibit similar fluorescent properties of
fully conjugated CPs.10 The backbone modification with flexible linker affects the self-assembly properties
of CPs, resulting in significantly changed cellular entry pathways.11

Despite successful cellular applications, the high molecular weights of CPs are not ideal for labelling or
delivery to intracellular organelles due to inefficient diffusion and trafficking ability. For organelles with
additional membranes such as nucleus and mitochondria, the necessary penetration of the organelle
membranes further decreases the labeling and delivery efficiency. For the first time, presented here is a
strategy to achieve efficient mitochondria labeling of live cells using intracellular degradation of CPNs.
Biodegradable CPNs were designed by self-assembly of disulfide containing CPs. Upon endocytosis, CPNs
were disassembled and degraded to low molecular weight, fluorescent conjugated oligomers (COs) that were
efficiently trafficked to mitochondria (Fig. 4.1). The results support that biodegradable CPNs are promising
materials for labeling and therapeutic delivery to mitochondria, which is an important therapeutic target given
that mitochondria dysfunction is related to various diseases such as cancer, obesity, diabetes, and
neurodegenerative disorders.12
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Figure 4.1. Chemical structures of PPEs with (PPE-1) and without (PPE-2) biodegradable linkers in the
backbone and a schematic illustration of cellular entry and mitochondria localization of biodegradable CPNs.
CPN-1 and CPN-2 were fabricated with the corresponding PPEs via self-assembly in water.

4.3 Results and Discussion.
Biodegradable poly(p-phenyleneethynylene)s (PPEs) were synthesized by polymerizing monomers
including a disulfide-containing monomer (see experimental). Disulfide bonds are reducible under a high
concentration of intracellular glutathione (~0.5-10 mM)13. To obtain the fluorescent properties comparable
to a fully conjugated PPE, the amount of disulfide monomer in the PPE backbone was maintained less than
50%. To improve mitochondria targeting function, triphenylphosphonium (TPP) salts were introduced by
reacting the PPEs containing bromine side chains with triphenylphosphine (see experimental). TPP is a wellknown mitochondria-targeting small molecule and has been used for modifying small molecules,
nanoparticles, and liposomes.14, 15 Proton and phosphorus nuclear magnetic resonance (NMR) spectroscopy
confirmed the quantitative introduction of TPP salts (see experimental). The resulting PPE-1 (M n = 9,300)
and -2 (M n = 16,000) were soluble in organic solvents such as dimethylsulfoxide (DMSO) and methanol.
The ratio of repeating units of PPE-1 was calculated as ~1.0:0.8 using proton NMR integration values,
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indicating that the average length of COs along PPE-1 backbone is around 5 repeating units (i.e., pentamer)
or slightly larger.
CPNs were prepared by diluting TPP-modified PPEs in DMSO with an excess amount of water (i.e., final
DMSO concentration of less than 1 %). Using fully conjugated PPEs, non-degradable CPNs were also
fabricated to support the concept that the degradability of CPNs is crucial for high intracellular organelle
targeting. The photophysical and physical properties of both CPNs were somewhat similar. Both CPNs
exhibit broad emission spectra centered on ~470 nm. Using nanoparticle tracking analysis, the mean
hydrodynamic diameters of CPN-1 and -2 were determined as 139.9 ± 3.0 and 152.7 ± 6.7 nm, respectively
(see Figure S4.25 and S4.27). The difference in the average size is believed to associate with the size
distribution of CPNs. Indeed, both CPNs exhibit very similar mode diameters (i.e., the diameter of the major
population) of 92–93 nm. Zeta potentials of CPN-1 and -2 were +24 and +29 mV, respectively. Attempts to
take transmission electron microscopic (TEM) images were not successful as CPNs heavily aggregated on a
copper grid during sample preparations.
The metabolic activities of human cervical carcinoma (HeLa) cells incubated with biodegradable CPN-1 and
non-degradable CPN-2, respectively, for overnight were monitored to evaluate the toxicity of CPNs.
Interestingly, while degradable CPN-1 exhibits no viability inhibition up to 40 µM, non-degradable CPN-2
exhibits substantially high toxicity starting from 10 μM (see Figure S4.35). To test whether the molecular
weights of PPEs are associated with the toxicity, a low molecular weight (M n = 6,960) non-degradable PPE
(PPE-3) as synthesized by breaking the monomer stoichiometric balance in polymerization. The CPN
fabricated with low molecular weight PPE (i.e., CPN-3) exhibits very similar toxicity to that of CPN-2,
suggesting that the toxicity of CPN-2 is not related to the molecular weight of the corresponding PPE.
Although further systematic investigations are necessary to better understand the backbone structure and the
cellular toxicity relationship, it is speculated that the degraded oligomers containing thiols may contribute to
the lower toxicity by reducing the level of reactive oxygen species.17
CPNs were taken up by live cells and found in the cytosolic compartment (Fig.4.2). Unlike CPN-2, which
exhibits a characteristic punctuated pattern, the fluorescent image of CPN-1 was somewhat diffused along
with some granular patterns (Fig. 4.2). The diffused pattern is indicative of disassembly of CPNs followed
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by degradation to COs via disulfide degradation under high intracellular glutathione concentration. Nondegraded CPNs were seen as punctuated dots. Nonetheless, the microscopic images are clearly different
between biodegradable CPN-1 and non-degradable CPN-2. The possibility of pre-degradation of CPN-1 in
extracellular environment followed by diffusion or uptake of COs by cells was ruled out , as disulfide
reduction at the extracellular environment will be very inefficient due to lower glutathione concentration (i.e.,
one to three orders of magnitude lower).13

Fig. 4.2. Microscopic images of HeLa cells incubated with CPNs for 18 h followed by mitochondria (red)
and nuclear (blue) staining. The scale bar is 20 µm.

The PPE stock concentration in DMSO is influential for CPN formation and thus for fluorescent microscopic
imaging. The higher stock concentration, the more punctuated spots observed in the microscopic images (see
Fig 4.3). As polymer concentration increases, the chances of interpolymer aggregation via π- π staking in a
poor solvent increase. The punctuated spots are indicative of aggregated nondegraded CPNs. Attempts to
degrade CPNs under high reducing conditions were not conclusive, assuming that the strength of
interpolymer interactions in an aqueous environment are somewhat strong. Partial backbone degradation to
induce de-aggregation of CPNs was speculated from slight blue shifts on both absorption and emission
wavelengths upon treating CPNs with excess amount of glutathione (see Fig. 4.4).
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Fig. 4.3. Confocal microscopic images of HeLa cells incubated with CPN-1 0.2 µM (top row) and 2 µM
(bottom row) for 18 h followed by mitochondria (red) staining. Scale bar is 20 µm.
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Fig. 4.4. Absorption (left) and emission (right) spectra of CPN-1 treated with 10 mM glutathione (GSH) for
0 and 18 h at 37˚C.
For analyzing subcellular localizations of CPNs, various organelles (i.e., nucleus, Golgi, endosome, and
mitochondria) were post-stained using commercially available dyes. The Pearson's Correlation Coefficient
(PCC) was used to quantitatively evaluate co-localization.18 PCC scores of 0 and 1 correspond to uncorrelated
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and perfectly linearly correlated colors, respectively. Mean PCC scores from three independent images of an
entire cell were selected and analyzed to increase the analysis objectivity. CPN-1 exhibited high
mitochondrial co-localization (PCC ~0.8), while minimal endosome (~0.3) and Golgi apparatus (~0.2) colocalizations were observed. Meanwhile, CPN-2 showed high endosomal co-localization (~0.7) with minimal
mitochondrial and Golgi apparatus co-localization. Non-degradable CPN-3, which was fabricated with low
molecular weight PPE-3, also exhibits punctuated staining pattern with low mitochondria localization (~0.4),
supporting that the degradability of CPNs is an important factor increasing mitochondria trafficking (see Fig.
4.5).

Fig. 4.5. Microscopic images of HeLa cells incubated with CPN-3 for 18 h followed by mitochondrial (red)
and nuclear (blue) staining. The scale bar is 15 μm.
The presence of punctuated spots in microscopic images and inefficient degradation of CPN-1 in a highly
reducing environment imply that CPNs are somewhat hydrophobic despite of the charged TPP groups. To
increase the hydrophilicity, CPNs were further complexed with an anionic linear polysaccharide, hyaluronic
acid (HA). When the same biodegradable CPN-1 was complexed with HA (CPN-1/HA) followed by
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incubation with HeLa cells for overnight, the mitochondria imaging pattern was improved substantially with
reduced punctuated spots (Fig. 4.6). As shown in Fig.4.6, CPN-1/HA exhibits characteristic mitochondrial
granular patterns and high PCC scores, while no changes were observed from CPN-2/HA complex. Nondegradable CPN exhibit punctuated fluorescent image patterns regardless of HA complexation.

Fig. 4.6. Confocal microscopic images of HeLa cells incubated with CPN/HA (green) for 18 h followed by
mitochondria (red) and nucleus (blue) staining. The scale bar is 20 µm.

To further confirm that CPN-1 indeed trafficked to mitochondria, live cells incubated with CPNs were treated
with a commercial mitochondria isolation kit followed by centrifugation to isolate a mitochondria fraction.
Fluorescence spectroscopic analysis of the mitochondrial fraction of live HeLa cells clearly supports the high
mitochondrial localization of CPN-1. As shown in Fig. 4.7, fluorescent signals were exclusively observed
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from the mitochondria fraction of live HeLa cells incubated with CPN-1. CPN-2 exhibited high cytosolic
fluorescent intensity compared to the mitochondria fraction, supporting the data from microscopic image
analysis.

Fig. 4.7. Fluorescence analysis of mitochondrial and cytosolic fractions of HeLa cells incubated with CPNs.
CPN-1 was found at the mitochondrial fraction, while CPN-2 was found mainly in the cytosolic fraction. The
error bar represents ±standard deviation (n = 3).

This dramatic subcellular localization difference between CPNs with the same side chains (i.e., TPP) implies
that self-assembly structures of CPNs possibly influence cellular entry routes and the intracellular fates.
Previously, it was found that CPs with flexible linkers tend to form aggregates with high interpolymer
interactions compared with CPs without the flexibility.19 Because of the flexible disulfide containing units,
the surface properties of CPN-1 will be different and influential for cellular interactions and subsequent
cellular entry. To test endocytosis pathways, live HeLa cells pretreated with pharmacological inhibitors of
various endocytosis pathways were incubated with CPNs for 2 h and mean fluorescence intensity of live cells
was monitored by flow cytometry.20 As shown in Fig. 4.8, CPNs use various endocytosis pathways to enter
HeLa cell, determined by the reduced uptake of CPNs under the inhibitors tested. In addition to caveolaemediated endocytosis (CvME), uptake of CPN-1 via macropinocytosis (MPC) was also noticeably reduced.
Although further mechanistic and trafficking studies are needed, it is speculated that the high mitochondria
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localization of CPN-1 is closely related to a series of cellular processes of MPC internalization of CPN-1,
better escape of macropinosomes, degradation of disulfide bonds to generate low molecular weight COs, and
increased diffusion for trafficking to mitochondria.

Fig. 4.8 Endocytosis inhibition study under pharmacological inhibitors treatments. Mean fluorescence
intensity of HeLa cell (Control), CPNs only (CPN), chlorpromazine (24.0 mM, CME), genistein (0.21 mM,
CvME), methyl-β-cyclodextrin (1.00 mM, CvME/MPC), LY294002 (0.12 mM, MPC1), and cytochalasin D
(0.04 mM, MPC2) were measured using flow cytometry. Error bars represent standard deviation. *p < 0.05

To determine whether the observed CPN-1 mitochondrial specificity is related to the degradation kinetics,
endosome and mitochondrial co-localizations were measured as a function of incubation time. Subcellular
localization was monitored by fluorescent microscopic imaging, with CPNs incubated for 3, 6, 12, and 18 h
in live HeLa cells. PCC scores between CPNs and mitochondrial or endosomal markers were measured and
averaged from three independent trials (Fig. 4.9). CPN-1 exhibited a time-dependent mitochondrial and
endosomal co-localization. As incubation time increased, CPN-1 localized more strongly toward the
mitochondria, with almost exclusive mitochondrial localization at 18 h incubation. CPN-2, meanwhile, did
not show time-dependent co-localization, exhibiting no significant change in mitochondrial or endosomal
localization as incubation time increased. Although CPN-2 has high concentration of mitochondria targeting
TPPs, the non-degradability, large molecular weight, and poor endosome escaping and diffusion efficiency
limit mitochondria targeting. The time-dependency of CPN-1 on co-localization supports that intracellular
degradation of biodegradable linkers play a significant role in mitochondrial trafficking of TPP functionalized
COs.
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Fig. 4.9. Time-course localizations of A) CPN-1 and B) CPN-2 on endosomes (open circles) and
mitochondria (filled circles). Subcellular localization of CPN-1 changes from endosome to mitochondria,
while CPN-2 remains constant regardless of incubation time. Error bars represent standard deviation from n
= 3.

4.4

Conclusion

In conclusion, a new strategy to achieve a unique mitochondrial-specific localization of CPs was presented.
It was demonstrated that disulfide-containing CPNs exhibit active cellular internalization as polymer
nanoparticles via a variety of endocytosis, and undergoes degradation to low molecular weight oligomers
that were efficiently trafficked to target mitochondria. The concept demonstrated here will lead to the
development of novel CP-based materials for improved intracellular sensing, labeling, and potential
therapeutic delivery.

4.5

Outlook

This chapter presented a strategy for mitochondrial targeting that was dependent on the biodegradability and
flexibility of the conjugated backbone. With mitochondria-specificity, CPNs could be used for sensing and
delivery applications by incorporating a reactive oxygen species (ROS)-sensitive functionality. Since the
writing of this chapter, a series of non-flexible-containing TPP copolymers with varying molecular weight
and a series of flexible TPP-containing copolymers with varying flexible unit incorporation were synthesized
and screened for mitochondrial-specificity. Preliminary results indicated that the presence of the flexible
linker and at relatively higher percentage (>40%) was crucial for mitochondrial localization. This is could be
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due to the hydrophobicity of the polymer backbone, which causes aggregation in aqueous environment. If
the polymer aggregates, the availability of the degradable linker in the backbone would be compromised and
degradation by glutathione would be difficult. A series of TPP-containing polymers that also incorporated
the hydrogen peroxide-sensitive moiety, aryl boronate, and degradable linker (Scheme 4.1). However, due to
the hydrophobicity of this group and in combination with the bulky TPP group, dense aggregation was
observed both in photophysical properties (red shifted spectra) and decreased emission intensity. The dense
aggregation led to non-specific binding to the cellular membrane, and low mitochondria localization, for both
linker and non-linker CPNs.
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Scheme 4.1: TPP (R1)-containing polymers with (PPE-L) and without (PPE) biodegradable linker and
boronate-moiety (R2).
To address these issues, more in-depth studies on the effect of the flexible linker for subcellular targeting are
needed. In addition, improving the hydrophilicity of the TPP-containing CPNs would provide information as
to how polymer solubility, CPN aggregation, and cellular uptake/trafficking can be modulated.
4.6

Experimental

Dr. Rajesh Kumar completed polymer synthesis and characterization. Dr. Eladio Mendez completed timecourse imaging and flow cytometry experiments.
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4.6.1

General Information

Chemicals, including solvents, were purchased from Fisher Scientific and used as received. Deuterated
solvents were purchased from Cambridge Isotope Laboratories (Cambridge, MA). UV-vis spectra were
recorded using a Varian Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a
FluoroLog-3 Spectrofluorometer (Jobin Yvon/Horiba). 9, 10-diphenylanthracene (QY = 1.0) in cyclohexane
was used as a fluorescence standard for QY determination. The average molecular weight (M n ) and
polydispersity (PDI = M w /M n ) of the polymers were determined by gel permeation chromatography (GPC)
against polystyrene standards using a Shimadzu high performance liquid chromatography (HPLC) system
fitted with PLgel 5 μm MIXED‐D columns and SPD‐20A ultraviolet−visible (UV−vis) detector. Nuclear
magnetic resonance (NMR) spectra were recorded on a 400 MHz Avance Bruker NMR spectrometer. 1H and
13

C NMR chemical shifts are given in ppm relative to Si(CH 3 ) 4 , with the solvent resonance used as an internal

reference. 1H NMR on the scale based on the middle peak (δ = 2.50 ppm) of the dimethyl sulfoxide DMSOd 6 solvent as an internal standard or 7.26 ppm for chloroform (CDCl 3 ) experiments. 31P NMR chemical
shifts are reported in ppm relative to H3PO4. The mass spectrometric data were obtained at the mass
spectrometry facility of Florida International University. Analytical thin layer chromatography (TLC) was
performed on TLC Silica gel 60 F254. The TLC plates were visualized by shortwave (254 nm) or longwave
(360 nm) UV light. Flash chromatography on silica gel (230–400 mesh) was performed. Fourier transform
infrared (FT-IR) spectrum was obtained on a PerkinElmer Spectrum 100 FT-IR Spectrometer; fine powder
sample was mounted on an attenuated total reflection cell.
4.6.2.1 Monomer Synthesis
Scheme S4.1: Synthetic route to M1
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4.6.2.2 Synthesis of compound 120
1, 4-Dihydroxy-2, 5-diiodobenzene (5.00 g, 13.80 mmol) was dissolved in acetone (20 mL) and the resulting
solution was added slowly to a stirred suspension of K 2 CO 3 (7.60 g, 55.25 mmol) and NaI (8.30 g, 55.25
mmol). The reaction mixture was allowed to stir for 10 min, followed by the slow addition of triethylene
glycol monochlorohydrin (TEG-Cl) (5.80 g, 34.53 mmol). The reaction was heated to 80 ºC for 12 h. The
solution was cooled to room temperature, the solvent was removed, and the resulting slurry was re-dissolved
in CH 2 Cl 2 (100 mL). The solution was extracted with water (100 mL x3) and the organic fractions were
collected and concentrated in vacuo until an oily residue remained. The crude product was purified by silica
gel chromatography (95:5 EA/Hexane). The product was off-white solid. Yield: 5.80 g (67.0%). 1H NMR
(400 MHz, CDCl 3 ): δ 7.24 (s, 2H), 4.09- 4.15 (t, 4H), 3.86-3.92 (t, 4H), 3.77-3.82 (m, 4H), 3.69-3.76 (m,
8H), 3.60-3.66 (m, 4H), 2.29 (br, 2H); 13C NMR (100 MHz, CDCl 3 ): δ 153.51, 123.21, 86.52, 72.51, 71.22,
70.54, 70.28, 69.66, 61.82.
4.6.2.3 Synthesis of monomer M121
A suspension of compound 1 (5.00 g, 7.98 mmol) was dissolved in 25 mL of DCM. Carbon tetrabromide
(8.00 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol) were added slowly to the reaction mass.
The mixture was stirred at room temperature for 2 h. The solvent was removed and the crude product was
purified by column chromatography (1: 4 EA / Hexane). The product was white solid. Yield: 5.30 g (81.2%).
1

H NMR (400 MHz, CDCl 3 ): δ 7.30 (s, 2H), 4.10-4.15 (t, 4H), 3.89-3.92 (t, 4H), 3.85-3.87 (t, 4H), 3.68-3.76

(m, 4H), 3.60-3.65 (m, 4H), 3.45-3.51 (m, 4H). 13C NMR (100 MHz, CDCl 3 ): δ 153.37, 123.49, 86.47, 71.30,
71.19, 70.71, 70.33, 69.70, 30.42.
Scheme S4.2: Synthetic route to M2
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Monomer 2 (M2) was synthesized according to literature procedure (Scheme S4.2).22
Scheme S4.3: Synthetic route to M3
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4.6.2.4 Synthesis of monomer M3

3,3'-Dithiodipropionic acid, 6 (1.00 g, 4.76 mmol) was dissolved in anhydrous THF (20 mL) in a round
bottom flask, which was evacuated and filled with nitrogen. N-methylmorpholine (0.90 g, 9.52 mmol) was
added, and the suspension was allowed to stir until the entire solid was dissolved. Isobutyl chloroformate
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(1.30 g, 9.52 mmol) was added, and the mixture was allowed to stir at room temperature for 15 min. A
solution of 4-ethynylaniline, 5 (1.10 g, 9.52 mmol) in anhydrous THF (10 mL) was prepared under a
N 2 atmosphere and transferred into the reaction flask using a cannula. The reaction was allowed to proceed
overnight, after which the reaction mixture was filtered. The filtrate was concentrated in vacuo and the
resulting solid was precipitated overnight from the DCM / diethyl ether solvent system. Yield: 0.70 g
(36.0%). 1H NMR (400 MHz, DMSO): δ 10.20 (s, 2H), 7.50-7.61 (d, 4H), 7.39-7.41 (d, 4H), 4.07 (s, 2H),
2.99-3.03 (t, 4H), 2.74-2.77 (t, 4H). 13C NMR (100 MHz, DMSO): δ 169.53, 139.68, 132.36, 118.94, 116.12,
83.49, 79.65, 36.08, 33.38. HRMS (ESI): Calc for C 22 H 20 N 2 O 2 S 2 [M+Na]+: 431.0858; found [M+Na]+ :
431.0801.

Figure S4.1. 1H NMR of M3 in DMSO-d 6
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Figure S4.2. 13C NMR of M3 in DMSO-d 6

4.6.3.1 Polymer Synthesis
General Procedure. A Schlenk flask was charged with monomer M1 (1.00 eqiv.), M2 (0.5 eqiv.), M3 (0.5
eqiv.), Pd[(PPh 3 ) 2 Cl 2 ] (0.10 equiv.), and CuI (0.05 equiv.). The Schlenk flask was evacuated and filled with
N 2 and solution of anhydrous dimethylformamide (4 mL) and diisopropylamine (1 mL) was degassed, and
2.5 mL of the mixed solution was transferred to the Schlenk flask using a cannular needle. The reaction was
allowed to stir at room temperature for 12 h. The solution was then added drop wise to methanol, resulting
in precipitation. After centrifugation (3 min, 4000 rpm) the supernatant was decanted, and the precipitate was
redissolved in DCM (1 mL) for further purification.
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4.6.3.2 Synthesis of PPE-1
Scheme S4.4: Synthetic route to PPE-1

PPE-1-Br. Using the general procedure described above, the polymerization of monomer M1 (100 mg, 0.133
mmol), M2 (30 mg, 0.066 mmol) and M3 (28 mg, 0.066 mmol) was carried out in presence of Pd[(PPh 3 ) 2 Cl 2 ]
(9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol). The resulting mixture was purified by precipitation in
methanol (x3) Yield: 105 mg (42.5 %). An aliquot was redissolved in THF, and the molecular weight was
obtained, and photo physical properties were characterized in DCM.
PPE-1-Br: GPC: M w =13.66 kDa; M n = 09.30 kDa; PDI = 1.42. UV-vis: λ max = 400 nm; fluo λ max = 467
nm; QY = 69% and ε = 42716.79 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl 3 ): δ 7.91
(br, 1H), 7.51 (br, 2H), 7.39 (br, 2H), 6.96 (br, 4H), 4.16 (br, 8H), 3.84 (br, 8H), 3.70 (br, 15H), 3.57 (br,
10H), 3.44 (br, 4H), 3.54 (br, 4H), 3.27 (br, 4H) 3.02 (br, 2H), 2.75 (br, 2H). FT-IR (neat): ν = 2924, 2868,
1671, 1589, 1512, 1408, 1352, 1265, 1214, 1097, 1041, 937, 838 cm-1.
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Synthesis of PPE-1.
Triphenyl phosphine (141 mg, 0.540 mmol) was dissolved in chloroform and the resulting solution was added
to a stirred suspension of PPE-1-Br (100 mg, 0.054 mmol). The reaction was heated to 85 ºC for 12 h. The
resulting mixture was purified by precipitation in ethyl acetate (x5). Yield: 70 mg (44.7%).
PPE-1: UV-vis: λ max = 405 nm; fluo λ max = 472 nm; QY = 40% and ε = 67606.65 M-1cm-1 (Per repeating
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 10.34 (br, 1H), 7.75 (br, 33H), 7.41 (br, 4H), 7.24 (br,
2H), 7.14 (br, 2H), 4.16 (br, 9H), 3.89 (br, 5H), 3.78 (br, 6H), 3.62 (br, 17H), 3.47 (br, 8H), 3.28 (br, 3H),
3.17 (br, 4H), 2.81 (br, 2H). 31P NMR (161.9 MHz, DMSO-d6): 25.38. FT-IR (neat): ν = 2921, 2870, 1683,
1597, 1520, 1430, 1408, 1210, 1099, 1047 cm-1.
CPN-1: UV-vis: λ max = 407 nm; Emission λ max = 470 nm; QY = 14% were measured using 1% DMSO in
water (v/v).

Figure S4.3. 1H NMR of PPE-1-Br in CDCl 3 .
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Figure S4.4. 1H NMR of PPE-1 in DMSO-d 6 .
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Figure S4.5. 31P NMR of PPE-1 in in DMSO-d 6 .

Figure S4.6. FT-IR of PPE-1-Br (neat).
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Figure S4.7. FT-IR of PPE-1 (neat).

Figure S4.8. UV-vis and emission spectra of PPE-1-Br in DCM.
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Figure S4.9. UV-vis and emission spectra of PPE-1 in DMSO.

Figure S4.10. UV-vis and emission spectra of CPN-1 1% DMSO in water (v/v).
4.6.3.3 Synthesis of PPE-2.
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Scheme S4.5: Synthetic route to PPE-2
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PPE-2-Br. Using the general procedure described above, the polymerization of monomer M1 (100 mg, 0.133
mmol) and M2 (60.0 mg, 0.133 mmol) was carried out in presence of Pd[(PPh 3 ) 2 Cl 2 ] (9.3 mg, 0.013 mmol),
and CuI (1.3 mg, 0.007 mmol). The resulting mixture was purified by precipitation in methanol (x3) Yield:
0.15 g (88.5 %). An aliquot was redissolved in THF, the molecular weight was obtained, and photo physical
properties were characterized in DCM.
PPE-2-Br: GPC: M w = 26.36 kDa; M n = 15.98 kDa; PDI = 1.65. UV-vis: λ max = 432 nm; fluo λ max = 473
nm; QY = 53% and ε = 23526.82 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl 3 ): δ 7.06
(br, 4H), 4.24 (br, 8H), 3.92 (br, 9H), 3.78 (br, 12H), 3.64 (br, 13H), 3.52 (br, 5H), 3.43 (br, 4H), 3.35 (br,
7H). FT-IR (neat): ν = 2923, 2870, 2197, 1510, 1423, 1270, 1241, 1092, 1060 cm-1.
Synthesis of PPE-2.
Triphenyl phosphine (270 mg, 1.02 mmol) was dissolved in chloroform and the resulting solution was added
to a stirred suspension of PPE-2-Br (100 mg, 0.102 mmol). The reaction was heated to 85 ºC for 12 h. The
resulting mixture was purified by precipitation in ethyl acetate (x5). Yield: 95 mg (61.7%).
PPE-2: UV-vis: λ max = 436 nm; fluo λ max = 478 nm; QY = 25% and ε = 46128.66 M-1 cm-1(Per repeating
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 7.75 (br, 30H), 7.15 (br, 4H), 4.13 (br, 8H), 3.91 (br,

87

4H), 3.77 (br, 6H), 3.61 (br, 16H), 3.45 (br, 12H), 3.27 (br, 4.H), 3.15 (br, 10H). 31P NMR (161.9 MHz,
DMSO-d6): 24.85. FT-IR (neat): ν = 3393, 2874, 2190, 1625, 1493, 1437, 1420, 1353, 1207, 1102, and 1046
cm-1.
CPN-2: UV-vis: λ max = 431 nm; fluo λ max = 469 nm; QY = 5% were measured using 1% DMSO in water
(v/v).

Figure S4.11. 1H NMR of PPE-2-Br in CDCl 3.
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Figure S4.12. 1H NMR of PPE-2 in DMSO-d 6 .

Figure S4.13. 31P NMR of PPE-2 in DMSO-d 6 .

89

Figure S4.14. FT-IR of PPE-2-Br (neat).

Figure S4.15. FT-IR of PPE-2 (neat).
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Figure S4.16. UV-vis and emission spectra of PPE-2-Br in DCM.

Figure S4.17. UV-vis and emission spectra of PPE-2 in DMSO.
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Figure S4.18. UV-vis and emission spectra of CPN-2 1% DMSO in water (v/v).
4.6.3.4 Synthesis of non-degradable PPE with low molecular weight.
PPE-3-Br. Using general procedure described above, the polymerization of monomer M1 (104.0 mg, 0.138
mmol) and M2 (50.0 mg, 0.110 mmol) in presence of Pd[(PPh 3 ) 2 Cl 2 ] (9.3 mg, 0.013 mmol), and CuI (1.3
mg, 0.007 mmol). Resulting mixture was purified by precipitation in methanol (x3) Yield: 0.09 g (67.6%).
An aliquot was redissolved in THF and molecular weight obtained and photo physical properties
characterized in DCM.
PPE-3-Br: GPC: M w = 09.62 kDa; M n = 06.96 kDa; PDI = 1.38. UV-vis: λ max = 428 nm; fluo λ max = 473
nm; QY = 15% and ε = 15931.37 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl 3 ): δ 7.05
(br, 4H), 4.24 (br, 9H), 3.92 (br, 9H), 3.78 (br, 12H), 3.72 (br, 2H), 3.65 (br, 13H), 3.51 (8H), 3.44 (br, 4H),
3.35 (br, 9H).
Synthesis of PPE-3.
Triphenyl phosphine (90 mg, 1.02 mmol) was dissolved in chloroform and resulting solution was added to a
stirred suspension of PPE-3-Br (33 mg, 0.102 mmol). The reaction was heated to 85ºC for 12 h. The resulting
mixture was purified by precipitation in ethyl acetate (x5). Yield: 26 mg (52.0%).
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PPE-3: UV-vis: λ max = 428 nm; fluo λ max = 476 nm; QY = 6% and ε = 29777.78 M-1 cm-1(Per repeating
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 7.76 (br, 30H), 7.14 (br, 4H), 4.16 (br, 8H), 3.91 (br,
4H), 3.76 (br, 6H), 3.61 (br, 14H), 3.45 (br, 12H), 3.26 (br, 4H), 3.14 (br, 9H). 31P NMR (161.9 MHz, DMSOd6): 24.84.
CPN-3: UV-vis: λ max = 427 nm; fluo λ max = 468 nm; QY = 5% were measured using 1% DMSO in water
(v/v).

Figure S4.19. 1H NMR of PPE-3-Br in CDCl 3.
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Figure S4.20. 1H NMR of PPE-3 in DMSO-d 6.

Figure S4.21. 31P NMR of PPE-3 in DMSO-d 6 .
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Figure S4.22. UV-vis and emission spectra of PPE-3-Br in DCM.

Figure S4.23. UV-vis and emission spectra of PPE-3 in DMSO.
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Figure S4.24. UV-vis and emission spectra of CPN-3 1% DMSO in water (v/v).
4.6.3.5 Particle formation and HA complexation.
Particles were prepared prior to each experiment from a concentrated polymer stock solution in DMSO by
diluting with an appropriate volume of filtered (0.22 µm PTFE syringe filter) deionized water (18 Ω). Sodium
hyaluronate (HA) was purchased from Lifecore (MW 40 KDa) and used as received. A stock solution was
prepared by dissolving 2.0 mg of HA in 1 mL of deionized water. CPN/HA complexes were prepared by
mixing CPN and HA at a molar ratio of 1 to 3 (based on polymer and disaccharide repeating unit) then
diluting to the desired concentration with deionized water. CPN/HA complexes were allowed to incubate for
30 minutes prior to measurement.
4.6.3.6 Determination of hydrodynamic diameters of CPNs and CPN/HA complexes.
Nanoparticle tracking analysis (NTA) measurements were performed with a LM10 HS (NanoSight,
Amesbury, United Kingdom), equipped with a sCMOS camera, sample chamber with a 488 nm blue laser,
and Viton fluoroelastomer o-ring. The CPN samples were prepared from concentrated stock solutions of
polymer in DMSO, at approximately 10 μM in a 0.5% DMSO (v/v) solution using deionized water (18
Ω) filtered through 0.22 μm polytetrafluoroethylene (PTFE) syringe filter. The samples were injected into
the sample chamber with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid
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reached the tip of the nozzle. All measurements were performed at 25°C using a LM14C temperature
controller (NanoSight, Amesbury, United Kingdom). Each sample was measured three times.
Table S4.1. Hydrodynamic diameters and zeta potential of CPNs.
Entry

Hydrodynamic
diameter (nm)

Zeta potential
(mV)

CPN-1

139.9 ± 3.0

+ 23.5 ± 1.84

CPN-1/HA

191.8 ± 2.6

- 44.4 ± 1.01

CPN-2

152.7 ± 6.7

+ 29.2 ± 3.56

CPN-2/HA

223.1 ± 6.9

- 42.7 ± 0.83

CPN-3

158.8 ± 16.4

+ 20.1 ± 5.87

1.8E+08

Concentration (particles/mL)

1.6E+08
1.4E+08

Mean:

139.9 ± 3.0 nm

Mode:

91.9 ± 6.7 nm

SD:

76.9 ± 5.3 nm

1.2E+08
1.0E+08
8.0E+07
6.0E+07
4.0E+07
2.0E+07
0.0E+00
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Figure S4.25. NTA for CPN-1.
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Figure S4.26. NTA for CPN-1/HA.
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Figure S4.27. NTA for CPN-2.
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Figure S4.28 NTA for CPN-2/HA.

Figure S4.29. NTA for CPN-3.
4.6.3.7 Determination of zeta potentials of CPNs and CPN/HA complexes
Dynamic light scattering (DLS) measurements were performed by Zetasizer nano-ZS (Zen 3600, Malvern
Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at room temperature. The CPN samples
were prepared from concentrated stock solutions of polymer dissolved in DMSO, at approximately 0.1 mM
in a 5% DMSO (v/v) solution using deionized water (18 Ω) filtered through 0.22 μm PTFE syringe filter.
Each sample was measured six times.
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Figure S4.30. Zeta potential of CPN-1.

Average = - 44.4 ± 1.01 mV

Figure S4.31. Zeta potential of CPN-1/HA.

Figure S4.32. Zeta potential of CPN-2.
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Average = - 42.7 ± 0.83 mV

Figure S4.33. Zeta potential of CPN-2/HA.

Figure S4.34. Zeta potential of CPN-3.
4.6.3.8 Degradation of CPN-1.
To test degradation under intracellular conditions, CPN-1 (5 µM in H 2 O) was treated with excess glutathione
(GSH) at 10 mM. The UV-vis and fluorescence emisson spectra (see Figure S34) were recorded for CPN-1
only, upon immediate addition of GSH, and after 18 h at 37˚C with GSH.
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4.6.4.1 General Cell Culture.
HeLa cells (human cervical cancer, purchased from ATCC) were seeded into a 100 x 20 mm style sterile
tissue culture dish (#353003 BD Falcon, Durham, NC, USA). Then, they were cultured in complete media:
Dulbecco’s minimum essential medium (DMEM)/high glucose (10 mL, HyClone, SH3024301) medium
containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin (P/S) for 24 h
under 5% CO 2 at 37°C. Then, they were subcultured every 48 h. pHRhodo Dextran 10 kDa (#P10361
Molecular probes, Life technologies, New York, USA), MitoTracker Deep Red (#M22425 Molecular probes,
Life technologies, New York, USA) and BODIPY-TR C5-ceramide-BSA complex (#B34400 Molecular
probes, Life technologies, New York, USA) were used for endosome, mitochondria, and Golgi apparatus
staining, respectively. The isolation of mitochondrial and cytosolic fractions of HeLa cells was performed
using an Eppendorf Centrifuge 5430R, Mitochondria Isolation Kit for for cultured cells (#89874, Thermo
Fisher Scientific), and Pierce BCA Protein Assay Kit (#23227, Thermo Fisher Scientific). Pharmacological
endocytosis inhibitors such as chlorpromazine hydrochloride (#ALX-270-171-G005, Enzo Life Sciences,
Inc.), genistein (#AC32827-1000, Acros Organics), methyl-β-cyclodextrin (#377110050, Acros Organics),
LY2994002 (#70920, Caymen Chemical), and cytochalasin D (#BML-T109-0001, Enzo Life Sciences, Inc.)
were purchased from Fisher Scientific.
4.6.4.2 Toxicity Assay
HeLa cells (ca. 10,000 cells per well), in 200 μL of complete medium, were seeded into a 96-well plate and
cultured for one day in a 5% CO 2 incubator at 37 °C. 4 mM of CPN-1, CPN-2 and CPN-3 stock solutions
were prepared by dissolving dried powder in DMSO. 2 mM, 1 mM, 0.5 mM, and 0.1 mM substock solutions
were made by diluting with DMSO. Final concentrations of 40 μM, 20 μM, 10 μM, 5 μM, and 1 μM of CPNs
were added into complete media by dilution with CPN-1, CPN-2, and CPN-3 stock solutions and then
incubated for 18 h. To measure toxicity, 10 μL of MTT solution (5 mg mL-1 in PBS, CALBIOCHEM,
Germany) and 90 μL of complete medium were then added into each well, and the plate was further incubated
for 4 h at 37 °C. After the formed MTT formazan crystals were dissolved in dimethyl sulfoxide (100 μL), the
absorbance intensity was measured by a microplate well reader (infinite M1000 PRO, TECAN, Switzerland)
at 540 nm. Relative cell viability (%) as a function of CPN concentration was expressed as a percentage
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relative to the untreated control cells. All measurements were performed in triplicate and standard deviation
was included in the error bar (see Figure S30).
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Figure S4.35. Cellular toxicity of CPN-1, CPN-2, and CPN-3.
4.6.4.3 Microscopic imaging, co-localization, and time-course subcellular localization.
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek Thermo Scientiﬁc)
and cultured in complete media (400 μL) for 24 h under 5% CO 2 at 37 °C. 80 μL of 20 μM CPNs in water
was added to the culture medium directly, and the cells were further cultured overnight (ﬁnal CPN
concentration: 4 μM). For endosome staining, pHRhodo Dextran 10kDa (5µM) was incubated for 30 min at
37°C. For Golgi apparatus staining, BODIPY-TR C5 -ceramide-BSA complex (ﬁnal 10 μM) was incubated
for 30 min at 4°C. For mitochondria staining, MitoTracker Deep Red (100 nM) was incubated for 30 min at
37°C. After washing with fresh medium, the cells were further incubated for 15 min at 37 °C. A 1 μL aliquot
of Hoechst (5 μg/mL) was added to the culture medium and incubated with the cells for 10 min at 37°C, and

ﬀered saline (PBS

washed two times with phosphate bu
10 min. Fluorescent images of the cells were obtained using a DeltaVision Elite Microscope System (Applied
Precision, Issaquah, Washington, USA) equipped with bandpass ﬁlters such as blue (410−460 nm, Hoechst),
green (500−550 nm, CPNs), and red (595-635nm, Golgi apparatus, endosome, and mitochondria) using a
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60X oil immersion lens (NA 1.42) and n = 1.520 immersion oil. Top and bottom of the chosen cells was
identified, and a Z-stack plot was imaged for each channel. Z-stack microscope images of each sample was
obtained as described above. Colocalization analysis was conducted for three independent cells per polymer
and per organelle (Golgi apparatus, endosome, and mitochondria). Colocalization analysis was conducted
using the microscope software (Softworx 5.0 application, Applied Precision, Issaquah, Washington, USA).
Region of interest (ROI) was selected to contain all of the cell. Pearson’s Correlation Coefficient (PCC) was
used to determine colocalization. Negative control of colocalization was performed by analysis of blue and
green channels staining the nucleus and CPN, respectively. Three independent images of an entire cell were
selected and analyzed to increase analysis objectivity.

Figure S4.36. Microscopic images of HeLa cells incubated with CPN-2 for 18 h followed by endosome
(red) and nuclear (blue) staining. The scale bar is 20 μm.
4.6.4.4 Confocal microscopic imaging, CPN/HA co-localization, and concentration-dependent colocalization.
HeLa cells were seeded into a 12-well plate (~50,000/well) with glass coverslip (#1254584, Fisher Scientific)
one day prior to CPN treatment and cultured in complete media (500 μL) for 24 h under 5% CO 2 at 37°C.
After cell attachment, fresh complete media (500 µL) containing 50 µL of 2 µM or 20 µM CPN in H 2 O (ﬁnal
CPN concentration: 0.2 μM or 2 µM, see Figure S37) was added and cultured for 18 h. For CPN/HA, fresh
complete media (500 µL) containing a premixed solution of 50 µL of 2 µM CPN in H 2 O (ﬁnal CPN
concentration: 0.2 μM) and 15 µL 20 µM HA was added and cultured for 18 h After incubation, cells were
washed with 1X PBS and stained with MitoTracker Deep Red (50 nM) in DMEM only (no FBS or P/S) for
30 min at 37°C. After washing with fresh DMEM for 15 min at 37°C, cells were ﬁxed with 4%
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paraformaldehyde for 10 min at room temperature. After washing with 1X PBS, a 1 μL aliquot of Hoechst
(5 μg/mL) was added to 199 μL PBS and incubated with the cells for 10 min at room temperature. Nuclear
staining is not shown in Figure S37 due to non-specific binding of aggregated CPNs at high concentration.
Cells were then washed three times with 1X PBS and coverslips were mounted on microscope slides
(#1125441, Fisher Scientific) using a 1:1 glycerol/PBS mounting medium. Fluorescent images of the cells
were obtained using an Olympus FluorView FV1200 confocal microscope (Melville, NY USA) equipped
with bandpass ﬁlters such as blue (417–477 nm, nucleus), green (513-556 nm, CPNs), and deep red (672712 nm, mitochondria) using a 60X oil immersion lens (NA 1.35) and n = 1.519 immersion oil. The top and
bottom of the samples were identified, and a Z-stack plot was imaged for each channel. Co-localization
analysis of the green (CPN) and red (mitochondria) channels was conducted for three independent images
using ImageJ software (version 1.50b, U. S. National Institute of Health, Bethesda, Maryland, USA). PCC
scores were calculated to determine co-localization by setting pixel threshold for the entire image per channel
and per sample in order to exclude noise and background signal.23
4.6.4.5 Isolation of Mitochondrial and cytosolic fractions of HeLa cells.
HeLa cells (ca. 10,000,000) were seeded into a 100 x 20 mm style sterile tissue culture dish (#353003 BD
Falcon, Durham, NC, USA) with 10 mL of complete medium. After 24 h incubation at 37 °C, cells were
treated with 5

-1and
M of
CPN-2,
C PN respectively, for 24 h. After washing with PBS three times, the

mitochondrial and the cytosolic fractions were isolated using a commercial kit (Mitochondria Isolation Kit
for cultured cells #89874, Thermo Fisher Scientific). Briefly, HeLa cells were isolated by scraping and
washed with PBS. The kit reagent A was added followed by incubating on ice for 2 min. The kit reagent B
was added followed by vortexing and incubation on ice. After 5 min of incubation, the kit reagent C was
added and the cells were centrifuged (700 x g at 4 °C). The pellet containing nuclei and cellular debris was
discarded and the supernatant was centrifuged (12,000 x g at 4 °C). The supernatant containing the cytosolic
fraction was removed and the pellet composed of mitochondria was washed with the kit reagent C. The pure
mitochondria fractions were isolated by centrifugation (12,000 x g at 4 °C). The mitochondrial fraction and
the cytosolic fraction were diluted to 200 µL 100% DMSO and 200 µL of 50% DMSO, respectively. Then
the total fluorescence intensities of the mitochondrial and the cytosolic fractions resulting from the excitation
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at 455 nm were measured, normalized by the amount protein (µg) of the fraction, and determined by BCA
protein assay (Pierce BCA Protein Assay Kit #23227, Thermo Fisher Scientific).
4.6.4.6 Flow Cytometry
HeLa cells incubated with CPNs were treated with trypan blue (Amresco Inc.) before flow cytometry
measurements (Accuri C6, USA). HeLa cells incubated with 10 μM of CPN for 4 h were treated with trypan
blue (200 μM) for 10 min. After washing with 1X PBS buffer three times, cells were detached by
trypsin/EDTA and fixed with 4 % paraformaldehyde. Post-cell treatment with trypan blue was conducted for
all flow cytometry analyses for entry kinetics and mechanisms.
4.6.4.7 Endocytosis Inhibition Assay
For endocytosis inhibition studies, HeLa cells were seeded into a 6-well plate (~200,000/well) one day before
CPN treatment. Cells were then treated without (control) or in the presence of pharmaceutical inhibitors
chlorpromazine (24.0 mM), genistein (0.21mM), methyl-β-cyclodextrin (1.00 mM), LY294002 (0.12 mM),
or cytochalasin D (0.04 mM) for 30 min before CPN treatment. After CPN treatment, cells were washed with
1X PBS three times followed by trypan blue treatment (0.20 mM) for 10 m. The detached cells were fixed
with 4 % paraformaldehyde in 1x PBS for 10 m and resuspended in a flow cytometry buffer (1X PBS
containing 5 % bovine serum albumin and 0.02 % sodium azide). 10,000 events per measurement were
counted and mean fluorescence intensity of CPN (FL2 channel, 518-548 nm wavelength range) was
measured. Averaged mean fluorescent intensity was calculated using three independent sample sets.

Figure S4.37. Fluorescent intensity plots obtained at the FL2 channel (518-548 nm).
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5.1

Abstract

Red emissive conjugated polymer nanoparticles (CPNs) grafted with folic acid (FA)-modified poly(ethylene
glycol) (PEG 2000 ) side chains were fabricated and complexed with hyaluronic acid (HA) for improved
targeting and labelling of HeLa cells. Modulation of uptake kinetics and amount of internalized CPNs was
achieved by electrostatic complexation as measured by flow cytometry and visualization by high resolution
fluorescence microscopy. These dual ligand-targeting CPNs designed for folate and hyaluronan receptors are
effective for labelling and bioimaging.
5.2

Introduction

Conjugated polymer nanoparticles (CPNs) possess excellent light harvesting and light amplifying properties
owing to their delocalized electronic structure along a π-conjugated backbone, making them excellent
materials for a variety of applications, such as optoelectronic devices, sensing, imaging, and drug delivery.14, 7, 28

These CPNs have become of significant interest in therapeutics and diagnostics (theranostics) as a

consequence of their desirable properties including low cytotoxicity, biocompatibility, facile synthesis, high
sensitivity and superior photostability.5 Structural modifications of CP side chains to incorporate ionic and
hydrophilic moieties (e.g.; charged functional groups and polyethylene glycol chains) allow for tunable
biophysical properties for improved biocompatibility and functionalized performance.10,31 Recently, CPNs
have been utilized as sensitive tumor imaging probes for both in vitro and in vivo applications.6,8,27,29 More
importantly, efficient delivery of CPNs to tumor cells has been achieved in theranostics and bioimaging by
utilizing cell surface receptors.8,26 Rapid delivery of desired materials in large quantities to a wide variety of
tumor cells has become feasible using targeting delivery vehicles.9 In these approaches, ligands are covalently
attached to CPNs to selectively interact/bind with overexpressed receptors on the cell surface. Although these
targeting approaches improves selectivity of CPNs towards tumor cells, it still suffers from the fact that these
nanomaterials (e.g., drug candidates, imaging agents) are often not highly tumor specific, and cause toxicity
to normal cells. To overcome this problem, some research groups have utilized a dual targeting approach to
improve the tumor selectivity of chemotherapy and imaging agents aiming to simultaneously target multiple
receptors on the cell surface.21 In their designs, two ligands are conjugated to the cargo via covalent

109

attachment. Upon interaction with cancer cells, each ligand binds to their specified receptors resulting in
improved selectivity while sparing unintentional targets (i.e., healthy cells).22
To address these issues, “dual targeting” CPNs have been designed for improved labelling and bioimaging.
In our approach, folic acid (FA) binding folate receptors (FR) and hyaluronic acid (HA) binding hyaluronan
receptors were chosen as targeting components as these will ultimately increase interactions between CPNs
and tumor cells. Folate receptors are composed of a glycosylphosphatidylinositol (GPI)-linked membrane
glycoprotein that exists in two membrane-bound isoforms, FR-α and FR-β,which are overexpressed in
ovarian, breast, endometrial, colorectal, and lung carinomas.23 Folic acid is easily internalized into the
cytoplasm as it has a very high affinity to these receptors (K d ~ 1 nM), which is an advantage for efficient
intracellular delivery,24 The binding affinity of FA to FR has been shown to remain very high even when
conjugated to other materials.11 Conjugation of FA to macromolecules presents synthetic issues given its
hydrophobic nature and limited solubility. However, FA has been shown to take on the properties of the
material after conjugation.32 Hyaluronic acid is an anionic, hydrophilic, and biodegradable high molecular
weight polymer (106 to 107 Da) that interacts through several receptors, including CD44 (Cluster Determinant
44), RHAMM (receptor for HA-mediated motility), HARE (HA receptor for endocytosis), and ICAM-1
(Intercellular Adhesion Molecule-1), which are overexpressed in tumor cells and multiple carcinomas.19,20
Hyaluronic acid is an excellent candidate for cancer cell targeting and has been used for more than 30 years
as a drug carrier and/or targeting moiety for biomaterials to target cancer cells.
Reported herein are highly fluorescent far-red emissive (600-800 nm) conjugated polymeric nanomaterials
bearing two types of targeting ligands: covalently attached FA and electrostatically complexed HA. The CP
contains a benzothiadiazole (BT)-doped poly(p-phenyleneethynylene) (PPE) hydrophobic backbone, which
emits in the far-red region. In general, the hydrophobic backbone of CPs causes polymer chains to aggregate
in aqueous solvent, resulting in decreased quantum yield and undesired nonspecific binding. To overcome
these drawbacks, the side chain of the polymer was modified with a quaternary ammonium group in a onepot synthesis, and poly(ethylene glycol) (PEG 2000 ) was conjugated onto the side chain of the CPs to improve
water solubility, reduce undesirable aggregation, and eliminate nonspecific interactions with cells. Folic acid
and PEG 2000 were attached to the CP side chain via simple “click reaction”, whereas HA was incorporated
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into the polymers via mixing in solution, by taking advantage of electrostatic and hydrophobic interactions.
Thus, the design principle reduces tedious synthetic effort to conjugate high molecular weight HA onto PPE.
Moreover, non-covalent complexation provided the freedom of fine-tuning the outer surface of the
nanomaterials with various HAs (i.e.; molecular weight and molar ratio).
Chapter V describes the synthesis, characterization, and effectiveness of a conjugated polymer-based dualtargeting imaging system. The hypothesis was tested in HeLa cells, which express both folate and hyaluronan
receptors. The results demonstrated that the dual-targeting imaging system can indeed be employed to image
cancer cells with heightened efficiency.
5.3

Results and Discussion

The grafted copolymers for CPN-PEG 2000 -FA and CPN-PEG 2000 , (shown in Figure 5.1) were prepared
utilizing azide functionalized PPE copolymers coupled with alkynyl end of PEG 2000 -FA and PEG 2000 ,
respectively (see experimental). Grafting efficiency of PEG 2000 -FA to the copolymer was determined to be
40% resulting in a triblock copolymer (see Figure S5.1). The grafting of PEG 2000 only was much more
efficient with all of the azide functionalized side chain converted resulting in a 1:1 copolymer. In addition,
the one-pot conversion to quaternary ammonium salt was only 50% because of synthetic conditions to control
benzothiadiazole incorporation (see Figure S5.4) After purification via dialysis and followed by freeze
drying, both PEG 2000 only and FA-attached PEG 2000 grafted conjugated polymers were used to construct
nanostructures through a self-assembly process. The polymers were first dissolved in good solvent (DMSO)
then added to deionized water under vigorous stirring to induce self-assembly.
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Figure 5.1. Chemical structures CPNs grafted with folic acid-modified PEG 2000 (CPN-PEG 2000 -FA) and
PEG 2000 only (CPN-PEG 2000 ).
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The UV-vis absorption and emission spectra of CPN-PEG 2000 -FA and CPN-PEG 2000 in water are shown in
Figure 5.2. The absorption maxima for CPN-PEG 2000 -FA and CPN-PEG 2000 are 488 and 483 nm,
respectively. These values are ~30 nm higher than the absorption maxima in THF, indicating hydrophobic
main chain induced aggregation and lengthening of the conjugated chains (see Figure S5.21). The emission
maxima for CPN-PEG 2000 -FA and CPN-PEG 2000 in water are 618 nm and 620 nm, respectively. The
significantly red emission compared to structurally similar PPE polymers without BTz units suggests
efficient donor-acceptor type energy transfer from PPE unit to BTz unit. Moreover, a slight increase in
emission maxima (~20 nm) in water compared to organic solvents such as chloroform, DCM and THF
indicates minimal chain-chain type aggregation in water. The emission quantum yields (Φ) for CPNPEG 2000 -FA and CPN-PEG 2000 are 0.55 and 0.50, respectively, calculated using coumarin 6 in ethanol as
the standard. The incorporated bulky side-chains (i.e.; PEG 2000 , FA, and quaternary ammonium moieties)
likely sterically hinder excessive inter-chain aggregation in water. Compared to the more green and red
emissive conjugated polymers typically used for nanoparticle fabrication and imaging, CPN-PEG 2000 -FA
and CPN-PEG 2000 have relatively higher quantum yields in water, which is ideal for NPs used in bioimaging.
CPN-PEG2000-FA

CPN-PEG2000

Figure 5.2. Absorption and emission spectra for (a) CPN-PEG 2000 -FA and (b) CPN-PEG 2000 in water
(Excitation = 480 nm, slit width = 3 nm, integration time = 0.1 s).

The resulting NPs had diameters ranging from 105 to 108 nm, as determined by NTA analysis (see Figure
5.6). The side chains with the nonionic diethylene oxide moiety and hydrophilic PEG 2000 apparently stabilize
the surface of the NPs, thereby hindering aggregation and precipitation. Typically, hydrophobic NPs
aggregate in water as a mechanism of water exclusion from the hydrophobic surface. It was expected that the
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CPNs fabricated from polymers containing hydrophilic side chains (i.e., PEG 2000 ) and ionic side chains (i.e.;
quaternary ammonium salt) will remain stable over time. To more thoroughly asses the stability of these NPs,
the size distribution of the colloidal suspension was checked after one month. No significant change to the
size distribution of the NPs, suggesting NPs are highly stable in water. High colloidal stability of the CPNs
and uniform particle formation were also confirmed by zeta potential measurements. Both CPN-PEG 2000 FA (ζ +89.7 ± 2.21 mV) and CPN-PEG 2000 (ζ +44.7 ± 1.02 mV) have very high positive surface charge with
narrow charge distribution in water (shown in Figure S5.22). The high positive charges can be attributed to
the presence of quaternary ammonium ions on the nanoparticle surface. While the high zeta potentials of
CPNs may cause issues upon interactions with cellular proteins, the particle surface can be further modified
with optimization of quaternary ammonium salt incorporation.
Both CPNs (FA functionalized and non-functionalized) showed limited cytotoxicity after 18 h of incubation,
only decreasing to 80% viability upon treatment with 40 µM CPN-PEG 2000 -FA (see Figure S5.23).
Moreover, this concentration of CPNs was approximately seven times higher than that of CPNs used for in
vitro experiments. The minimal toxicity of the CPNs towards HeLa cells, in spite of presence of ionic side
chains, was attributed to the presence of biocompatible PEG 2000 in the outer layer of the polymer.5 Toxicity
of the CPN/HA complexes were not measured, since HAs are known to be nontoxic and have been used to
reduce toxicity of polyethyleneimine (PEI) cationic polymers.
Flow cytometry experiments were performed to quantitate the efficacy of CPNs for dual-targeting in tumor
cells. The CPNs were complexed with HA at different ratios using 40 and 100 kDa HA, as it is known that
molecular weight of HA plays a role in receptor interactions and biodistribution.27 It was expected that the
molar ratio between CPN and HA will be an important factor to optimize when using different MW HAs.
Our previous work indicated that complexation of cationic CPNs with 30 µM of 100 kDa HA increased
cancer cell labelling and this served as a starting point for screenings.29 To improve maximum fluorescence
signal from cell internalized CPN/HA complexes, several ratios of CPN/HA complexes were investigated.
The HeLa cells were incubated for 18 h in presence of CPN/HA complexes at molar ratios of 1:1, 1:2, and
1:5. After incubation, cells were treated with trypan blue (200 µM) to quench fluorescence originating from
CPNs attached to the cell membrane, which was verified in solution (Figure S5.24). Trypan blue is known to
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absorb energy in the wavelength range that CPNs emit fluorescence, and treatment is an established method
to quench extracellular fluorescence.33-36 Mean fluorescence intensities (average of three replicates)
determined by the scattering of control cells (Figure S5.25) were plotted against different ratios of CPN/HA
complexes with 40 and 100 kDa HA as shown in Figure 5.3. From these results, it was concluded that 40k
HA showed higher fluorescence for internalized CPN/HA complexes. The HeLa cells exhibited maximum
fluorescence intensity at CPN-PEG 2000 -FA/HA ratio of 1:1, with a two-fold increase using 40k HA. Any
excess of HA further reduced the fluorescence intensity, which could be the result of excess HA and negative
charges that will not favor uptake of the CPNs at the cell surface. The control CPN-PEG 2000 showed
maximum fluorescence intensity at 1:2 ratio (CPN-PEG 2000 /HA), however, the increase in fluorescence was
very minimal compared CPN-PEG 2000 -FA. A similar trend was observed for 100 kDa HA, with a greater
reduction in fluorescence compared to 40 kDa HA. Moreover, complexation with 100 kDa HA gave viscous
solutions with aggregated particles for both CPN-PEG 2000 -FA and CPN-PEG 2000 . Thus, on the basis of
these experiments we optimized CPN/HA formulation ratio to 1:1 for CPN-PEG 2000 -FA and 1:2 for CPNPEG 2000 complexed with 40 kDa HA for further studies.
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Figure 5.3. Cellular uptake of CPN-PEG 2000 -FA (a) and CPN-PEG 2000 (b) complexed with 40 kDa and 100
kDa HA at various ratios after 18 h incubation. Error bars represent standard deviation from n = 3.

The effectiveness of the dual targeting CPNs was investigated in a time course experiment. It was anticipated
that internalization of the CPN-PEG 2000 -FA/HA complex would occur via both folate and hyaluronan
receptors, and these events would enhance uptake of the complex resulting in an increased fluorescence signal
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from inside the cells. Figure 5.4 shows a comparison plot for fluorescence associated with internalized CPNs
and CPN/HA complexes at different incubation time. In the case of CPN-PEG 2000 -FA only, maximum
fluorescence was obtained after 18 h of incubation. Typically, folate receptor mediated endocytosis is rapid
(~0.5 h) for free FA and FA conjugated to small molecules,11 but when FA is conjugated to macromolecules
(i.e., PPEs), maximum uptake can range 4-24 h.12,13 Upon complexation of CPN-PEG 2000 -FA with HA (1:1)
ratio, the maximum fluorescence was obtained at 8 h, with 6X increase in intensity compared to CPNPEG 2000 -FA only. The maximum uptake time of 8 h has been for reported for similar HA-conjugated NPs
under various formulations.14 This observation indicates an increase in CPN uptake in shorter time because
of hyaluronan mediated endocytosis, and more importantly, modulation of endocytosis can be achieved for
enhanced uptake by simple mixing with HA. It is hypothesized that the substantial increase in uptake of the
CPN-PEG 2000 -FA/HA complex results from increased interactions through hyaluronan receptors as HA has
been shown to modulate multiple receptors during mediated endocytosis.14 By utilizing HA with CPNPEG 2000 -FA, it is also hypothesized that a cooperative effect contributes to the substantial uptake increase
due to multiple ligands/receptors and CPNs at the cell surface.18 The cooperative effect can be attributed to
the availability of both FA and HA on the outside of CPN/HA complex for receptor –ligand interactions. It
is assumed that the CPNs form random complexes with HA as there are no significant changes in UV
absorption and emission spectral shapes upon complexation with HA, indicating no significant structural
reorganization of polymer chains (see Figure 5.5). There is also an increase in particle size and broadening
of particle size distributions (see Figure 5.6), which indicate random complex formation. Similar uptake
values at 18 h for both CPN-PEG 2000 -FA and CPN-PEG 2000 -FA/HA are speculated to be driven by FR
mediated endocytosis with recycling of receptors back to the cell surface.11 Time course experiments with
CPN-PEG 2000 exhibited a more intense signal (3X) from cells upon incubation with mixing with HA (1:2)
for 4 h, with similar maximum uptake time. This suggests that the kinetics of endocytosis for both CPNPEG 2000 and CPN-PEG 2000 /HA are driven by factors independent from hyaluronan mediated endocytosis.
Both CPN/HA complexes display a decrease in uptake after maximum uptake time, which could be attributed
to inefficient endosomal escape at longer incubation times. Further studies are needed to better understand
the kinetics of the dual ligand system.
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Figure 5.4. Plot of fluorescence intensities of CPN vs incubation time at optimized formulation of CPN/HA
showing, (a) six-fold enhancement of CPN-PEG 2000 -FA uptake (8h vs 18h), (b) three-fold enhancement of
CPN-PEG 2000 uptake at 4 h. Error bars represent standard deviation from n = 3.

Figure 5.5. UV-absorption (top row) and emission (bottom row) spectra for CPN-PEG 2000 -FA (left
column) and CPN-PEG 2000 (right column) complexed with 40 kDa HA at 1:1 and 1:2 molar ratios,
respectively.
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(a)

Sample

Mean size (nm)

CPN-PEG2000-FA

105.5 ± 1.4

CPN-PEG2000-FA/HA

202.6 ± 2.2

CPN-PEG2000

107.9 ± 4.5

CPN-PEG2000/HA

233.4 ± 22.7

(b)
CPN-PEG2000-FA

CPN-PEG2000

CPN-PEG2000-FA/HA

CPN-PEG2000/HA

Figure 5.6. Mean sizes (a) and size distributions (b) as measured by NTA of CPN/HA complexes.
The results from the previous flow cytometry uptake studies and microscopic imaging experiments suggest
different endocytosis mechanisms involved during uptake of CPNs and CPN/HA complexes. Mechanistic
studies for CPN and CPN/HA complexes were performed using several known endocytic inhibitors and
competitive inhibition by adding free FA and free HA to the culture medium prior to CPN treatment. As
shown in Figure 5.7, there was a significant reduction in uptake of CPN-PEG 2000 -FA via CvME, as well as
reduced uptake via MPC and excess FA. These results are expected as FR are known to be on the cell surface
and as well as within caveolae.16,23 Similar pathways were inhibited for CPN-PEG 2000 -FA/HA, with
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significant reduction from excess HA. The inhibition studies indicate that CPN-PEG 2000 -FA follows typical
folate-mediated endocytosis and when electrostatically complexed with HA, displays both folate and
hyaluronan receptor mediated endocytosis. The control CPN-PEG 2000 displayed reduced update via CME,
CvME, and MPC pathways, whereas CPN-PEG 2000 /HA showed reduced uptake via MPC and excess HA.
These results suggest that CPN-PEG 2000 has multiple endocytosis pathways, which could be attributed to
the hydrophilic nature of the PEG 2000 side chain that allows for longer circulation time,17 and may not be as
specific as CPN-PEG 2000 -FA. While it is evident that there are different uptake mechanisms for CPNs only
and CPN/HA complexes, mechanistic studies did not provide definitive results, which could be the explained
by the differences in optimal uptake times and the time dependence of intracellular trafficking.
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Figure 5.7. Effect of endocytosis inhibitors of CPN-PEG 2000 -FA (left) and CPN-PEG 2000 (right) using
chlorpromazine (24 µM) for clathrin mediated endocytosis (CME), genistein (210 μM) for caveolae mediated
endocytosis (CvME), methyl-β-cyclodextrin (1000 μM) for CME and macropinocytosis (CvME/MPC),
LY294002 (120 μM) for macropinocytosis (MPC1), or cytochalasin D (0.04 mM) for macropinocytosis
(MPC2) incubated 30 minutes before CPN treatment. For blocking any potential pathways of FA (folate) and
HA (hyaluronan), cells were treated with excess FA (1 mM) and HA (100 kDa, 1.5 mM), respectively, for
one hour before CPN treatment. Average values are reported (n = 3) with standard deviation represented in
error bars. *p = 0.01.
High resolution fluorescence microscopy was used to visualize the distribution of internalized CPNs. After
incubation of cells with CPNs and CPN/HA complexes for desired time, cells were washed with PBS, fixed
with 4% paraformaldehyde, and then treated with Hoechst dye to differentiate nuclei. After a final washing
with PBS, the fixed cells were observed under a high resolution microscope. For each sample top and bottom
of the selected cells were identified, and a Z-stack plot was imaged for each channel. Although some
internalization of CPNs was observed after just 2 h incubation, the optimal incubation time for each CPN/HA
complex is reported here, which is 8 h and 4 h for CPN-PEG 2000 -FA/HA and CPN-PEG 2000 /HA,
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respectively. As shown in Figure 5.8a, the overlay image obtained from the blue and red channels for CPNPEG 2000 -FA showed red fluorescence dots in the cytoplasm and surrounding the nucleus, as well as outside
of the cell. The incorporation of PEG 2000 to the side chains was intended to prevent nonspecific binding, yet
some is still observed. Interestingly in the case of CPN-PEG 2000 -FA/HA complex, it is speculated that the
polymers were internalized as large dense aggregates as seen in the contrast image (Figure 5.8f), indicating
a strong non-covalent association between CPN-PEG 2000 -FA and HA, with essentially no nonspecific
binding observed after complexation. Moreover, the fluorescence intensity of CPN-PEG 2000 -FA/HA
complex increased significantly compared to the only CPN-PEG 2000 -FA, shown in the overlay image (Figure
5.6b). Similarly, a stronger more fluorescent signal was observed when cells were treated with CPNPEG 2000 /HA (Figure 5.8d) than CPN-PEG 2000 only (Figure 5.8c). While CPN-PEG 2000 displayed punctuated
dots in the cytoplasm, CPN-PEG 2000 /HA shows punctuated dots as well as diffuse red signal throughout the
cytoplasm, indicating a difference in uptake mechanism. These results emphasize and visually display the
involvement of hyaluronan mediated endocytosis for significantly enhancing internalization of CPN/HA
complexes.

A)

CPN-PEG2000/HA

CPN-PEG2000

CPN-PEG2000-FA/HA

CPN-PEG2000-FA

B)

C)

D)

F)

G)

H)

Overlay

E)

15 µm

Contrast

Figure 5.8. High-resolution fluorescence microscopic images (top row) of blue (nuclei) and red (CPNs)
channel overlay, and contrast images (bottom row) of cellular uptake in HeLa cells for CPN-PEG 2000 -FA (a
and e), CPN-PEG 2000 -FA/HA (b and f), CPN-PEG 2000 (c and g), and CPN-PEG 2000 /HA (d and h). Scale
bar is 15 µm.
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5.4

Conclusion

In conclusion, highly fluorescent “dual-targeting” CPNs for bioimaging have been developed. The design
utilizes simple synthetic strategies to modify the side chain of the conjugated polymer while conserving the
emission of the polymer backbone in water. Specifically, ionic side chains and PEG 2000 were incorporated
into the polymer to create stable water-soluble nanomaterials. During PEG conjugation, the FA was
selectively attached to the one end of PEG to ensure than they are available on the surface of the CPNs to
bind with folate receptors of overexpressing cancer cells. The second ligand, HA, was incorporated as an
electrostatic complex with CPNs via non-covalent interactions. High resolution fluorescence microscopy and
inhibition studies confirmed that enhanced uptake of CPNs/HA complex was via receptor mediated
endocytosis. Improved uptake was quantified as 6X higher for CPN-PEG 2000 -FA/HA complex and 3X
higher for CPN-PEG 2000 /HA complex than CPNs only. Furthermore, these CPNs show minimal inherent
toxicity toward HeLa cells. Therefore, the present study suggests that the dual ligand approach enhances the
targeting efficiency of CPNs and could be very useful as nontoxic, biocompatible, highly fluorescent
bioimaging agents. Utilization of these CPNs as far-red emissive imaging agents for sensitive animal study
is underway. Moreover, incorporation of therapeutic agents in the side chain of the polymers will be
investigated to develop water-soluble CPNs as a nontoxic and biodegradable delivery agent.
5.5

Outlook

This chapter presented a dual ligand approach to improve cellular interactions and uptake in cancer cells. The
incorporation of the PEG 2000 side chain provides increased solubility, but PEG 2000 -FA side chain poses a
synthetic challenge to control the amount of incorporation as a result of the poor solubility of FA. An
alternative method would be to modify the azide functionalized monomer side chain to increase
hydrophilicity to then use a shorter ethylene oxide coupled to FA. By utilizing a shorter ethylene oxide chain,
a clear understanding of uptake kinetics and pathways would provide useful information as to the role that
folate and hyaluronan receptors play. Another alternative approach would be use microwave-assisted
polymerization, which the Moon lab has recently started exploring. Under microwave irradiation,
polymerization conditions are much more controlled and produce more reproducible results because of
uniform heating and shorter reaction times. In order to accurately assess the dual ligand approach, a series of
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three CPNs are needed: CPN with PEG only side chain, CPN with PEG-FA side chain, and CPN with PEGFA complexed with HA. Since copolymers were used, a variation in co-polymer blocks was obtained based
on synthetic approach. The first step would be to make an CPN array composed of non-BTZ doped PPEs
with controlled incorporation of FA to accurately assess cellular interactions of FA and HA. Next, controlled
incorporation of BTz units to the PPE backbone would provide a unique red emissive platform for improved
sensitivity compared to green CPNs. A clear understanding of uptake pathways as function of the folate and
hyaluronan receptors could be discerned from a defined CPN array. Subcellular localization studies of the
dual targeting CPNs would provide information how modulating cell surface interactions affects subcellular
trafficking and intracellular fate.
5.6

Experimental

All monomer and polymer synthesis/characterization and cell toxicity assay were completed Dr. Rajib
Choudhury.
5.6.1

Materials.

Aluminium oxide (neutral, STD grade, 150 mesh, 50 Å), Dimethyl formamide (99.8%), methyl sulfoxide
(99.0%+), dichloromethane (99.8%+), hydroxybenzotriazole (HPLC, 99.0%+), folic acid (97.0%+), 5hexynoic acid (97%) and N-(dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride were purchased
from Sigma-Aldrich. Sodium chloride (laboratory grade), sodium azide (laboratory grade), silver oxide
(99.0%+), sodium iodide, sodium sulfate, magnesium sulfate, ammonium chloride, sulfuric acid,
hydrochloric

acid,

ethyl

acetate

(99.0%+),

hexane,

tetrahydrofuran

(99.0%+),

N,N,N',N'-

tetramethylethylenediamine (97%+), N, N´-dicyclohexylcarbodiimide (99.0%+) and diethyl ether (99.8%+)
were purchased from Fisher Chemical. Celite-545, triethyl amine (99.0%+), tetrahydrofuran (99.0%+),
copper iodide (98%+), potassium iodide (99.0%+), triphenyl phosphine (99.0%+), p-toluenesulfonyl chloride
(99.0%+),

4-dimethylaminopyridine

(99.0%+),

diisopropylethyl

amine

(99.5%+)

and

bis(triphenylphosphine)palladium (II) chloride (98%) were purchased from Acros. Acetone and methyl
alcohol (anhydrous >99.9%) were purchased from Marcon Fine Chemicals. PEG 2000 was obtained from Alfa
Aesar. Copper bromide (99.0%+) was obtained from Fluka. 4,7-dibromo-2,1,3-benzothiodiazole was
purchased from Ark Pharm Inc. Carbon tetrabromide (99%) and (trimethylsilyl)acetylene (99%) were
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purchased from Oakwood Chemical. Silica gel (40-63 µm) was obtained from Silicycle Inc. Thin layer
chromatography plates (TLC silica gel 60 F254) was obtained from Merck. All deuterated solvents were
purchased from Cambridge Iosotope Laboratories, Inc (Cambridge, MA). PEG 2000 was freeze dried before
use. N, N´-dicyclohexylcarbodiimide was recrystallized from chloroform and dried overnight under high
vacuum before use. All chemicals were used without further purification unless stated otherwise.
All biological reagents were used without further purification. HeLa cells (human cervical cancer) was
purchased from ATCC. 100 x 20 mm style sterile tissue culture dish (#353003 BD Falcon, Durham, NC,
USA), 96-well plate (#3795 Costar clear polystyrene 96-well plates, Corning Life Sciences Plastic), 12-well
plate (#130185 BioLite 12-well plates, Thermo Scientific), minimum essential medium (MEM)/Earle’s
balanced salt solution (EBSS, HyClone, SH30024), fetal bovine serum (FBS, Hyclone FetalClone I serum,
SH3008002, GE Healthcare), 100 U/mL penicillin and 100 μg/mL streptomycin (Penicillin/Streptomycin
Mixture, Fisher BioReagents, BP2959-50), and MTT(CALBIOCHEM, Germany) were purchased from
Fisher Scientific. Sodium hyaluronate (HA) was purchased from Lifecore (MW 40K and 100 K) and used
as received. Stock solutions were prepared by dissolving 2.3 mg and 2.2 mg of 40K and 100K HA,
respectively, in 1 mL deionized water. Pharmacological endocytosis inhibitors such as chlorpromazine
hydrochloride (Assay Designs, Inc), genistein (Acros Organics), methyl-β-cyclodextrin (Acros Organics),
LY2994002 (Caymen Chemical), and cytochalasin D (Assay Designs, Inc) were purchased from Fisher
Scientific. Trypan blue was purchased from Amresco, Inc. and used as received.
5.6.2

Instrumentation.

Nuclear magnetic resonance (NMR) data were recorded on a Bruker Avance 400 spectrometer operating at
400 MHz for 1H NMR and 100.6 MHz for
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C NMR at 25 oC. The acquired data was processed in the

TOPSPIN 3.1 software. Chemical shifts are represented in parts per million (ppm) and referenced to CDCl 3
(δ ~7.26 ppm), DMSO (δ ~2.50 ppm) solvent peak. The spectra were recorded with a spectral width (SW) of
8 ppm and 64 k data points. UV-vis data were collected on a Varian Cary 50 Bio spectrometer. Fluorescence
spectra were obtained using a FluoLog-3 Spectrofluorometer (Jobin Yvon/Horiba). Quantum yields were
calculated using Coumarin 6 (QY = 0.6) in ethyl alcohol as a fluorescence standard. Graphs were plotted
using Origin 9.1 software (OriginLab, Northampton, MA, USA). Fourier transform infrared (FT-IR) spectra
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were recorded on a PerkinElmer Spectrum 100 FT-IR Spectrometer. For each sample, 16 spectra were
collected at a 4 cm-1 spectral resolution and with a spectral width ranging from 4000 cm-1 to 700 cm-1.
Background subtraction and pick picking were performed in the OMNIC software. High-resolution mass
spectrometry data were recorded on a Bruker Daltonics ultrOTOF Q mass spectrometer with electron
ionization mode.
5.6.3

Monomer design.

Monomers were synthesized according to procedures described in literature and synthetic routes for
monomers M1 and M2 are shown Scheme S5.1. Alkoxy side chains were incorporated in the aromatic rings
to enhance solubility of the monomers and corresponding conjugated polymers in organic solvents.
Moreover, to enhance aqueous solubility of the resulting polymer nanoparticles (NPs), bromo groups were
incorporated in the terminal position of the alkoxy side chain of M1 which was replaced in situ by triethyl
amine during Sonogashira polymerization at elevated temperature, resulting in a water soluble quaternary
ammonium ion.
Compound 3 (1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diiodobenzene) was prepared from readily
available compound 2. Compound 4 was obtained via Sonogashira reaction of 3 with trimethylsilyl acetylene,
which was then stirred in the solution of methanol and potassium carbonate to afford final M1 in 58% yield.
Presence of two terminal alkyne protons was confirmed by comparing the integration ratio of signal at 3.34
ppm with aromatic signals at 7.00 ppm (see Figure S1 for full NMR spectra). Compound 6 was prepared
from 5 via Appel reaction, then the terminal bromides were converted into azides by reaction with sodium
azide in DMF at 70oC for 6 hours. 1H-NMR and 13C NMR spectroscopy confirmed that the conversion of the
terminal bromides into azides was quantitative (see figure S2, S3 for 1H and 13C NMR of M2). The product
was also characterized by IR spectroscopy. The typical band at ~2100 cm−1 owing to the conversion of the
bromide termini into azide group appeared as expected (Figure S4).
M3 (FA-PEG 2000 -propargyl) was prepared using a modified procedure reported by Mahou et.al. (as shown
in Scheme S5.1).25 First, mono-tosyl PEG 2000 was synthesized with 90% yield. Subsequently, the tosyl end
group was converted into azide and then into amine group. 1H NMR spectroscopy confirmed that conversion
of azide to amine was quantitative. The amine end group of compound 9 was then successfully coupled to
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hex-5-ynoic acid to afford 10. Finally, M3 was prepared from DCC/DMAP coupling reaction of FA with 10,
as a 1:1 mixture of 10 and M3. The mixture was used without further purification for grafting of conjugated
polymers.

A)

R1
I

I
R1

R2

CBr4, PPh3
DCM
r.t
81%

I

I
R2

2

B)

R3

R3

R2

4

NaN3, DMF
o
70 C
43%

R1 =
R =

R5

6

M2

H

O

n

n = 45

H

Ag2O, KI, TsCl
DCM
r.t.
83%

HO
NH
O

O
O

n

O

H

O

OTs

7
O
N
H

n

H
N

NaN3, DMF
o
70 C
92%

N

N

N
O

NH
O

M3

H

R3 =
R =

O

R5 =

O

4

C)
O

O
O

2

I

I

R2

M1

Side chain legend:

R5
I

R4

5

K2CO3, MeOH
TMS
r.t.
58%

TMS

3

I

R2

R2

R4

CBr4, PPh3
DCM
r.t

I

I

TMS
PdCl2(PPh3)2, CuI
Et3N, THF
o
60 C

O

N3

n

8

O

O
O
O
O
O

PPh3, MeOH
reflux
69%

O

OH

O

Br

OH
Br
N3

H

O

NH
n 2

9

hex-5-ynoic acid, EDC
HOBt, DIPEA, DMF

r.t.
51%

NH2
DCC, DMAP
DMSO
r.t.
41%

NH

10

O

H
n

O

Scheme S5.1. Synthesis of monomers (M1, M2) and heterodifunctional PEG 2000 (M3).
5.6.4

Monomer synthesis.

Synthesis of 1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene (M1). Following literature
procedure, synthesis of M1 was carried out in three steps starting from readily available compound 2. Briefly,
Carbon tetrabromide (8.0 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol) were added to a
stirred solution of 2 in DCM under nitrogen atmosphere. The resulting solution was stirred for 2 h at room
temperature. After the solvent was removed the residue was purified by silica gel chromatography (ethyl
acetate/hexane 1:4) to give a white solid compound (3). Yield (5.3 g, 81.2%). 1H NMR (400 MHz, CDCl 3 )
δ 7.26 (s, 2H), 4.14 (t, 4H), 3.91 (t, 4H), 3.85 (t, 4H), 3.81 (t, 4H), 3.73 (t, 4H), 3.50 (t, 4H). 13C NMR (100.6
MHz, CDCl 3 ) δ 153.4, 123.5, 86.5, 71.3, 71.2, 70.7, 70.3, 69.7, 30.4.
Under nitrogen atmosphere, Pd(PPh 3 ) 2 Cl 2 (0.23 g, 0.33 mmol) and CuI (0.031 g, 0.16 mmol) were added to
a solution of 3 (2.24 g, 3.3 mmol) in 30 mL of anhydrous THF and trimethylamine mixture (2:1).
Trimethylsilylacetylene (0.97 g, 9.8 mmol) was slowly added to the mixture at room temperature. The
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reaction mixture was then refluxed under nitrogen for 3 h. The solvent was removed under reduced pressure.
The residue was passed through a short column of silica gel with hexane as the eluent. The evaporation of
the solvent led to a yellow solid which was used in next step without further purification. In a 100 mL round
bottom flask, 4 (4.38 g, 6.0 mmol), K 2 CO 3 (1.65g, 12 mmol) were added in 30 mL MeOH. The resulting
slurry was stirred for 3 h. The progression of the reaction was monitored by thin layer chromatography. After
4 h, solvent was evaporated to dryness and purified by silica gel column chromatography (hexane as eluent).
Yield (2.0 g, 58%). 1H NMR (400 MHz, CDCl 3 ) δ 7.00 (s, 2H), 4.15 (t, 4H), 3.87 (t, 4H), 3.81 (t, 4H), 3.78
(t, 4H), 3.76 (t, 4H), 3.69 (t, 4H), 3.47 (t, 4H), 3.33 (s, 2H). 13C NMR (100.6 MHz, CDCl 3 ) δ 154.1, 118.5,
113.6, 82.7, 79.6, 71.3, 71.1, 70.7, 69.7, 69.6, 30.3. HRMS (ESI) m/z calcd. for [C 22 H 28 Br 2 O 6 ] 548.0232;
found for [C 22 H 28 Br 2 O 6 + H]+ 549.0295.
Synthesis of 1,4-bis(2-(2-azidoethoxy)ethoxy)-2,5-diiodobenzene (M2). This compound was synthesized
according to procedures described in literature. The product was white crystals (0.5g, 43%). 1H NMR (400
MHz, CDCl 3 ) δ 7.24 (s, 2H), 4.10 (t, 4H), 3.88 (t, 4H), 3.79 (t, 4H), 3.69 (t, 4H), 3.39 (t, 4H). 13C NMR
(100.6 MHz, CDCl 3 ) δ 153.2, 123.5, 86.5, 71.3, 71.2, 70.8, 70.3, 70.1, 69.7, 50.7.
Synthesis of α-tosyl-ω-hydroxyl PEG 2000 (7). PEG (2000 g/mol, 20.0 g, 0.01 mol), previously freeze-dried,
was dissolved in 250 mL of anhydrous DCM. Ag 2 O (1.5 eqv., 3.55 g, 0.015 mol) and KI (0.2 eqv., 0.332 g,
0.002 mol) were added. To this rapidly stirred solution, TsCl (1.05 eqv., 2.0 g, 0.0105 mol) was added in one
portion. The reaction mixture was stirred for 18h at room temperature before filtration over a filter cell cake
and solvent removal by rotary evaporation was performed. The crude product was dissolved in 30 mL DCM
and then precipitated by dropwise addition into diethyl ether (300 mL, 3x). The white hygroscopic compound
was collected by vacuum filtration under nitrogen atmosphere and dried overnight under high vacuum. Yield
(18 g, 83%). 1H NMR (400 MHz, DMSO-d 6 ) δ 7.78 (d, 2H), 7.48 (d, 2H), 4.56 (t, 1H), 4.11 (d, 2H), 3.50
(br, 191H), 2.42 (s, 3H). 13C NMR (100.6 MHz, DMSO-d 6 ) δ 144.9, 132.4, 130.1, 127.6, 72.4, 69.9, 69.8,
67.9, 60.2, 21.0. IR (neat) υ 3454, 2882, 2865, 1464, 1339, 1098, 1055 cm-1.
Synthesis of α-azide-ω-hydroxyl PEG 2000 (8). In a 250 mL round-bottom flask α-tosyl-ω-hydroxyl PEG (7,
10 g, 0.0046 mol) was dissolved in 50 mL dry DMF. Then NaN 3 (5.0 eqv., 1.5 g, 0.023 mol) was added in
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one portion. The reaction mixture was stirred overnight at 70 °C under nitrogen atmosphere. After cooling
down to room temperature and filtration, DMF was removed under vacuum. Excess NaN 3 was quenched by
addition of water. The crude product was dissolved in 200 mL DCM and washed thrice with brine and twice
with water. The organic layer was dried over sodium sulfate, reduced to a small volume by rotary evaporation,
and finally precipitated by dropwise addition into diethyl ether (250 mL, 3x). The white precipitate was
collected by vacuum filtration and dried overnight under high vacuum. Yield (8.7 g, 92%). 1H NMR (400
MHz, DMSO-d 6 ) δ 4.57 (br, 1H), 3.68 (t, 2H), 3.50 (br, 206H). 13C NMR (100.6 MHz, DMSO-d 6 ) δ 72.3,
69.8, 69.2, 60.2, 49.9. IR (neat) υ 3454, 2882, 2865, 2108, 1464, 1343, 1274, 1103, 1055 cm-1.
Synthesis of α-amine-ω-hydroxyl PEG 2000 (9). α-azide-ω-hydroxyl PEG 2000 (8, 4.0 g, 0.00195 mol) and PPh 3
(3.0 eqv., 1.53 mg, 0.00585 mol) were dissolved in 30 mL MeOH. The resulting mixture was refluxed
overnight under nitrogen atmosphere at 70 oC and then cooled down to room temperature. After solvent
removal by rotary evaporation, the crude mixture was dissolved in 20 mL DCM, washed twice with brine
and dried over sodium sulfate. Solvent was evaporated to dryness, dissolved in 5 mL DCM and precipitated
in diethyl ether (200 mL, 3x). White powder was collected by vacuum filtration and dried overnight under
high vacuum. Yield (2.7 g, 69%). 1H NMR (400 MHz, DMSO-d 6 ) δ 4.58 (br, 1H), 3.51 (br, 204H), 2.64 (t,
2H). 13C NMR (100.6 MHz, DMSO-d 6 ) δ 72.3, 69.8, 60.2. IR (neat) υ 3454, 2879, 1466, 1344, 1276, 1098
cm-1.
Synthesis of α-(hex-5-ynamide)-ω-hydroxyl PEG 2000 (10). α-amine-ω-hydroxyl PEG 2000 (9, 4.63g, 0.0023
mol), 5-hexynoic acid (0.283 g, 0.0025 mol) were dissolved in 10 mL anhydrous DMF, followed by addition
of EDC (1.2 eqv., 0.431 g, 0.00278 mol), HOBt (1.2 eqv., 0.375 g, 0.00278 mol) and DIPEA (1.2 eqv., 0.359
g, 0.00278 mol). The reaction mixture was stirred for 24 h under nitrogen atmosphere at room temperature
and then filtered to remove insoluble byproducts. The filtrate was concentrated under high vacuum and
precipitated in diethyl ether (100 ml). Solid precipitate was collected under vacuum filtration, dissolved in
20 mL DCM, washed thrice with deionized water and then dried over sodium sulfate. Solvent was evaporated
under rotary evaporation, precipitated in diethyl ether (100 mL, 2x) and collected under vacuum filtration.
Yield (2.5 g, 51%). 1H NMR (400 MHz, DMSO-d 6 ) δ 7.89 (t, 2H), 4.59 (t, 2H), 3.51 (br, 200H), 2.77 (s,
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1H), 2.12-2.18 (m, 4H), 1.61-1.68 (m, 2H).

C NMR (100.6 MHz, DMSO-d 6 ) δ 171.7, 84.1, 72.3, 71.3,
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69.7, 60.1, 34.4, 24.3, 17.2. IR (neat) υ 3424, 3274, 2887, 1651, 1467, 1340, 1103 cm-1.
Synthesis of heterodifunctional α-(hex-5-ynamide)-ω-folic acid PEG 2000 (M3). Folic acid (92.74 mg, 0.210
mmol), DCC (43.32 mg, 0.210 mmol) were dissolved in 10 ml anhydrous DMSO, under nitrogen atmosphere,
followed by addition of DMAP (10 mol%, 2.56 mg) and α-(hex-5-ynamide)-ω-hydroxyl PEG 2000 (10, 400
mg, 0.191 mmol). The reaction mixture was stirred in the dark at room temperature for 24h and then
centrifuged to remove the insoluble byproduct, dicyclohexylurea. The supernatant was concentrated in vacuo
to 2 mL and precipitated into 50 mL DCM. The insoluble, unreacted folic acid was removed via vacuum
filtration and the filtrate concentrated in vacuo. The resulting residue was dissolved in 2 mL DCM and
precipitated in 50 mL diethyl ether. The step was repeated two more times. The precipitated product was
collected via centrifugation and dried overnight under high vacuum. 1H NMR signal integration was used to
determine the conjugation efficiency (50%) and the mixture was not separated. Yield (200 mg, 41%). 1H
NMR (400 MHz, DMSO-d 6 ) δ 11.49 (s, 1H), 8.65 (d, 1H), 8.19 (d, 1H), 7.88 (t, 1H), 7.65 (d, 2H), 7.45 (d,
2H), 6.93 (d, 1H), 6.62 (m, 2H), 4.57 (t, 2H), 4.48 (t, 1H), 3.52 (br, 219H), 2.76 (s, 1H), 2.31 (t, 1H), 2.15
(m, 4H), 1.63 (m, 2H). IR (neat) υ 3500-2500 (br), 1692, 1601, 1510, 1300, 1205 cm-1.
5.6.4

Polymer synthesis.

Conjugated polymers PPE1 and PPE2 were obtained by Sonogashira cross-coupling polymerization
between

monomers

M1

and

M2

and

commercially

available

monomer

4,7-

dibromobenzo[c][1,2,5]thiadiazole in yield of 50~60% as red solids (Scheme S5.2 and S5.3). Both polymers
are partially soluble in boiling THF and chloroform but fully soluble in DMF, DMSO, MeOH, and H 2 O.
Upon drying they strongly aggregate and do not redissolve in H 2 O but solubility in DMSO and DMF remains
unaffected. Minimal solubility in THF and cationic side chains of the polymers precluded the measurement
of their molecular weight by gel permeation chromatography (GPC).
5.6.4.1 Synthesis of PPE1.
A Schlenk flask was loaded with 1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene (M1,
26.4 mg, 0.048 mmol), 1,4-bis(2-(2-azidoethoxy)ethoxy)-2,5-diiodobenzene (M2, 14.15 mg, 0.024 mmol),
4,7-dibromobenzo[c][1,2,5]thiadiazole (7.07 mg, 0.024 mmol), Pd(PPh 3 ) 2 Cl 2 (1.69 mg, 0.0024 mmol) and
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CuI (0.228 mg, 0.0012 mmol). The flask was degassed and back-filled with nitrogen for 2 minutes and 4 mL
of air-free solvent (Et 3 N : DMF; 2:1) was added via a cannula. The mixture was heated at 65 oC for 12 h
under nitrogen atmosphere. The solution was then cooled to room temperature and transferred dropwise to
ethyl acetate, resulting in precipitation. Precipitate was collected via centrifugation (3 mins., 4000 rpm),
dissolved in 1 mL DMF and mixed with 10 mL MeOH. The resulting viscous solution was filtered through
PTFE syringe filter (cut-off 0.45 µm). Filtrate was evaporated to low volume (~0.5 mL) in vacuo, precipitated
in 40 mL ethyl acetate (3x). The supernatant was discarded and the solid red precipitated was collected, dried
under high vacuum for 12 h prior to 1H NMR and FTIR characterization. Yield (39 mg, 50%). 1H NMR (400
MHz, DMSO-d 6 ) δ 7.99 (br m, 0.5 H), 7.34 (br, 1H), 7.20 (br, 2H), 4.24 (br, 6H), 3.86-3.39 (br, 26H), 3.28
(br, 12H), 1.13 (br, 18H). IR (neat) υ 3411, 2926, 2870, 2100, 1492, 1463, 1417, 1275, 1216, 1117 cm-1. UVVis (THF) λ max = 452nm, ε = 59171.59 M-1cm-1 (per repeating unit), emission (THF) λ max = 578 nm, Q.Y. =
0.31 (in THF).
5.6.4.2 Synthesis of CPN-PEG 2000 -FA.
Heterodifunctional α-(hex-5-ynamide)-ω-folic acid PEG 2000 grafted conjugated polymer (CPN-PEG 2000 FA) was synthesized by click reaction. PPE1 (7.0 mg, 0.0076 mmol) and M3 (29.2 mg, 0.0114 mmol) were
dissolved in 4 mL of anhydrous DMF in a flame-dried and nitrogen-purged vial. Then, CuBr (0.33 mg, 0.0023
mmol) and TEMED (0.267 mg, 0.0023 mmol) were added sequentially. The vial was degassed and backfilled with nitrogen for 2 minutes and stirred for 48 h at 30 oC. The reaction mixture was exposed to air and
passed through a short column of alumina to remove unreacted CuBr. The crude polymer was obtained by
precipitation into diethyl ether. Then it was dissolved in 1 mL of DMSO, added into 10 mL deionized water
and washed with 10 mL DCM (10x). The aqueous fraction was collected, dialyzed (dialysis membrane,
MWCO: 5000) with 2 L deionized water to remove DMSO and unreacted PEG 2000 . The pure polymer was
recovered by lyophilization. 1H NMR (400 MHz, DMSO-d 6 ) δ 8.02 (br, 0.7 H), 7.88 (br, 0.3H), 7.79 (br,
0.7H), 7.56 (br, 0.54H), 7.5-7.1 (br, m, 4.2H), 4.64 (br, 0.78H),4.24 (br, 6H), 4.0-3.52 (br, m, 23H), 3.51 (br,
68H), 3.28 (br, 12H), 2.15 (br, m, 1.6H), 1.65 (br, m, 0.72H), 1.13 (br, 18H). IR (neat) υ 3600-2500 (br),
2104, 1642, 1603, 1492, 1454, 1342, 1275, 1101 cm-1. UV-Vis (H 2 O) λ max = 481 nm, emission (H 2 O) λ max
= 618 nm, Q.Y. = 0.55 (in water).
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5.6.4.3 Characterization of PPE1 and CPN-PEG 2000 -FA.
Comparison between the integrated areas for the methyl groups of quaternary ammonium ion at 1.13 ppm
and methylene hydrogens at 3.28 ppm to that of aryl hydrogens at 7.20-7.34 ppm and hydrogens on ethoxy
chains at ~3.59-4.24 ppm in the 1H NMR spectrum of PPE1 reveals that 50% of M1 has been incorporated
as quaternary ammonium ions in the side chain. Similarly, integration comparison between the aromatic
signals in BTz and all other signals from polymeric backbone, as well as side chains, suggest 25%
incorporation of BTz units in the polymer.
N

N

O

O

O

N3

O

O

0.5

PPE1

O

O

O

N

S

0.5
N

n

CPN-PEG2000-FA

Scheme S5.2. Synthesis of water-soluble PPE1 from readily available monomers via Sonogashira coupling
and grafting to yield CPN-PEG 2000 -FA.
The quantitative character of the ‘click’ reaction was determined by 1H-NMR in DMSO-d 6 . Figure S5.1
shows the comparison of 1H-NMR spectra of PPE1 (top spectra) with the final PEG 2000 -FA grafted
copolymer (CPN-PEG 2000 -FA, bottom spectra) obtained after the dipolar cycloaddition with PEG 2000 -FA.
New signal at 3.51 ppm is assigned to the repeat unites –CH 2 –CH 2 –O– from PEG 2000 , while signals at 1.65
ppm and 2.15 ppm are assigned to methylene protons r and q+s, respectively. The peak at 4.64 ppm is related
to the protons from FA. Moreover, signals at δ 7.20-7.56, 7.79 and 8.01 are assigned to FA, where signal at
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7.88 ppm is characteristic to amide signal of the PEG derivative. Also, NMR signal integration indicates
presence of proton from triazole linkage buried at δ 7.20-7.56 ppm. Similarly, the ratio of proton integrals
belonging to PPE1 to that of PEG 2000 -FA suggests 40% incorporation of the latter via click reaction.

Figure S5.1. 1H NMR spectra of PPE1 (top) and CPN-PEG 2000 -FA (bottom) in DMSO-d 6 . *indicates
unassigned signal.
To prepare the grafted copolymers CPN-PEG 2000 -FA and CPN-PEG 2000 , the azide functionalized PPEs
were coupled with alkynyl end of PEG 2000 -FA and PEG 2000 , respectively, by the Huisgen 1,3-dipolar
cycloaddition. For CPN-PEG 2000 -FA, “click reaction” between PPE1 and M3 in presence of catalytic
amount of TEMED and CuBr in DMF at room temperature afforded CPN-PEG 2000 -FA in 45% yield. An
excess of alkynyl-terminated PEG 2000 -FA (2.0 equivalent) was used in order to increase the grafting
efficiency. The crude copolymer was first washed with excess DCM (10x) to remove unreacted PEG 2000 and
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other organic impurities followed by dialysis (5 kDa molecular weight cut-off dialysis membrane). Complete
removal of free FA was confirmed by monitoring absorption of FA in the aqueous supernatant (Figure S5.2).

Figure S5.2. UV-vis absorption spectra of folic acid in the supernatant showing complete removal of folic
acid from CPN-PEG 2000 -FA solution via dialysis (dialysis membrane, MWCO: 5000).
FTIR was utilized as the preliminary characterization method to determine whether the azide displacement
and click reaction occurred. The organic azide provides a unique absorbance in the IR spectrum at ~21002108 cm-1. The absorption at 2107 cm−1 for CPN-PEG 2000 -FA characteristic of the azide termini which
almost disappeared in favor of a new absorptions at 1642 cm−1 and 1603 cm-1 characteristic of the amide
group and triazole unsaturations, respectively. Additionally, the acid functional group of PEG 2000 -FA gives
rise to a characteristic broad and strong stretch from 3600 to 2500 cm−1.
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Figure S5.3. FTIR spectra of PPE1 (gray line) and CPN-PEG 2000 -FA (black line).
5.6.4.4. Synthesis of PPE2.
Using the general polymerization procedure described above, polymerization of 1,4-bis(2-(2-(2bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene
azidoethoxy)ethoxy)-2,5-diiodobenzene

(M1,

(M2,

26.4

14.15

mg,
mg,

0.048
0.024

mmol),

1,4-bis(2-(2-

mmol),

4,7-

dibromobenzo[c][1,2,5]thiadiazole (7.07 mg, 0.024 mmol) in presence of Pd(PPh 3 ) 2 Cl 2 (1.69 mg, 0.0024
mmol) and CuI (0.228 mg, 0.0012 mmol) yielded polymer PPE2 in 57% (47mg). 1H NMR (400 MHz,
DMSO-d 6 ) δ 8.11-7.82 (br m, 0.45H), 7.31 (br, 1H), 7.18 (br, 2H), 4.23 (br, 6H), 3.87-3.58 (br, 27.6H), 3.27
(br, 6.6H), 1.12 (br, 6.79H). IR (neat) υ 3403, 2924, 2869, 2102, 1489, 1454, 1414, 1276, 1216, 1221 cm-1.
UV-Vis (THF) λ max = 448nm, ε = 57876.53 M-1cm-1 (per repeating unit), emission (THF) λ max = 575 nm,
Q.Y. = 0.35 (in THF).
5.6.4.5. Synthesis of CPN-PEG 2000 .
Using the general click reaction procedure described above, reaction of PPE2(13.18 mg, 0.016 mmol) and
α-(hex-5-ynamide)-ω-hydroxyl PEG 2000 (10, 34 mg, 0.016 mmol), in presence of CuBr (0.6864 mg, 0.0048
mmol) and TEMED (0.557 mg, 0.0048 mmol) yielded CPN-PEG 2000 . 1H NMR (400 MHz, DMSO-d 6 ) δ
7.87 (t, 1H), 7.29-7.17 (br, 4H), 4.56 (t, 0.5H), 4.23 (br, 6H), 3.85-3.67 (br, 26H), 3.50 (br, 212H), 2.15 (m,
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4H), 1.65 (m, 2H), 1.13 (br, 9H). IR (neat) υ 3600-2500 (br), 2104, 1642, 1603, 1492, 1454, 1342, 1275,
1101 cm-1. UV-Vis (H 2 O) λ max = 480 nm, emission (H 2 O) λ max = 620 nm, Q.Y. = 0.48 (in water).

PPE2

CPN-PEG2000

Scheme S5.3. Click reaction of alkyne end-functionalized PEG 2000 onto azide end-functionalized PPE2 to
yield CPN-PEG 2000 .
4.6.4.6 Characterization of PPE2 and CPN-PEG 2000.
A similar “click reaction” strategy was employed to synthesize CPN-PEG 2000 (Scheme S5.3). After
purification via dialysis and freeze drying, a red solid powder was collected which was used for nanoparticle
preparation. 1H NMR integral ratio between PPE2 and alkynyl ended PEG 2000 (10) indicates incorporation
complete of PEG 2000 into the polymer chain.
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Figure S5.4.1H NMR spectrum of PPE2 in DMSO-d 6 .

Figure S5.5.1H NMR spectra of CPN-PEG 2000 in DMSO-d 6 .
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PPE2
CPN-PEG2000

Figure S5.6. FTIR spectra of PPE2 (green line) and CPN-PEG 2000 (black line).

5.6.5

Nanoparticle preparation.

PEG 2000 -folic acid grafted conjugated polymers were dissolved in HPLC grade DMSO by stirring overnight.
The conjugated polymer nanoparticles were prepared by adding the stock solution in deionized water with
vigorous stirring. DMSO and unreacted PEG 2000 -Folic acid were removed by washing the water dispersible
with HPLC grade dichloromethane. Finally, the nanoparticles were filtered through a 0.5 µm PTFE syringe
filters.
5.6.6

Determination of hydrodynamic diameter of CPNs.

Light scattering measurements were performed using a NanoSight LM10 HS Instrument (Nanosight Ltd.,
Amesbury, UK) equipped with a sCMOS camera using deionized water (DI H 2 O, 18 Ω) as dispersant. A
Class 3B laser (488 nm blue laser) source was used as the light source and all experiments were performed
at a temperature of 25oC monitored by a LM14C temperature controller (NanoSight, Amesbury, United
Kingdom). CPN samples in water were filtered through PTFE syringe filters (cut-off 0.45 µm) prior to
injecting in the sample chamber to remove dust or any larger aggregates. Samples were then injected into the
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chamber with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid reached the tip
of the nozzle. A video of typically 60 seconds duration was taken, with a frame rate of 30 frames per second.
Each video was then analyzed by NTA software (NanoSight Ltd.) to give the mean, mode, and standard
deviation of nanoparticle size distribution together with an estimate of concentration (particles/mL). Each
sample was measured three times.
5.6.7

Determination of zeta potential of CPNs.

Zeta potential of CPNs were measured by Zetasizer nano–ZS (Zen 3600, Malvern Instruments Ltd.) using a
folded disposable capillary cell (Catalog # DTS1060) at 25oC. The nanoparticle dispersions (in DI water)
were concentrated to approximately 0.5 mM to achieve reliable results. Instrument settings were
automatically determined by Malvern technology software on a sample-to-sample basis for measurement
position (in mm), attenuator intensity (laser power), and number of runs per measurement. Each sample was
measured six times.
5.6.8

General cell culture.

HeLa cells (human cervical cancer, purchased from ATCC) were seeded into a 100 x 20 mm style sterile
tissue culture dish (#353003 BD Falcon, Durham, NC, USA). The cells were grown in minimum essential
medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL, HyClone, SH30024) medium supplemented
with 10% fetal bovine serum (FBS), and 100 µg/mL penicillin and 100 µg/mL streptomycin for 24 h under
5% CO 2 / 95% air at 37 °C. The cells were continuously maintained in the culture medium and subcultured
every 48 h.
5.6.9

Cellular toxicity study.

HeLa cells (ca. 10,000 cells per well), in 200 μL of complete medium, were seeded into a 96-well plate and
allowed to attach for one day at 37 °C under a humidified atmosphere of 5% CO 2 / 95% air. Stock solution
of CPNs were added into complete media and diluted to the required amount of CPNs. After addition of
CPNs, the cells were incubated for another 18 h. Cells were washed with warm PBS and incubated with fresh
medium containing MTT (5 mg mL-1 in PBS, CALBIOCHEM, Germany) for 4 h at 37 oC. Dimethyl sulfoxide
(100 µL) was added to solubilize the purple formazan crystals formed by proliferating cells. Absorbance was
measured by a microplate well reader (infinite M1000 PRO, TECAN, Switzerland) at 590 nm. Relative cell
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viability (%) as a function of CPNs concentration was expressed as a percentage relative to the untreated
control cells. All measurements were performed in triplicate and standard deviation was included in the error
bar.
5.6.10

Cell uptake studies by flow cytometry.

HeLa cells were seeded into a 12-well plate (~40,000/well) one day prior to CPN treatment. Cells were then
incubated with 6 µM of CPN for 1, 2, 4, 8, and 18h. For complexation with HA, CPN was mixed with HA
(40K and 100K) at molar ratios (based on repeating unit of CPN and HA) of 1:0 (control), 1:1, 1:2, and 1:5.
The CPN/HA complexes were allowed to incubate approximately 30 minutes prior to incubating with cells.
After incubation with cells, samples were treated with trypan blue (200 μM) for 10 minutes at 37˚C and
washed three times with 1X PBS. Cells were detached with trypsin/EDTA and fixed with 4%
paraformaldehyde for 10 minutes at room temperature, then resuspended in flow cytometry buffer (1X PBS
containing 5% bovine serum albumin and 0.02% sodium azide). 10,000 events per measurement were
recorded within the gate of control cells, which was selected based on forward and side scattering of control
cells to eliminate data collection from dead cells and artifacts. Mean fluorescence intensity of CPNs (FL3
channel, 590-620 nm wavelength range) was obtained using three independent sample sets and accounting
for variation in cell autofluorescence. For uptake plots, values were normalized to control cells.
5.6.11

Cell inhibition assays.

For endocytosis pathway studies, HeLa cells were seeded into a 12-well plate (~40,000/well) one day prior
to CPN treatment. Cells were then treated without (control) or in the presence of pharmaceutical inhibitors
chlorpromazine (24 µM) for clathrin mediated endocytosis (CME), genistein (210 μM) for caveolae mediated
endocytosis (CvME), methyl-β-cyclodextrin (1000 μM) for CME and macropinocytosis (CvME/MPC),
LY294002 (120 μM) for macropinocytosis (MPC1), or cytochalasin D (40 µM) for macropinocytosis
(MPC2) for 30 minutes before CPN treatment. For blocking any potential pathways of FA and HA, cells
were treated with excess FA (1 mM) and HA (100K, 1.5 mM) for one hour before CPN treatment. After CPN
treatment, cells were prepared as discussed in previous section. For inhibition assays, values were normalized
to CPN.

137

5.6.12

Cell uptake studies by microscopy.

HeLa cells were seeded into a 12-well plate (~20,000/well) with glass coverslip (#1254584, Fisher Scientific)
one day prior to CPN treatment and cultured in a minimum essential medium (MEM)/Earle’s balanced salt
solution (EBSS) (500 μL) medium containing 10% fetal bovine serum (FBS) and 100 U/m penicillin for 24
h under 5% CO 2 at 37 °C. CPNs and CPN/HA complexes were prepared in fresh culture medium (500 μL),
and added to cells after washing with 1X PBS and removing media, then cultured for 4, 8, and 18 h (ﬁnal
CPN concentration: 6 μM). After incubation, cell were washed with PBS and ﬁxed with 4%
paraformaldehyde for 10 min. After washing with 1X PBS, a 1 μL aliquot of Hoechst (5 μg/mL) was added
to 1X PBS and incubated with the cells for 10 min at room temperature. Cells were then washed three times
with 1X PBS and coverslips were mounted on microscope slides (#1125441, Fisher Scientific) using a 1:1
glycerol/PBS mounting medium. Fluorescent images of the cells were obtained using a DeltaVision Elite
Microscope System (Applied Precision, Issaquah, Washington, USA) equipped with bandpass ﬁlters such as
blue (410−460 nm, Hoechst) and red (595-635nm, CPNs) using a 60X oil immersion lens (NA 1.42) and η
= 1.520 immersion oil . Top and bottom of the chosen cells was identified, and a Z-stack plot was imaged
for each channel. Deconvolution of each channel was performed using the microscope software (Softworx
5.0 application, Applied Precision, Issaquah, Washington, USA) and supplied method file using 50 iterations
per channel and high noise filtering setting.
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5.6.13

Characterization data.

Figure S5.7. 1H NMR spectrum of M1 in CDCl 3 .

Figure S5.8. 1H NMR spectrum of M2 in CDCl 3 .
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Figure S5.9. 13C NMR spectrum of M2 in CDCl 3 .

Figure S5.10. IR Spectrum of M2 showing –N 3 stretch at 2095.8 cm-1.
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Figure S5.11. 13C NMR spectrum of M1 in CDCl 3 .

Figure S5.12. 1H NMR spectrum of 7 in DMSO-d 6 .
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Figure S5.13. 13C NMR spectrum of 7 in DMSO-d 6 .

Figure S5.14. 1H NMR spectrum of 8 in DMSO-d 6 .
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Figure S5.15. 13C NMR spectrum of 8 in DMSO-d 6 .

Figure S5.16. 1H NMR spectrum of 9 in DMSO-d 6 .
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Figure S5.17. 13C NMR spectrum of 9 in DMSO-d 6 .

Figure S5.18. 1H NMR spectrum of 10 in DMSO-d 6 .
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Figure S5.19. 13C NMR spectrum of 10 in DMSO-d 6 .

Figure S5.20. 1H NMR spectrum of 1:1 mixture of M3 and 10 in DMSO-d 6 .
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Figure S5.21. Absorption and emission spectra for PPE2 in THF (Excitation = 400 nm, slit width = 2 nm,
integration time = 0.1 s).

Average = +89.7 ± 2.21 mV
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Figure S5.22. Zeta potential for CPN-PEG 2000 -FA (a) and CPN-PEG 2000 (b).
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CPN-PEG2000-FA

CPN-PEG2000

Figure S5.23. Toxicity of CPNs toward HeLa cells. Cell viability against varying concentration of CPNs is
plotted as columns.
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Figure S5.24. Quenching experiment showing normalized emission spectra of CPN-PEG 2000 -FA and CPNPEG 2000 with (dashed lines) and without (solid lines) trypan blue (TB) treatment of 200 µM in water for 10
minutes at 37˚C.
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Cell gate

CPN1

CPN1 + HA

CPN2

CPN2 + HA

Figure S5.25. Representative scatterplots (top row) and intensity plots (bottom row) for optimized conditions
for CPN-PEG 2000 -FA/HA (8 h, 40K 1:1), and CPN-PEG 2000 /HA (4 h, 40K 1:2). 10,000 events per
measurement were recorded within the gate of control cells, which was selected based on forward and side
scattering of control cells (top left) to eliminate data collection from dead cells and artifacts.
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CHAPTER VI
General Conclusions

The development of CP-based biomaterials would provide a novel class of polymeric materials useful for a
variety of applications. The use of CPNs has become of significant interest in biomedical applications as a
consequence of their desirable properties including facile synthesis, high sensitivity, superior photostability,
low cytotoxicity, and biocompatibility. The photophysical excellence and robustness of CP-based
nanomaterials are particularly useful for labelling target cells. The synthetic versatility of CPs allows the easy
modification of the conjugated backbone to tune emission and side chain structures to adjust biocompatibility
through increased water solubility, controlled biodegradability, and incorporation of targeting. Structural
modifications of CP side chains to incorporate ionic and hydrophilic moieties allow for tunable biophysical
properties for improved biocompatibility and functionalized performance. Depending on the solubility of CP
chains and the nature of interaction between CPs and analytes, structural changes can occur in individual CP
chains or multiple chain aggregates, which correspond to changes in CP optical properties. These changes in
optical properties present the opportunity of a CP-based sensor. Structural modifications result in changes in
self-assembly and subsequent cellular interactions, which allows for a structure-function relationship to be
established.
The second chapter presented a strategy for modulating particle shape using ionic complexation with HA in
a backbone flexibility-dependent fashion. The incorporation of a semi-flexible, non-conjugated moiety into
the backbone resulted in the formation of core-shell nanoparticles when a cationic CPN was treated with a
polyanion compared to the control CPN with a rigid, fully conjugated backbone. The core-shell nanoparticles
exhibited high specificity to cancer cells with low adsorption to normal cells, because of HA’s affinity to
overexpressed receptors on cancer cells. While in Chapter II, the semi-flexible CPN displayed enhanced
targeting of cancer cells over normal cells, additional work showed there was no significant increase in
internalization of the semi-flexible CPN, only changes to subcellular localization. Complexation of the semiflexible CPN with polyanions led to increased accumulation in different organelles compared to control
polymers with rigid backbone. Differences in subcellular localization were expected based on the dramatic
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changes from spherical to core-sell particles. While ionic complexation led to increased labelling of cancer
cells, a strategy to improve targeting and increase internalization of CPNs was explored in Chapter V using
a dual ligand targeting approach.
The dramatic differences in ionic complexation determined by backbone flexibility led to the work in Chapter
III. A systematic investigation on ionic complexation of CPNs that vary by side chain and backbone structure
with biologically important anionic polysaccharides was conducted in the third chapter. A simple approach
to differential sensing of biologically important molecules was presented. A systematic approach to
understanding the effect of side chain and backbone structure was employed to establish a structure-function
relationship. To improve differential sensing, an array of more structurally diverse CPNs could be utilized,
which would lead to more dramatic differential interactions of CPNs and analytes. By developing structural
diverse arrays, sensitivity can be greatly improved. Additional work using a controlled series of CPNs with
PPE and PPB-type connectivity and incorporation of a flexible, non-conjugated linker displayed backbonedependent complexation with HA. The work in Chapters II and III presented how backbone flexibility affects
ionic interactions, but subcellular localization studies would provide more information how exactly backbone
connectivity affects cellular interactions, which was the explored in the fourth chapter

Chapter IV presented a strategy for mitochondrial targeting using the triphenylphosphonium (TPP) group
that was dependent on the biodegradability and flexibility of the conjugated backbone. The subcellular
localization and cellular toxicity were affected by backbone flexibility and molecular weight, in a timedependent fashion. The degradable, flexible linker allowed the CPN to be degraded to conjugated oligomers
that could more easily diffuse after endocytosis and traffic to the mitochondria. The TPP-containing CPNs
were treated with HA to improve solubility, and displayed modulated cellular interactions based on backbone
structure. Additional work using a series of varying molecular weight nonflexible TPP-containing
copolymers and flexible TPP-containing copolymers with varying flexible unit incorporation indicated that
the presence of the flexible linker and at relatively higher percentage (>40%) was crucial for mitochondrial
localization. This finding could be the result of the hydrophobicity of the polymer backbone, which causes
aggregation in aqueous environment, and compromises the availability of the degradable linker to
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intracellular glutathione. A series of TPP-containing polymers that also incorporated the hydrogen peroxidesensitive moiety, aryl boronate, and degradable linker were synthesized. However, because of the
hydrophobicity of this group and in combination with the bulky TPP group, dense aggregation was observed.
To address these issues, additional more in-depth studies on the effect of the flexible linker for subcellular
targeting are needed. In addition, improving the hydrophilicity of the TPP-containing CPNs would provide
information as to how polymer solubility, CPN aggregation, and cellular uptake/trafficking can be modulated.
Chapter V detailed the synthesis of dual-targeting red emissive CPNs grafted with folic acid (FA) side chains
and complexed with hyaluronic acid (HA). Modulation of uptake kinetics and amount of internalized CPNs
was achieved by the dual ligand-targeting CPNs designed for folate and hyaluronan receptors. The grafting
of PEG 2000 -FA side chain posed a synthetic challenge to control the amount of incorporation because of the
poor solubility of FA. The synthetic approach would need to be modified to increase hydrophilicity to favor
coupling of FA. Additional work is under way to use microwave-assisted polymerization, which would
provide more reproducible results because of uniform heating and shorter reaction times. To assess accurately
the dual ligand approach, a series of three CPNs are needed: CPN with PEG only side chain, CPN with PEGFA side chain, and CPN with PEG-FA complexed with HA. Since copolymers were used, a variation in copolymer blocks was obtained based on synthetic approach. A CPN array with controlled incorporation of FA
to accurately assess cellular interactions of FA and HA would provide a clearer understanding of uptake
pathways as function of the folate and hyaluronan receptors. Subcellular localization studies of targeting
CPNs would provide information how modulating cell surface interactions affects subcellular trafficking and
intracellular fate.
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